0000793171 2025-11-01 2026-04-30 0000793171 2026-06-15 0000793171 2026-04-30 0000793171 2025-10-31 0000793171 us-gaap:NonrelatedPartyMember 2026-04-30 0000793171 us-gaap:NonrelatedPartyMember 2025-10-31 0000793171 us-gaap:RelatedPartyMember 2026-04-30 0000793171 us-gaap:RelatedPartyMember 2025-10-31 0000793171 us-gaap:SeriesAPreferredStockMember 2026-04-30 0000793171 us-gaap:SeriesAPreferredStockMember 2025-10-31 0000793171 VTRO:SeriesAOnePreferredStockMember 2026-04-30 0000793171 VTRO:SeriesAOnePreferredStockMember 2025-10-31 0000793171 us-gaap:ProductMember 2026-02-01 2026-04-30 0000793171 us-gaap:ProductMember 2025-02-01 2025-04-30 0000793171 VTRO:ProductSalesRelatedPartiesMember 2026-02-01 2026-04-30 0000793171 VTRO:ProductSalesRelatedPartiesMember 2025-02-01 2025-04-30 0000793171 2026-02-01 2026-04-30 0000793171 2025-02-01 2025-04-30 0000793171 VTRO:SeriesAOnePreferredStockMember 2026-02-01 2026-04-30 0000793171 VTRO:SeriesAOnePreferredStockMember 2025-02-01 2025-04-30 0000793171 us-gaap:ProductMember 2025-11-01 2026-04-30 0000793171 us-gaap:ProductMember 2024-11-01 2025-04-30 0000793171 VTRO:ProductSalesRelatedPartiesMember 2025-11-01 2026-04-30 0000793171 VTRO:ProductSalesRelatedPartiesMember 2024-11-01 2025-04-30 0000793171 2024-11-01 2025-04-30 0000793171 VTRO:SeriesAOnePreferredStockMember 2025-11-01 2026-04-30 0000793171 VTRO:SeriesAOnePreferredStockMember 2024-11-01 2025-04-30 0000793171 us-gaap:PreferredStockMember 2024-10-31 0000793171 us-gaap:CommonStockMember 2024-10-31 0000793171 us-gaap:AdditionalPaidInCapitalMember 2024-10-31 0000793171 us-gaap:TreasuryStockCommonMember 2024-10-31 0000793171 us-gaap:RetainedEarningsMember 2024-10-31 0000793171 2024-10-31 0000793171 us-gaap:PreferredStockMember 2025-01-31 0000793171 us-gaap:CommonStockMember 2025-01-31 0000793171 us-gaap:AdditionalPaidInCapitalMember 2025-01-31 0000793171 us-gaap:TreasuryStockCommonMember 2025-01-31 0000793171 us-gaap:RetainedEarningsMember 2025-01-31 0000793171 2025-01-31 0000793171 us-gaap:PreferredStockMember 2025-10-31 0000793171 us-gaap:CommonStockMember 2025-10-31 0000793171 us-gaap:AdditionalPaidInCapitalMember 2025-10-31 0000793171 us-gaap:TreasuryStockCommonMember 2025-10-31 0000793171 us-gaap:RetainedEarningsMember 2025-10-31 0000793171 us-gaap:PreferredStockMember 2026-01-31 0000793171 us-gaap:CommonStockMember 2026-01-31 0000793171 us-gaap:AdditionalPaidInCapitalMember 2026-01-31 0000793171 us-gaap:TreasuryStockCommonMember 2026-01-31 0000793171 us-gaap:RetainedEarningsMember 2026-01-31 0000793171 2026-01-31 0000793171 us-gaap:PreferredStockMember 2024-11-01 2025-01-31 0000793171 us-gaap:CommonStockMember 2024-11-01 2025-01-31 0000793171 us-gaap:AdditionalPaidInCapitalMember 2024-11-01 2025-01-31 0000793171 us-gaap:TreasuryStockCommonMember 2024-11-01 2025-01-31 0000793171 us-gaap:RetainedEarningsMember 2024-11-01 2025-01-31 0000793171 2024-11-01 2025-01-31 0000793171 us-gaap:PreferredStockMember 2025-02-01 2025-04-30 0000793171 us-gaap:CommonStockMember 2025-02-01 2025-04-30 0000793171 us-gaap:AdditionalPaidInCapitalMember 2025-02-01 2025-04-30 0000793171 us-gaap:TreasuryStockCommonMember 2025-02-01 2025-04-30 0000793171 us-gaap:RetainedEarningsMember 2025-02-01 2025-04-30 0000793171 us-gaap:PreferredStockMember 2025-11-01 2026-01-31 0000793171 us-gaap:CommonStockMember 2025-11-01 2026-01-31 0000793171 us-gaap:AdditionalPaidInCapitalMember 2025-11-01 2026-01-31 0000793171 us-gaap:TreasuryStockCommonMember 2025-11-01 2026-01-31 0000793171 us-gaap:RetainedEarningsMember 2025-11-01 2026-01-31 0000793171 2025-11-01 2026-01-31 0000793171 us-gaap:PreferredStockMember 2026-02-01 2026-04-30 0000793171 us-gaap:CommonStockMember 2026-02-01 2026-04-30 0000793171 us-gaap:AdditionalPaidInCapitalMember 2026-02-01 2026-04-30 0000793171 us-gaap:TreasuryStockCommonMember 2026-02-01 2026-04-30 0000793171 us-gaap:RetainedEarningsMember 2026-02-01 2026-04-30 0000793171 us-gaap:PreferredStockMember 2025-04-30 0000793171 us-gaap:CommonStockMember 2025-04-30 0000793171 us-gaap:AdditionalPaidInCapitalMember 2025-04-30 0000793171 us-gaap:TreasuryStockCommonMember 2025-04-30 0000793171 us-gaap:RetainedEarningsMember 2025-04-30 0000793171 2025-04-30 0000793171 us-gaap:PreferredStockMember 2026-04-30 0000793171 us-gaap:CommonStockMember 2026-04-30 0000793171 us-gaap:AdditionalPaidInCapitalMember 2026-04-30 0000793171 us-gaap:TreasuryStockCommonMember 2026-04-30 0000793171 us-gaap:RetainedEarningsMember 2026-04-30 0000793171 VTRO:FormerChiefExecutiveOfficerAndPresidentMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2026-02-01 2026-04-30 0000793171 VTRO:FormerChiefExecutiveOfficerAndPresidentMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2025-11-01 2026-04-30 0000793171 VTRO:FormerChiefExecutiveOfficerAndPresidentMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2025-02-01 2025-04-30 0000793171 VTRO:FormerChiefExecutiveOfficerAndPresidentMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-11-01 2025-04-30 0000793171 VTRO:JackZamoraMember 2026-04-30 0000793171 VTRO:CustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2026-02-01 2026-04-30 0000793171 VTRO:CustomerTwoMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2026-02-01 2026-04-30 0000793171 VTRO:CustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2025-02-01 2025-04-30 0000793171 VTRO:CustomerTwoMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2025-02-01 2025-04-30 0000793171 VTRO:CustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2025-11-01 2026-04-30 0000793171 VTRO:CustomerTwoMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2025-11-01 2026-04-30 0000793171 VTRO:CustomerThreeMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2025-11-01 2026-04-30 0000793171 VTRO:CustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-11-01 2025-04-30 0000793171 VTRO:CustomerTwoMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-11-01 2025-04-30 0000793171 VTRO:CustomerOneMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2025-11-01 2026-04-30 0000793171 VTRO:CustomerTwoMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2025-11-01 2026-04-30 0000793171 VTRO:FormerChiefExecutiveOfficerAndPresidentMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2025-11-01 2026-04-30 0000793171 VTRO:ForeignVendorMember us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember 2026-02-01 2026-04-30 0000793171 VTRO:ForeignVendorMember us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember 2025-11-01 2026-04-30 0000793171 VTRO:ForeignVendorMember us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember 2025-02-01 2025-04-30 0000793171 VTRO:ForeignVendorMember us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember 2024-11-01 2025-04-30 0000793171 VTRO:CustomerOneMember VTRO:AccountsReceivablesMember us-gaap:CustomerConcentrationRiskMember 2025-11-01 2026-04-30 0000793171 VTRO:CustomerTwoMember VTRO:AccountsReceivablesMember us-gaap:CustomerConcentrationRiskMember 2025-11-01 2026-04-30 0000793171 VTRO:CustomerOneMember VTRO:AccountsReceivablesMember us-gaap:CustomerConcentrationRiskMember 2024-11-01 2025-10-31 0000793171 srt:MinimumMember 2026-04-30 0000793171 srt:MaximumMember 2026-04-30 0000793171 VTRO:ResearchAndDevelopmentProductsMember 2026-02-01 2026-04-30 0000793171 VTRO:ResearchAndDevelopmentProductsMember 2025-02-01 2025-04-30 0000793171 VTRO:AlloRxStemCellsToForeignThirdPartyClinicsMember 2026-02-01 2026-04-30 0000793171 VTRO:AlloRxStemCellsToForeignThirdPartyClinicsMember 2025-02-01 2025-04-30 0000793171 VTRO:InfiniViveProductsMember 2026-02-01 2026-04-30 0000793171 VTRO:InfiniViveProductsMember 2025-02-01 2025-04-30 0000793171 VTRO:FitoreProductsMember 2026-02-01 2026-04-30 0000793171 VTRO:FitoreProductsMember 2025-02-01 2025-04-30 0000793171 VTRO:ResearchAndDevelopmentProductsMember 2025-11-01 2026-04-30 0000793171 VTRO:ResearchAndDevelopmentProductsMember 2024-11-01 2025-04-30 0000793171 VTRO:AlloRxStemCellsToForeignThirdPartyClinicsMember 2025-11-01 2026-04-30 0000793171 VTRO:AlloRxStemCellsToForeignThirdPartyClinicsMember 2024-11-01 2025-04-30 0000793171 VTRO:InfiniViveProductsMember 2025-11-01 2026-04-30 0000793171 VTRO:InfiniViveProductsMember 2024-11-01 2025-04-30 0000793171 VTRO:FitoreProductsMember 2025-11-01 2026-04-30 0000793171 VTRO:FitoreProductsMember 2024-11-01 2025-04-30 0000793171 VTRO:DeferredRevenueMember 2025-10-31 0000793171 VTRO:DeferredRevenueMember 2025-11-01 2026-04-30 0000793171 VTRO:DeferredRevenueMember 2026-04-30 0000793171 VTRO:DeferredRevenueMember 2024-10-31 0000793171 VTRO:DeferredRevenueMember 2024-11-01 2025-10-31 0000793171 2024-11-01 2025-10-31 0000793171 us-gaap:EmployeeStockOptionMember 2025-11-01 2026-04-30 0000793171 us-gaap:EmployeeStockOptionMember 2024-11-01 2025-04-30 0000793171 us-gaap:WarrantMember 2025-11-01 2026-04-30 0000793171 us-gaap:WarrantMember 2024-11-01 2025-04-30 0000793171 VTRO:TwoThousandTwentyTwoSeriesConvertibleNotesPayableCommonSharesMember 2025-11-01 2026-04-30 0000793171 VTRO:TwoThousandTwentyTwoSeriesConvertibleNotesPayableCommonSharesMember 2024-11-01 2025-04-30 0000793171 VTRO:TwoThousandTwentyThreeSeriesConvertibleNotesPayableStockSettlementMember 2025-11-01 2026-04-30 0000793171 VTRO:TwoThousandTwentyThreeSeriesConvertibleNotesPayableStockSettlementMember 2024-11-01 2025-04-30 0000793171 VTRO:TwoThousandTwentyThreeSeriesConvertibleNotesPayableStockSettledWarrantsIssuableMember 2025-11-01 2026-04-30 0000793171 VTRO:TwoThousandTwentyThreeSeriesConvertibleNotesPayableStockSettledWarrantsIssuableMember 2024-11-01 2025-04-30 0000793171 VTRO:TwoThousandTwentyThreeSeriesBConvertibleNotesPayableStockSettledMember 2025-11-01 2026-04-30 0000793171 VTRO:TwoThousandTwentyThreeSeriesBConvertibleNotesPayableStockSettledMember 2024-11-01 2025-04-30 0000793171 VTRO:TwoThousandTwentyThreeSeriesBConvertibleNotesPayableStockSettledWarrantsIssuableMember 2025-11-01 2026-04-30 0000793171 VTRO:TwoThousandTwentyThreeSeriesBConvertibleNotesPayableStockSettledWarrantsIssuableMember 2024-11-01 2025-04-30 0000793171 VTRO:TwoThousandTwentyFourSeriesSeniorSecuredConvertibleNotesPayableStockSettledMember 2025-11-01 2026-04-30 0000793171 VTRO:TwoThousandTwentyFourSeriesSeniorSecuredConvertibleNotesPayableStockSettledMember 2024-11-01 2025-04-30 0000793171 VTRO:TwoThousandTwentyFourSeriesSeniorSecuredConvertibleNotesPayableStockSettledWarrantsIssuableMember 2025-11-01 2026-04-30 0000793171 VTRO:TwoThousandTwentyFourSeriesSeniorSecuredConvertibleNotesPayableStockSettledWarrantsIssuableMember 2024-11-01 2025-04-30 0000793171 VTRO:TwoThousandTwentyFourPrefundedWarrantsMember 2025-11-01 2026-04-30 0000793171 VTRO:TwoThousandTwentyFourPrefundedWarrantsMember 2024-11-01 2025-04-30 0000793171 VTRO:TwoThousandTwentyFivePrefundedWarrantsMember 2025-11-01 2026-04-30 0000793171 VTRO:TwoThousandTwentyFivePrefundedWarrantsMember 2024-11-01 2025-04-30 0000793171 VTRO:TwoThousandTwentyFiveSeriesSeniorSecuredConvertibleNotesPayableStockSettledMember 2025-11-01 2026-04-30 0000793171 VTRO:TwoThousandTwentyFiveSeriesSeniorSecuredConvertibleNotesPayableStockSettledMember 2024-11-01 2025-04-30 0000793171 VTRO:TwoThousandTwentyFiveSeriesSeniorSecuredConvertibleNotesPayableStockSettledWarrantsIssuableMember 2025-11-01 2026-04-30 0000793171 VTRO:TwoThousandTwentyFiveSeriesSeniorSecuredConvertibleNotesPayableStockSettledWarrantsIssuableMember 2024-11-01 2025-04-30 0000793171 VTRO:SeriesAOneConvertiblePreferredStockMember 2025-11-01 2026-04-30 0000793171 VTRO:SeriesAOneConvertiblePreferredStockMember 2024-11-01 2025-04-30 0000793171 VTRO:TwoThousandTwentyThreeSeriesConvertibleNotesPayableMember 2026-04-30 0000793171 VTRO:TwoThousandTwentyThreeSeriesBConvertibleNotesPayableMember 2026-04-30 0000793171 VTRO:TwoThousandTwentyFourSeniorSecuredConvertibleNotesPayableMember 2026-04-30 0000793171 VTRO:TwoThousandTwentyFiveSeniorSecuredConvertibleNotesPayableMember 2026-04-30 0000793171 VTRO:TwoThousandTwentyThreeSeriesConvertibleNotesPayableMember 2025-10-31 0000793171 VTRO:TwoThousandTwentyThreeSeriesBConvertibleNotesPayableMember 2025-10-31 0000793171 VTRO:TwoThousandTwentyFourSeniorSecuredConvertibleNotesPayableMember 2025-10-31 0000793171 VTRO:TwoThousandTwentyFiveSeniorSecuredConvertibleNotesPayableMember 2025-10-31 0000793171 us-gaap:FairValueInputsLevel3Member us-gaap:DerivativeMember 2025-10-31 0000793171 us-gaap:FairValueInputsLevel3Member us-gaap:DerivativeMember 2024-10-31 0000793171 us-gaap:FairValueInputsLevel3Member us-gaap:DerivativeMember 2025-11-01 2026-04-30 0000793171 us-gaap:FairValueInputsLevel3Member us-gaap:DerivativeMember 2024-11-01 2025-10-31 0000793171 us-gaap:FairValueInputsLevel3Member us-gaap:DerivativeMember 2026-04-30 0000793171 VTRO:TwoThousandTwentyThreeSeriesConvertibleNotesPayableMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2026-02-01 2026-04-30 0000793171 VTRO:TwoThousandTwentyThreeSeriesConvertibleNotesPayableMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2025-11-01 2026-04-30 0000793171 VTRO:TwoThousandTwentyThreeSeriesConvertibleNotesPayableMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2025-02-01 2025-04-30 0000793171 VTRO:TwoThousandTwentyThreeSeriesConvertibleNotesPayableMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2024-11-01 2025-04-30 0000793171 VTRO:TwoThousandTwentyFourSeniorSecuredConvertibleNotesPayableMember 2026-02-01 2026-04-30 0000793171 VTRO:TwoThousandTwentyFourSeniorSecuredConvertibleNotesPayableMember 2025-11-01 2026-04-30 0000793171 VTRO:TwoThousandTwentyFourSeniorSecuredConvertibleNotesPayableMember 2025-02-01 2025-04-30 0000793171 VTRO:TwoThousandTwentyFourSeniorSecuredConvertibleNotesPayableMember 2024-11-01 2025-04-30 0000793171 VTRO:SeriesAOnePreferredStockMember 2025-02-24 2025-02-24 0000793171 VTRO:TwoThousandTwentyFiveSeniorSecuredConvertibleNotesPayableMember 2026-02-01 2026-04-30 0000793171 VTRO:TwoThousandTwentyFiveSeniorSecuredConvertibleNotesPayableMember 2025-11-01 2026-04-30 0000793171 VTRO:TwoThousandTwentyFiveSeniorSecuredConvertibleNotesPayableMember 2025-02-01 2025-04-30 0000793171 VTRO:TwoThousandTwentyFiveSeniorSecuredConvertibleNotesPayableMember 2024-11-01 2025-04-30 0000793171 srt:MinimumMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2026-04-30 0000793171 srt:MaximumMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2026-04-30 0000793171 srt:MinimumMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2025-10-31 0000793171 srt:MaximumMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2025-10-31 0000793171 us-gaap:MeasurementInputExpectedDividendPaymentMember 2026-04-30 0000793171 us-gaap:MeasurementInputExpectedDividendPaymentMember 2025-10-31 0000793171 srt:MinimumMember us-gaap:MeasurementInputOptionVolatilityMember 2026-04-30 0000793171 srt:MaximumMember us-gaap:MeasurementInputOptionVolatilityMember 2026-04-30 0000793171 srt:MinimumMember us-gaap:MeasurementInputOptionVolatilityMember 2025-10-31 0000793171 srt:MaximumMember us-gaap:MeasurementInputOptionVolatilityMember 2025-10-31 0000793171 srt:MinimumMember us-gaap:MeasurementInputExpectedTermMember 2025-11-01 2026-04-30 0000793171 srt:MaximumMember us-gaap:MeasurementInputExpectedTermMember 2025-11-01 2026-04-30 0000793171 srt:MinimumMember us-gaap:MeasurementInputExpectedTermMember 2024-11-01 2025-10-31 0000793171 srt:MaximumMember us-gaap:MeasurementInputExpectedTermMember 2024-11-01 2025-10-31 0000793171 us-gaap:TrademarksAndTradeNamesMember 2026-04-30 0000793171 VTRO:PatentsKnowHowAndUnpatentedTechnologyMember 2026-04-30 0000793171 us-gaap:CustomerRelationshipsMember 2026-04-30 0000793171 us-gaap:GoodwillMember 2025-11-01 2026-04-30 0000793171 us-gaap:GoodwillMember 2026-04-30 0000793171 us-gaap:TrademarksAndTradeNamesMember 2025-10-31 0000793171 VTRO:PatentsKnowHowAndUnpatentedTechnologyMember 2025-10-31 0000793171 us-gaap:CustomerRelationshipsMember 2025-10-31 0000793171 us-gaap:GoodwillMember 2024-11-01 2025-10-31 0000793171 us-gaap:GoodwillMember 2025-10-31 0000793171 VTRO:UnsecuredSixPercentageNotePayableRelatedPartyDebtMember 2026-02-01 2026-04-30 0000793171 VTRO:UnsecuredSixPercentageNotePayableRelatedPartyDebtMember 2025-02-01 2025-04-30 0000793171 VTRO:UnsecuredSixPercentageNotePayableRelatedPartyDebtMember 2025-11-01 2026-04-30 0000793171 VTRO:UnsecuredSixPercentageNotePayableRelatedPartyDebtMember 2024-11-01 2025-04-30 0000793171 VTRO:UnsecuredSixPercentageNotePayableRelatedPartyDebtMember 2026-04-30 0000793171 VTRO:UnsecuredSixPercentageNotePayableRelatedPartyDebtMember 2025-10-31 0000793171 VTRO:UnsecuredFourPercentageNotePayableRelatedPartyDebtMember 2026-02-01 2026-04-30 0000793171 VTRO:UnsecuredFourPercentageNotePayableRelatedPartyDebtMember 2025-02-01 2025-04-30 0000793171 VTRO:UnsecuredFourPercentageNotePayableRelatedPartyDebtMember 2025-11-01 2026-04-30 0000793171 VTRO:UnsecuredFourPercentageNotePayableRelatedPartyDebtMember 2024-11-01 2025-04-30 0000793171 VTRO:UnsecuredFourPercentageNotePayableRelatedPartyDebtMember 2026-04-30 0000793171 VTRO:UnsecuredFourPercentageNotePayableRelatedPartyDebtMember 2025-10-31 0000793171 VTRO:TwoThousandTwentyTwoSeriesConvertibleNotesMember 2022-06-01 2022-06-30 0000793171 VTRO:TwoThousandTwentyTwoSeriesConvertibleNotesMember 2022-07-01 2022-07-31 0000793171 VTRO:TwoThousandTwentyTwoSeriesConvertibleNotesMember 2022-06-30 0000793171 VTRO:TwoThousandTwentyTwoSeriesConvertibleNotesMember 2022-07-31 0000793171 VTRO:TwoThousandTwentyTwoSeriesConvertibleNotesMember 2026-02-01 2026-04-30 0000793171 VTRO:TwoThousandTwentyTwoSeriesConvertibleNotesMember 2025-02-01 2025-04-30 0000793171 VTRO:TwoThousandTwentyTwoSeriesConvertibleNotesMember 2025-11-01 2026-04-30 0000793171 VTRO:TwoThousandTwentyTwoSeriesConvertibleNotesMember 2024-11-01 2025-04-30 0000793171 VTRO:TwoThousandTwentyTwoSeriesConvertibleNotesMember 2026-04-30 0000793171 VTRO:TwoThousandTwentyTwoSeriesConvertibleNotesMember 2025-10-31 0000793171 VTRO:TwoThousandTwentyThreeSeriesConvertibleNotesStockSettledMember 2023-01-05 2023-01-06 0000793171 VTRO:TwoThousandTwentyThreeSeriesConvertibleNotesStockSettledMember 2023-01-06 0000793171 VTRO:TwoThousandTwentyThreeSeriesConvertibleNotesStockSettledMember 2023-03-01 2023-03-31 0000793171 VTRO:TwoThousandTwentyThreeSeriesConvertibleNotesStockSettledMember 2023-04-01 2023-04-30 0000793171 VTRO:TwoThousandTwentyThreeSeriesConvertibleNotesStockSettledMember 2023-03-31 0000793171 VTRO:TwoThousandTwentyThreeSeriesConvertibleNotesStockSettledMember 2023-04-30 0000793171 VTRO:TwoThousandTwentyThreeSeriesConvertibleNotesStockSettledMember 2023-06-01 2023-06-30 0000793171 VTRO:TwoThousandTwentyThreeSeriesConvertibleNotesStockSettledMember 2023-07-01 2023-07-31 0000793171 VTRO:PurchaseAgreementMember 2025-11-01 2026-04-30 0000793171 2023-01-31 0000793171 2023-01-01 2023-01-31 0000793171 2023-03-01 2023-03-31 0000793171 2023-06-01 2023-06-30 0000793171 2023-03-31 0000793171 2023-06-30 0000793171 VTRO:JanuaryTwoThousandTwentyThreeWarrantsMember 2023-04-30 0000793171 VTRO:JanuaryTwoThousandTwentyThreeNotesAndJanuaryTwoThousandTwentyThreeWarrantsMember 2023-01-31 0000793171 VTRO:MarchTwoThousandTwentyThreeWarrantsMember 2023-03-31 0000793171 VTRO:MarchTwoThousandTwentyThreeNotesAndMarchTwoThousandTwentyThreeWarrantsMember 2023-03-31 0000793171 VTRO:JuneTwoThousandTwentyThreeWarrantsMember 2023-06-30 0000793171 VTRO:JuneTwoThousandTwentyThreeNotesAndJuneTwoThousandTwentyThreeWarrantsMember 2023-06-30 0000793171 VTRO:JanuaryTwoThousandTwentyThreeNotesMember 2026-04-30 0000793171 VTRO:JanuaryTwoThousandTwentyThreeNotesMember 2025-04-30 0000793171 VTRO:JanuaryTwoThousandTwentyThreeNotesMember 2026-02-01 2026-04-30 0000793171 VTRO:JanuaryTwoThousandTwentyThreeNotesMember 2025-11-01 2026-04-30 0000793171 VTRO:JanuaryTwoThousandTwentyThreeNotesMember 2025-02-01 2025-04-30 0000793171 VTRO:JanuaryTwoThousandTwentyThreeNotesMember 2024-11-01 2025-04-30 0000793171 VTRO:MarchTwoThousandTwentyThreeNotesMember 2026-04-30 0000793171 VTRO:MarchTwoThousandTwentyThreeNotesMember 2025-04-30 0000793171 VTRO:MarchTwoThousandTwentyThreeNotesMember 2026-02-01 2026-04-30 0000793171 VTRO:MarchTwoThousandTwentyThreeNotesMember 2025-11-01 2026-04-30 0000793171 VTRO:MarchTwoThousandTwentyThreeNotesMember 2025-02-01 2025-04-30 0000793171 VTRO:MarchTwoThousandTwentyThreeNotesMember 2024-11-01 2025-04-30 0000793171 VTRO:JuneTwoThousandTwentyThreeNotesMember 2026-04-30 0000793171 VTRO:JuneTwoThousandTwentyThreeNotesMember 2025-04-30 0000793171 VTRO:JuneTwoThousandTwentyThreeNotesMember 2026-02-01 2026-04-30 0000793171 VTRO:JuneTwoThousandTwentyThreeNotesMember 2025-11-01 2026-04-30 0000793171 VTRO:JuneTwoThousandTwentyThreeNotesMember 2025-02-01 2025-04-30 0000793171 VTRO:JuneTwoThousandTwentyThreeNotesMember 2024-11-01 2025-04-30 0000793171 VTRO:JanuaryTwoThousandTwentyThreeNotesMember 2025-10-31 0000793171 VTRO:MarchTwoThousandTwentyThreeNotesMember 2025-10-31 0000793171 VTRO:JuneTwoThousandTwentyThreeNotesMember 2025-10-31 0000793171 VTRO:TwoThousandTwentyFourSeniorSecuredConvertibleNotesMember 2023-11-16 0000793171 VTRO:TwoThousandTwentyFourSeniorSecuredConvertibleNotesMember 2024-01-10 0000793171 VTRO:TwoThousandTwentyFourSeniorSecuredConvertibleNotesMember 2023-11-16 2023-11-16 0000793171 VTRO:TwoThousandTwentyFourSeniorSecuredConvertibleNotesMember 2024-01-10 2024-01-10 0000793171 VTRO:TwoThousandTwentyFourSeniorSecuredConvertibleNotesMember 2024-04-11 0000793171 VTRO:TwoThousandTwentyFourSeniorSecuredConvertibleNotesMember 2024-04-11 2024-04-11 0000793171 VTRO:TwoThousandTwentyFourSeniorSecuredConvertibleNotesMember 2024-05-13 0000793171 VTRO:TwoThousandTwentyFourSeniorSecuredConvertibleNotesMember 2024-05-13 2024-05-13 0000793171 VTRO:TwoThousandTwentyFourSeniorSecuredConvertibleNotesMember 2024-06-21 0000793171 VTRO:TargetConsolidationAgreementMember 2024-07-16 2024-07-16 0000793171 VTRO:TargetConsolidationAgreementMember 2024-07-16 0000793171 VTRO:SeriesTwoThousandTwentyFourWarrantsMember VTRO:TwoThousandTwentyFourSeniorSecuredConvertibleNotesMember 2025-11-01 2026-04-30 0000793171 VTRO:SeriesTwoThousandTwentyFourWarrantsMember VTRO:TwoThousandTwentyFourSeniorSecuredConvertibleNotesMember 2026-04-30 0000793171 VTRO:SeriesTwoThousandTwentyFourWarrantsMember VTRO:TwoThousandTwentyFourJanuarySeniorSecuredConvertibleNotesMember 2025-11-01 2026-04-30 0000793171 VTRO:SeriesTwoThousandTwentyFourWarrantsMember VTRO:TwoThousandTwentyFourAprilSeniorSecuredConvertibleNotesMember 2025-11-01 2026-04-30 0000793171 VTRO:SeriesTwoThousandTwentyFourWarrantsMember VTRO:TwoThousandTwentyFourMaySeniorSecuredConvertibleNotesMember 2025-11-01 2026-04-30 0000793171 VTRO:SeriesTwoThousandTwentyFourWarrantsMember VTRO:TwoThousandTwentyFourJanuarySeniorSecuredConvertibleNotesMember 2026-04-30 0000793171 VTRO:SeriesTwoThousandTwentyFourWarrantsMember VTRO:TwoThousandTwentyFourAprilSeniorSecuredConvertibleNotesMember 2026-04-30 0000793171 VTRO:SeriesTwoThousandTwentyFourWarrantsMember VTRO:TwoThousandTwentyFourMaySeniorSecuredConvertibleNotesMember 2026-04-30 0000793171 VTRO:TwoThousandTwentyFourJanuarySeniorSecuredConvertibleNotesMember 2025-11-01 2026-04-30 0000793171 VTRO:TwoThousandTwentyFourJanuarySeriesNotesMember 2025-11-01 2026-04-30 0000793171 VTRO:TwoThousandTwentyFourJanuarySeriesNotesMember 2026-04-30 0000793171 VTRO:TwoThousandTwentyFourNovemberSeniorSecuredConvertibleNotesMember 2026-04-30 0000793171 VTRO:TwoThousandTwentyFourNovemberSeniorSecuredConvertibleNotesMember 2025-04-30 0000793171 VTRO:TwoThousandTwentyFourJanuarySeriesNotesMember 2025-04-30 0000793171 VTRO:TwoThousandTwentyFourJanuarySeriesNotesMember 2026-02-01 2026-04-30 0000793171 VTRO:TwoThousandTwentyFourJanuarySeriesNotesMember 2025-02-01 2025-04-30 0000793171 VTRO:TwoThousandTwentyFourJanuarySeriesNotesMember 2024-11-01 2025-04-30 0000793171 VTRO:TwoThousandTwentyFourAprilSeniorSecuredConvertibleNotesMember 2025-11-01 2026-04-30 0000793171 VTRO:TwoThousandTwentyFourAprilSeniorSecuredConvertibleNotesMember 2026-04-30 0000793171 VTRO:TwoThousandTwentyFourAprilSeniorSecuredConvertibleNotesMember 2026-02-01 2026-04-30 0000793171 VTRO:TwoThousandTwentyFourAprilSeniorSecuredConvertibleNotesMember 2025-02-01 2025-04-30 0000793171 VTRO:TwoThousandTwentyFourAprilSeniorSecuredConvertibleNotesMember 2024-11-01 2025-04-30 0000793171 VTRO:TwoThousandTwentyFourAprilSeniorSecuredConvertibleNotesMember 2026-02-24 0000793171 VTRO:TwoThousandTwentyFourAprilSeniorSecuredConvertibleNotesMember 2026-02-24 2026-02-24 0000793171 VTRO:TwoThousandTwentyFourMaySeniorSecuredConvertibleNotesMember 2025-11-01 2026-04-30 0000793171 VTRO:TwoThousandTwentyFourMaySeniorSecuredConvertibleNotesMember 2026-04-30 0000793171 VTRO:TwoThousandTwentyFourMaySeniorSecuredConvertibleNotesMember 2026-02-01 2026-04-30 0000793171 VTRO:TwoThousandTwentyFourMaySeniorSecuredConvertibleNotesMember 2025-02-01 2025-04-30 0000793171 VTRO:TwoThousandTwentyFourMaySeniorSecuredConvertibleNotesMember 2024-11-01 2025-04-30 0000793171 VTRO:TwoThousandTwentyFourMaySeniorSecuredConvertibleNotesMember 2026-02-24 0000793171 VTRO:TwoThousandTwentyFourMaySeniorSecuredConvertibleNotesMember 2026-02-24 2026-02-24 0000793171 VTRO:TwoThousandTwentyFourSeniorSecuredConvertibleNotesMember 2025-11-01 2026-04-30 0000793171 VTRO:TwoThousandTwentyFourSeniorSecuredConvertibleNotesMember 2024-11-01 2025-04-30 0000793171 VTRO:TwoThousandTwentyFourSeniorSecuredConvertibleNotesMember 2026-04-30 0000793171 VTRO:TwoThousandTwentyFourSeniorSecuredConvertibleNotesMember 2025-10-31 0000793171 VTRO:TwoThousandTwentyFourSeniorNoteMember 2025-03-31 0000793171 VTRO:TwoThousandTwentyFourSeniorNoteMember 2025-03-01 2025-03-31 0000793171 VTRO:TwoThousandTwentyFourSeniorNoteMember 2025-11-01 2026-04-30 0000793171 VTRO:TwoThousandTwentyFourSeniorNoteMember 2025-03-03 0000793171 VTRO:TwoThousandTwentyFiveSeniorSecuredConvertibleNotesMember 2025-02-27 0000793171 VTRO:TwoThousandTwentyFiveSeniorSecuredConvertibleNotesMember 2025-02-27 2025-02-27 0000793171 VTRO:TwoThousandTwentyFiveSeniorSecuredConvertibleNotesMember 2025-04-25 0000793171 VTRO:TwoThousandTwentyFiveSeniorSecuredConvertibleNotesMember 2025-04-25 2025-04-25 0000793171 VTRO:TwoThousandTwentyFiveSeniorSecuredConvertibleNotesMember 2025-05-21 0000793171 VTRO:TwoThousandTwentyFiveSeniorSecuredConvertibleNotesMember 2025-05-21 2025-05-21 0000793171 VTRO:TwoThousandTwentyFiveSeniorSecuredConvertibleNotesMember 2025-10-27 0000793171 VTRO:TwoThousandTwentyFiveSeniorSecuredConvertibleNotesMember 2025-10-27 2025-10-27 0000793171 VTRO:SeriesTwoThousandTwentyFiveWarrantsMember VTRO:TwoThousandTwentyFiveSeniorSecuredConvertibleNotesMember 2025-11-01 2026-04-30 0000793171 VTRO:SeriesTwoThousandTwentyFiveWarrantsMember VTRO:TwoThousandTwentyFiveSeniorSecuredConvertibleNotesMember 2026-04-30 0000793171 VTRO:SeriesTwoThousandTwentyFourWarrantsMember VTRO:FebruaryTwoThousandTwentyFiveNotesMember 2025-11-01 2026-04-30 0000793171 VTRO:SeriesTwoThousandTwentyFiveWarrantsMember VTRO:AprilTwoThousandTwentyFiveWarrantsMember 2025-11-01 2026-04-30 0000793171 VTRO:SeriesTwoThousandTwentyFiveWarrantsMember VTRO:MayTwoThousandTwentyFiveWarrantsMember 2025-11-01 2026-04-30 0000793171 VTRO:SeriesTwoThousandTwentyFiveWarrantsMember VTRO:OctoberTwoThousandTwentyFiveWarrantsMember 2025-11-01 2026-04-30 0000793171 VTRO:FebruaryTwoThousandTwentyFourNotesAndAprilTwoThousandTwentyFourWarrantsMember 2026-04-30 0000793171 VTRO:FebruaryTwoThousandTwentyFourNotesAndAprilTwoThousandTwentyFourWarrantsMember 2026-04-30 0000793171 VTRO:MayTwoThousandTwentyFiveWarrantsMember 2026-04-30 0000793171 VTRO:OctoberTwoThousandTwentyFiveWarrantsMember 2026-04-30 0000793171 VTRO:FebruaryTwoThousandTwentyFourNotesAndAprilTwoThousandTwentyFourWarrantsMember 2025-11-01 2026-04-30 0000793171 VTRO:FebruaryTwoThousandTwentyFiveNotesAndFebruaryTwoThousandTwentyFourWarrantsMember 2026-04-30 0000793171 VTRO:AprilTwoThousandTwentyFiveNotesAndAprilTwoThousandTwentyFourWarrantsMember 2025-11-01 2026-04-30 0000793171 VTRO:AprilTwoThousandTwentyFiveNotesAndAprilTwoThousandTwentyFourWarrantsMember 2026-04-30 0000793171 VTRO:MayTwoThousandTwentyFiveNotesAndMayTwoThousandTwentyFiveWarrantsMember 2025-11-01 2026-04-30 0000793171 VTRO:MayTwoThousandTwentyFiveNotesAndMayTwoThousandTwentyFiveWarrantsMember 2026-04-30 0000793171 VTRO:OctoberTwoThousandTwentyFiveNotesAndOctoberTwoThousandTwentyFiveWarrantsMember 2025-11-01 2026-04-30 0000793171 VTRO:OctoberTwoThousandTwentyFiveNotesAndOctoberTwoThousandTwentyFiveWarrantsMember 2026-04-30 0000793171 VTRO:TwoThousandTwentyFiveFebruarySeriesNotesMember 2025-11-01 2026-04-30 0000793171 VTRO:TwoThousandTwentyFiveFebruarySeriesNotesMember 2026-04-30 0000793171 VTRO:TwoThousandTwentyFiveFebruarySeriesNotesMember 2025-04-30 0000793171 VTRO:TwoThousandTwentyFiveFebruarySeriesNotesMember 2026-02-01 2026-04-30 0000793171 VTRO:TwoThousandTwentyFiveFebruarySeriesNotesMember 2025-02-01 2025-04-30 0000793171 VTRO:TwoThousandTwentyFiveFebruarySeriesNotesMember 2024-11-01 2025-04-30 0000793171 VTRO:TwoThousandTwentyFiveAprilSeriesNotesMember 2025-11-01 2026-04-30 0000793171 VTRO:TwoThousandTwentyFiveAprilSeriesNotesMember 2026-04-30 0000793171 VTRO:TwoThousandTwentyFiveAprilSeriesNotesMember 2025-04-30 0000793171 VTRO:TwoThousandTwentyFiveAprilSeriesNotesMember 2026-02-01 2026-04-30 0000793171 VTRO:TwoThousandTwentyFiveAprilSeriesNotesMember 2025-02-01 2025-04-30 0000793171 VTRO:TwoThousandTwentyFiveAprilSeriesNotesMember 2024-11-01 2025-04-30 0000793171 VTRO:TwoThousandTwentyFiveMaySeriesNotesMember 2025-11-01 2026-04-30 0000793171 VTRO:TwoThousandTwentyFiveMaySeriesWarrantsMember 2026-04-30 0000793171 VTRO:TwoThousandTwentyFiveMaySeriesNotesMember 2026-04-30 0000793171 VTRO:TwoThousandTwentyFiveMaySeriesNotesMember 2025-04-30 0000793171 VTRO:TwoThousandTwentyFiveMaySeriesNotesMember 2026-02-01 2026-04-30 0000793171 VTRO:TwoThousandTwentyFiveMaySeriesNotesMember 2025-02-01 2025-04-30 0000793171 VTRO:TwoThousandTwentyFiveMaySeriesNotesMember 2024-11-01 2025-04-30 0000793171 VTRO:TwoThousandTwentyFiveOctoberSeriesNotesMember 2026-04-30 0000793171 VTRO:TwoThousandTwentyFiveOctoberSeriesNotesMember 2025-11-01 2026-04-30 0000793171 VTRO:TwoThousandTwentyFiveOctoberSeriesNotesMember 2025-04-30 0000793171 VTRO:TwoThousandTwentyFiveOctoberSeriesNotesMember 2026-02-01 2026-04-30 0000793171 VTRO:TwoThousandTwentyFiveOctoberSeriesNotesMember 2025-02-01 2025-04-30 0000793171 VTRO:TwoThousandTwentyFiveOctoberSeriesNotesMember 2024-11-01 2025-04-30 0000793171 VTRO:TwoThousandTwentyFiveSeniorSecuredConvertibleNotesMember 2026-02-01 2026-04-30 0000793171 VTRO:TwoThousandTwentyFiveSeniorSecuredConvertibleNotesMember 2025-02-01 2025-04-30 0000793171 VTRO:TwoThousandTwentyFiveSeniorSecuredConvertibleNotesMember 2025-11-01 2026-04-30 0000793171 VTRO:TwoThousandTwentyFiveSeniorSecuredConvertibleNotesMember 2024-11-01 2025-04-30 0000793171 VTRO:TwoThousandTwentyFiveSeniorSecuredConvertibleNotesMember 2026-04-30 0000793171 VTRO:TwoThousandTwentyFiveSeniorSecuredConvertibleNotesMember 2025-10-31 0000793171 VTRO:SeriesAOneConvertiblePreferredStockMember 2025-05-31 0000793171 VTRO:SeriesAOneConvertiblePreferredStockMember 2026-04-30 0000793171 VTRO:SeriesAOneConvertiblePreferredStockMember 2025-10-31 0000793171 VTRO:AOnePreferredStockMember 2026-04-30 0000793171 VTRO:AOnePreferredStockMember 2025-11-01 2026-04-30 0000793171 VTRO:SeriesAOneConvertiblePreferredStockMember 2026-02-01 2026-04-30 0000793171 VTRO:SeriesAOneConvertiblePreferredStockMember 2024-11-01 2025-10-31 0000793171 2026-01-05 2026-01-05 0000793171 us-gaap:CommonStockMember 2026-01-05 2026-01-05 0000793171 us-gaap:WarrantMember 2026-04-30 0000793171 VTRO:PrefundedWarrantsMember 2024-11-16 0000793171 2024-11-16 0000793171 VTRO:PrefundedWarrantsMember 2025-01-27 0000793171 2023-11-01 2024-10-31 0000793171 VTRO:WarrantsAMember 2024-11-01 2025-10-31 0000793171 VTRO:WarrantsBMember 2024-11-01 2025-10-31 0000793171 VTRO:WarrantsAMember 2025-11-01 2026-04-30 0000793171 VTRO:WarrantsBMember 2025-11-01 2026-04-30 0000793171 VTRO:PrefundedWarrantsMember 2025-11-01 2026-04-30 0000793171 VTRO:PrefundedWarrantsMember 2024-10-31 0000793171 VTRO:PrefundedWarrantsMember 2024-11-01 2025-10-31 0000793171 VTRO:PrefundedWarrantsMember 2025-10-31 0000793171 VTRO:PrefundedWarrantsMember 2026-04-30 0000793171 VTRO:OtherWarrantsMember 2024-10-31 0000793171 VTRO:OtherWarrantsMember 2024-11-01 2025-10-31 0000793171 VTRO:OtherWarrantsMember 2025-10-31 0000793171 VTRO:OtherWarrantsMember 2025-11-01 2026-04-30 0000793171 VTRO:OtherWarrantsMember 2026-04-30 0000793171 VTRO:ChristopherFurmanMember VTRO:EmploymentAgreementsMember 2022-07-05 2022-07-06 0000793171 VTRO:JohnEvansMember VTRO:ConsultingAgreementMember 2025-11-01 2026-04-30 0000793171 VTRO:JamesMusickMember VTRO:MusickAgreementMember 2020-12-01 2020-12-01 0000793171 VTRO:JackZamoraMember 2026-04-30 0000793171 VTRO:JackZamoraMember 2025-10-31 0000793171 VTRO:JackZamoraMember 2026-02-01 2026-04-30 0000793171 VTRO:JackZamoraMember 2025-02-01 2025-04-30 0000793171 VTRO:JackZamoraMember 2025-11-01 2026-04-30 0000793171 VTRO:JackZamoraMember 2024-11-01 2025-04-30 0000793171 srt:ChiefExecutiveOfficerMember 2025-11-01 2026-04-30 0000793171 srt:ChiefExecutiveOfficerMember 2025-10-31 0000793171 VTRO:OperationSegmentsMember 2026-02-01 2026-04-30 0000793171 VTRO:OperationSegmentsMember 2025-02-01 2025-04-30 0000793171 VTRO:OperationSegmentsMember 2025-11-01 2026-04-30 0000793171 VTRO:OperationSegmentsMember 2024-11-01 2025-04-30 0000793171 VTRO:SeriesAOnePreferredStockMember us-gaap:SubsequentEventMember 2026-05-01 2026-05-01 0000793171 VTRO:SeriesAOnePreferredStockMember us-gaap:SubsequentEventMember 2026-05-15 0000793171 us-gaap:SubsequentEventMember 2026-05-15 0000793171 VTRO:TwoThousandTwentyFiveSeriesNotesMember VTRO:SeriesAOnePreferredStockMember us-gaap:SubsequentEventMember 2026-05-15 0000793171 VTRO:TwoThousandTwentyTwoSeriesNotesMember VTRO:SeriesAOnePreferredStockMember us-gaap:SubsequentEventMember 2026-05-15 0000793171 VTRO:TwoThousandTwentyThreeSeriesNotesMember VTRO:SeriesAOnePreferredStockMember us-gaap:SubsequentEventMember 2026-05-15 iso4217:USD shares iso4217:USD shares pure VTRO:Segment false --10-31 Q2 0000793171 10-Q true 2026-04-30 2026 false 001-41766 VITRO BIOPHARMA, INC. NV 84-1012042 3200 Cherry Creek Drive South Suite 410 Denver CO 80209 (855) 848-7627 Yes Yes Non-accelerated Filer true false false 4517651 0.001 122577 604183 62244 80526 2250 2250 138919 134833 40311 40311 364051 862103 3171581 3171581 312370 327608 59930 42168 163820 156631 294526 360681 8438 8438 4374716 4929210 2390844 2317673 22610 22610 22610 22610 525387 525387 968275 1041833 970000 970000 970000 970000 125000 593750 6596624 4764588 66032 150000 860 5043 111327 136813 16625515 5679141 183199 223868 767288 767288 1221958 1221958 200000 200000 374829 367166 722521 636296 5799081 31835 5505710 460629 387531 319983 474838 4282242 15583736 20907757 21262877 5000000 5000000 0.001 0.001 250000 250000 0 0 750000 750000 129065 35000 129 35 129 35 19230770 19230770 0.001 0.001 4517651 4460535 4517 4460 35008001 32547333 84000 84000 -51461688 -48801495 -16533041 -16333667 4374716 4929210 446295 509334 2250 446295 511584 103798 134827 342497 376757 1404747 1236638 109806 222431 -1172056 -1082312 508965 395960 -312550 440346 -514 -1553225 -1478786 -39912 -1593137 -1478786 -0.35 -0.35 -0.33 -0.33 4517651 4517651 4460535 4460535 975712 943458 18000 975712 961458 221261 227919 754451 733539 2739722 3365055 279027 296314 99700 -2363998 -2927830 1011695 499653 300000 343938 -312550 -1235000 728050 5097 -2660193 -4313448 -66959 -2727152 -4313448 -0.61 -0.61 -0.97 -0.97 4493065 4493065 4460535 4460535 4460535 4460 29028260 -84000 -37949693 -9000973 528000 528000 990000 990000 408234 408234 -2834662 -2834662 4460535 4460 30954494 -84000 -40784355 -9909401 322734 322734 -1478786 -1478786 4460535 4460 31277228 -84000 -42263141 -11065453 35000 35 4460535 4460 32547333 -84000 -48801495 -16333667 50000 50 999950 1000000 57116 57 -57 291630 291630 -1106968 -1106968 85000 85 4517651 4517 33838856 -84000 -49908463 -16149005 5000 5 99995 100000 39065 39 781261 781300 47268 47268 240621 240621 -1553225 -1553225 129065 129 4517651 4517 35008001 -84000 -51461688 -16533041 -2660193 -4313448 300000 343938 728050 5097 16043 61968 15238 15238 66155 60961 891430 367356 532251 730968 528000 -312550 -1235000 -18282 -76168 -2250 2250 4086 51188 17581 373171 418233 22610 -66155 -60961 -73558 31834 73098 73098 -4855 54326 -1536429 -1118703 33805 7189 2781 -40994 -2781 1100000 5350000 4370000 225000 4183 6801 1095817 748199 -481606 -373285 604183 571360 122577 198075 97 4872 57 468750 47269 4760115 4760115 <p id="xdx_809_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_zI0V0sbBkcqf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1 – <span id="xdx_821_zFmWWO365KSk">NATURE OF ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Nature of Organization and Description of Business</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vitro Biopharma, Inc. (the “Company”) was incorporated under the laws of the State of Nevada on March 31, 1986, under the name Imperial Management, Inc. On December 17, 1986, the Company merged with Labtek, Inc., a Colorado corporation, with the Company being the surviving entity and the name of the Company was changed to Labtek, Inc. The name was then changed to Vitro Diagnostics, Inc. on February 6, 1987. From November of 1990 through July 31, 2000, the Company was engaged in the development, manufacturing, and distribution of purified human antigens (“Diagnostics”) and related technologies. The Company also developed cell technology including immortalization of certain cells, which allowed entry into other markets besides Diagnostics. In August 2000, the Company sold the Diagnostics business, following which it focused on developing therapeutic products, its stem cell technology, patent portfolio and proprietary technology and cell lines for applications in autoimmune disorders and inflammatory disease processes and stem cell research. On February 3, 2021, the Company filed an amendment to the articles of incorporation with the Nevada Secretary of State, changing the name of the Company to Vitro BioPharma, Inc.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Summary of Significant Accounting Policies</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zV5Qzmyp6Ral" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basis of Presentation</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The interim consolidated financial statements included herein have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and note disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) have been condensed or omitted pursuant to such rules and regulations, although the Company believes that the disclosures included herein are adequate to make the information presented not misleading. These interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended October 31, 2025, as filed with the SEC (“Form 10-K”). Unless otherwise noted in this Interim Report, there have been no material changes to the disclosures contained in the notes to the audited financial statements for the year ended October 31, 2025, contained in the Form 10-K.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Consolidated Balance Sheet as of October 31, 2025, was derived from the audited financial statements included in the Form 10-K. In management’s opinion, the unaudited interim Consolidated Balance Sheet, Statements of Operations, Statements of Changes in Shareholders’ Deficit and Statements of Cash Flows, contained herein, reflect all adjustments, consisting solely of normal recurring items, which are necessary for the fair presentation of the Company’s financial position, results of operations and cash flows on a basis consistent with that of the Company’s prior audited consolidated financial statements. The results of operations for the interim periods may not be indicative of results to be expected for the full fiscal year. Certain prior period amounts were reclassified to conform to the current presentation on the Consolidated Financial Statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying consolidated financial statements are presented in U.S. dollars in conformity with accounting principles generally accepted in the United States of America (“GAAP”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_841_eus-gaap--ConsolidationPolicyTextBlock_zsJHYHYVFpei" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basis of Consolidation</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The consolidated financial statements include the operations of the Company and its wholly owned subsidiary, InfiniVive MD, LLC (“InfiniVive”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84E_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zlIqYVKjl1Fg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Reclassifications</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain amounts in the prior period have been reclassified to conform with current period presentation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_849_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zCMi4om0n3c3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cash Equivalents</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the purposes of the Balance Sheets and Statements of Cash Flows, the Company considers all highly liquid debt instruments purchased with an original maturity of three months or less to be cash equivalents.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84E_eus-gaap--ConcentrationRiskCreditRisk_zzAv510yp4la" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Concentration of Credit Risk</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which at times, may exceed the Federal depository insurance coverage limits. The Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Concentrations</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the three and six months ended April 30, 2026 and 2025, <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20260201__20260430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--TitleOfIndividualAxis__custom--FormerChiefExecutiveOfficerAndPresidentMember_z51eW5yDHfNl" title="Concentration risk percentage">0</span>% and <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20251101__20260430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--TitleOfIndividualAxis__custom--FormerChiefExecutiveOfficerAndPresidentMember_zWlyAVqzdun5" title="Concentration risk percentage">0</span>%, and <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250201__20250430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--TitleOfIndividualAxis__custom--FormerChiefExecutiveOfficerAndPresidentMember_zaav4CFpfmPf" title="Concentration risk percentage">0</span>% and <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20241101__20250430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--TitleOfIndividualAxis__custom--FormerChiefExecutiveOfficerAndPresidentMember_zcmyFHLuly3" title="Concentration risk percentage">2</span>% respectively, of the Company’s total revenues were derived from sales to an entity controlled by the Company’s former Chief Executive Officer and President, Dr. Jack Zamora (“Dr. Zamora”) (Note 10). Dr. Zamora is also a <span id="xdx_908_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20260430__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--JackZamoraMember_zpszeoiQ30fc" title="Ownership percentage">29</span>% stockholder. During the three months ended April 30, 2026, <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20260201__20260430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerOneMember_zl4E5NOWd1Nh" title="Concentration risk percentage">25%</span> and <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20260201__20260430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerTwoMember_zGjaP4KnFfgb" title="Concentration risk percentage">12%</span> of the Company’s total revenue was attributable to product sales to two customers. During the three months ended April 30, 2025, two customers accounted for <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250201__20250430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerOneMember_zsDhG5EAHkw3" title="Concentration risk percentage">33%</span> and <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250201__20250430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerTwoMember_zXYTfEwUSjVf" title="Concentration risk percentage">24%</span> of the Company’s revenues. Other than the revenues derived through sales to the customers referenced herein, no customer accounted for greater than 10% of the Company’s gross sales for the three months ended April 30, 2026 or 2025. During the six months ended April 30, 2026, <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20251101__20260430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerOneMember_z75dmqqgnBCd" title="Concentration risk percentage">28</span>%, <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20251101__20260430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerTwoMember_z67KzXUgxCr6" title="Concentration risk percentage">13</span>% and <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20251101__20260430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerThreeMember_zlFj6Jg0Rhvk" title="Concentration risk percentage">11</span>% of the Company’s total revenue was attributable to product sales to three customers. During the six months ended April 30, 2025, two customers accounted for <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20241101__20250430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--TitleOfIndividualAxis__custom--CustomerOneMember_zGILEkppjq72" title="Concentration risk percentage">36</span>% and <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20241101__20250430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--TitleOfIndividualAxis__custom--CustomerTwoMember_zAI9InP8LCj1" title="Concentration risk percentage">22</span>% of the Company’s revenues. Other than the revenues derived through sales to the customers referenced herein, no customer accounted for greater than 10% of the Company’s gross sales for the six months ended April 30, 2026 or 2025.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of April 30, 2026, two customers accounted for <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20251101__20260430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--TitleOfIndividualAxis__custom--CustomerOneMember_zesyFydxEzTh" title="Concentration risk percentage">26</span>% and <span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20251101__20260430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--TitleOfIndividualAxis__custom--CustomerTwoMember_znEhjnCtkAb5" title="Concentration risk percentage">10</span>% of total accounts receivable, respectively. No other customer accounted for more than 10% of total accounts receivable. As of April 30, 2026, Dr. Zamora accounted for <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20251101__20260430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--TitleOfIndividualAxis__custom--FormerChiefExecutiveOfficerAndPresidentMember_zGQ3B6HeVhbf" title="Concentration risk percentage">0</span>% of accounts receivable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the three and six months ended April 30, 2026 and 2025, foreign purchasers accounted for <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20260201__20260430__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--ForeignVendorMember_zPE4KnpJGLci" title="Concentration risk percentage">86</span>% and <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20251101__20260430__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--ForeignVendorMember_z9ZQmCEMzqWe" title="Concentration risk percentage">50</span>%, and <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250201__20250430__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--ForeignVendorMember_z5u4SgQPeO6f" title="Concentration risk percentage">72</span>% and <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20241101__20250430__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--ForeignVendorMember_zj2e6fPrmusd" title="Concentration risk percentage">68</span>% of total revenues, respectively. All sales to foreign customers were conducted in US Dollars.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_843_eus-gaap--FairValueOfFinancialInstrumentsPolicy_z4jCrMyaN2yj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financial Instruments</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value of the Company’s assets and liabilities, which qualify as financial instruments under Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) 820, “Fair Value Measurements and Disclosures,” approximates the carrying amounts represented in the balance sheets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_841_eus-gaap--UseOfEstimates_zk60Z6n1p5dh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Use of Estimates</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_eus-gaap--RevenueRecognitionPolicyTextBlock_z5l9zdlL9N91" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Revenue Recognition</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of January 1, 2018, the Company adopted Revenue from Contracts with Customers (Topic 606) (“ASC 606”). The new guidance sets forth a new five-step revenue recognition model which replaces the prior revenue recognition guidance in its entirety and is intended to eliminate numerous industry-specific pieces of revenue recognition guidance that have historically existed in GAAP. The underlying principle of the new standard is that a business or other organization will recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects what it expects to receive in exchange for the goods or services. To determine the appropriate amount of revenue to be recognized for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following steps: (i) identify the contract(s) with the customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract and (v) recognize revenue when (or as) each performance obligation is satisfied. The Company adopted the standard using the modified retrospective method and the adoption did not have a material impact on the Company’s consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For each performance obligation identified in accordance with ASC 606, the Company determines at contract inception whether it satisfies the performance obligation over time (in accordance with paragraphs 606-10-25-27 through 25-29) or satisfies the performance obligation at a point in time (in accordance with paragraph 606-10-25-30). If an entity does not satisfy a performance obligation over time, the performance obligation is satisfied at a point in time.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Control is considered transferred over time if any one of the following criteria is met:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The customer simultaneously receives and consumes the benefits of the asset or service which the entity performs;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The entity’s performance creates or enhances an asset; or</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The entity’s performance creates or enhances an asset that has no alternative use to the entity and the entity has the right to payment for work completed to date.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For certain contracts to which the Company is party, it uses the recognition over time method to recognize revenue.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognizes revenue when performance obligations with the customer are satisfied. Product sales occur once control is transferred upon shipment to the customer at the time of the sale. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring goods and services. The Company’s revenue is primarily derived from the sources listed below:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Sale of research and development product</i></b>: <i>Sales of research and development product include the sale of stem cell medium</i>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Sale of therapeutic product: </i></b><i>Includes cell culture media to be used in therapeutic treatment, i.e. sales to Foreign Third-Party Clinics.</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Shipping: </i></b><i>Includes amounts charged to customers for shipping products. These amounts are included with the various types of revenue described in the table below.</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Fitore product sales online: </i></b><i>Includes internet sales, via the Fitore Nutrition website, of dietary supplements called Stemulife, Spectrum+, Easy Sleep and Thought Calmer. The Company stopped selling Fitore products in March 2025.</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>InfiniVive product sales: </i></b><i>InfiniVive, via call-in and online orders, sells exosomes and daily cosmetic serum</i>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Disaggregation of revenue</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_895_eus-gaap--DisaggregationOfRevenueTableTextBlock_zM1UdTeMVtp9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following tables summarize the Company’s revenue for the reporting periods, disaggregated by product or service type:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B0_zAQ9pmoPy8Dc" style="display: none">SCHEDULE OF DISAGGREGATION OF REVENUE</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20260201__20260430_zDLj8p4Ri7I8" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Three Months</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ended<br/> April 30, 2026</b></span></p></td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20250201__20250430_zWmKuVwjd169" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Three Months</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ended<br/> April 30, 2025</b></span></p></td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Revenues:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--ResearchAndDevelopmentProductsMember_zNP4HdPS0pvl" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 60%; text-align: left">Research and development products</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">164,797</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">122,328</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--AlloRxStemCellsToForeignThirdPartyClinicsMember_zD7flPdzMrM1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">AlloRx Stem Cells to Foreign Third-Party Clinics</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">101,780</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">365,825</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--InfiniViveProductsMember_zrJD6P6XBbsd" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">InfiniVive products</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">179,718</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">22,449</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--FitoreProductsMember_zRiZ4bTbCZDi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Fitore products</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0764">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">982</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zegnkYeVsa08" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">446,295</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">511,584</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following tables summarize the Company’s revenue for the reporting periods, disaggregated by product or service type:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20251101__20260430_zFMX7Oxrnm6f" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Six Months</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ended<br/> April 30, 2026</b></span></p></td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20241101__20250430_zlCDJQLyk1X7" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Six Months</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ended<br/> April 30, 2025</b></span></p></td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Revenues:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--ResearchAndDevelopmentProductsMember_zO8af2X19bjl" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 60%; text-align: left">Research and development products</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">248,517</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">239,898</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--AlloRxStemCellsToForeignThirdPartyClinicsMember_zPXtVwJxPSBa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">AlloRx Stem Cells to Foreign Third-Party Clinics</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">486,056</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">649,266</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--InfiniViveProductsMember_zAi9baANXn43" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">InfiniVive products</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">241,139</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">69,387</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--FitoreProductsMember_zljdCcCpN1Oa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Fitore products</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0779">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,907</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_z8Ho8H4ybmRi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">975,712</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">961,458</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A2_zYdqgxvcvh9k" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_841_ecustom--DeferredRevenuePolicyTextBlock_zbhCAnfFzsz" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Deferred Revenue</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has recorded deferred revenue in connection with a Joint Operating Agreement (as subsequently amended, the “JOA”) executed between the Company and European Wellness/BIO PEP USA (“BIO PEP”). Pursuant to this JOA, which expired in accordance with its terms on July 31, 2023 and has not been renewed, the Company was obligated to use its best efforts to identify, develop and deliver various potential active pharmaceutical ingredients and to oversee the development of a recombinant cell line by a third-party service provider. The Company was also engaged to establish a Quality Management System to be utilized by BIO PEP in their pursuit of FDA authorizations. Prior to its expiration, our work under the JOA had been suspended since April 2023 pending discussions regarding amounts believed to be owed to us under that agreement for work already completed. If those discussions are unsuccessful, we may not be able to collect all of the amounts believed to be owed to us or the other amounts originally expected to be received by us under the agreement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company records as deferred revenue amounts for which the Company has been paid but for which it has not yet achieved and delivered related milestones or when the level of effort required to complete performance obligations under an arrangement cannot be reasonably estimated under the terms of the related agreement. Deferred revenue is classified as current or long-term based on when management estimates the revenue will be recognized. As of October 31, 2025 and April 30, 2026, the Company has net deferred $<span id="xdx_905_eus-gaap--DeferredRevenueCurrent_iI_c20260430_zZQsFAluD60a" title="Deferred revenue"><span id="xdx_90A_eus-gaap--DeferredRevenueCurrent_iI_c20251031_zcyat8uBNf94" title="Deferred revenue">525,387</span></span> in revenue, which is composed of $<span id="xdx_90A_eus-gaap--DeferredIncomeCurrent_iI_c20251031_ze1LjADjHaJi" title="Composed of deferred revenue"><span id="xdx_901_eus-gaap--DeferredIncomeCurrent_iI_c20260430_zhv9eR6BeUt6" title="Composed of deferred revenue">685,005</span></span> of deferred revenue, less $<span id="xdx_902_ecustom--PrepaidProjectCosts_iI_c20251031_z2gt09NYGyS6" title="Prepaid project cost"><span id="xdx_905_ecustom--PrepaidProjectCosts_iI_c20260430_zwMMtofz6e7h" title="Prepaid project cost">159,618</span></span> of prepaid project costs. The amount recorded as net deferred revenue will be recognized if and when the Company achieves and delivers the milestones under the terms of the agreement. The Company did not recognize any of this net deferred revenue during the three and six months ended April 30, 2026 and 2025.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_899_ecustom--ScheduleOfDeferredRevenueTableTextBlock_zpgKm7grYJ2k" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The table below summarizes Deferred Revenues as of April 30, 2026:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B2_zaVNPOu1CC2d" style="display: none">SUMMARY OF DEFERRED REVENUES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">October 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Project</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Income</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recognized</b></span></p></td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Net Revenue Deferred</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">April 30, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%; text-align: justify; padding-bottom: 1pt">Deferred Revenue</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--DeferredRevenue_iS_c20251101__20260430__us-gaap--RegulatoryLiabilityAxis__custom--DeferredRevenueMember_zxBXHIkfJVq6" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Deferred Revenue Beginning">525,387</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--OtherIncome_iN_di_c20251101__20260430__us-gaap--RegulatoryLiabilityAxis__custom--DeferredRevenueMember_zRgEPomJ3AKg" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Other Project Income Recognized"><span style="-sec-ix-hidden: xdx2ixbrl0803">-</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--DeferredRevenueRevenueRecognized1_c20251101__20260430__us-gaap--RegulatoryLiabilityAxis__custom--DeferredRevenueMember_zaN7zJ8OV5Y6" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Revenue Deferred"><span style="-sec-ix-hidden: xdx2ixbrl0805">-</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--DeferredRevenue_iE_c20251101__20260430__us-gaap--RegulatoryLiabilityAxis__custom--DeferredRevenueMember_zF4lLbxZk2Uk" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Deferred Revenue Ending">525,387</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--DeferredRevenue_iS_c20251101__20260430_zMTT1zM3g3ya" style="border-bottom: Black 2.5pt double; text-align: right" title="Deferred Revenue Beginning">525,387</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--OtherIncome_iN_di_c20251101__20260430_zlNBeC1xbswg" style="border-bottom: Black 2.5pt double; text-align: right" title="Other Project Income Recognized"><span style="-sec-ix-hidden: xdx2ixbrl0811">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--DeferredRevenueRevenueRecognized1_c20251101__20260430_zQMIuCQ27k8k" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue Deferred"><span style="-sec-ix-hidden: xdx2ixbrl0813">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--DeferredRevenue_iE_c20251101__20260430_zwcH4HNNcJni" style="border-bottom: Black 2.5pt double; text-align: right" title="Deferred Revenue Ending">525,387</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The table below summarizes Deferred Revenues as of October 31, 2025:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">October 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Project</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Income</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recognized</b></span></p></td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Net Revenue Deferred</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">October 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%; text-align: justify; padding-bottom: 1pt">Deferred Revenue</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--DeferredRevenue_iS_c20241101__20251031__us-gaap--RegulatoryLiabilityAxis__custom--DeferredRevenueMember_z4D9SmIJrtv9" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Deferred Revenue Beginning">525,387</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--OtherIncome_iN_di_c20241101__20251031__us-gaap--RegulatoryLiabilityAxis__custom--DeferredRevenueMember_zOsmcYG9B3ol" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Other Project Income Recognized"><span style="-sec-ix-hidden: xdx2ixbrl0819">-</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--DeferredRevenueRevenueRecognized1_c20241101__20251031__us-gaap--RegulatoryLiabilityAxis__custom--DeferredRevenueMember_zdefCLrDZgi7" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Revenue Deferred"><span style="-sec-ix-hidden: xdx2ixbrl0821">-</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--DeferredRevenue_iE_c20241101__20251031__us-gaap--RegulatoryLiabilityAxis__custom--DeferredRevenueMember_z7saJdk5gvS6" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Deferred Revenue Ending">525,387</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--DeferredRevenue_iS_c20241101__20251031_z7Oiisn0T9Sk" style="border-bottom: Black 2.5pt double; text-align: right" title="Deferred Revenue Beginning">525,387</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--OtherIncome_iN_di_c20241101__20251031_zHBfUuYHOWxb" style="border-bottom: Black 2.5pt double; text-align: right" title="Other Project Income Recognized"><span style="-sec-ix-hidden: xdx2ixbrl0827">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--DeferredRevenueRevenueRecognized1_c20241101__20251031_zHKrXPrArKd9" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue Deferred"><span style="-sec-ix-hidden: xdx2ixbrl0829">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--DeferredRevenue_iE_c20241101__20251031_zn7cEHakm7X6" style="border-bottom: Black 2.5pt double; text-align: right" title="Deferred Revenue Ending">525,387</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A9_zjB7A5ylbUA7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zNLwO4SzF5n6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Accounts Receivable</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts receivable consists of amounts due from customers. The Company considers accounts more than 30 days old to be past due. The Company uses the current expected credit loss method for recognizing bad debts. When an account is deemed uncollectible, it is written off against the allowance. The Company generally does not require collateral for its accounts receivable. As of April 30, 2026 and October 31, 2025, total accounts receivable, including related party amounts of $<span id="xdx_90B_eus-gaap--AccountsReceivableNet_iI_c20260430__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zQEQRRDLG4N6" title="Accounts receivables">0</span> and $<span id="xdx_902_eus-gaap--AccountsReceivableNet_iI_c20251031__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zX8fpxUGIy2" title="Accounts receivables">2,250</span>, amounted to $<span id="xdx_90D_eus-gaap--AccountsReceivableNet_iI_c20260430__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_zxKygm9VO442" title="Accounts receivables">62,244</span> and $<span id="xdx_902_eus-gaap--AccountsReceivableNet_iI_c20251031__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_zhzfYDxKkXS9" title="Accounts receivables">82,776</span>, respectively, net of allowances. The Company monitors accounts receivable for collectability and when doubt as to the realization of amounts recorded arises, an allowance is recorded and/or accounts deemed to be uncollectible will be written off. As of April 30, 2026 and October 31, 2025, the allowance for credit losses was $<span id="xdx_90A_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_c20260430_zsSUM8PMeLrf" title="Allowance for doubtful accounts receivable">0</span> and $<span id="xdx_90E_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_c20251031_zy89EhsbyArj" title="Allowance for doubtful accounts receivable">0</span>, respectively. No bad debt expense was recognized during the six months ended April 30, 2026 and 2025.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of April 30, 2026, two customers accounted for <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20251101__20260430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--AccountsReceivablesMember__srt--TitleOfIndividualAxis__custom--CustomerOneMember_z1BGDZAYe5gd" title="Concentration risk percentage">26</span>% and <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20251101__20260430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--AccountsReceivablesMember__srt--TitleOfIndividualAxis__custom--CustomerTwoMember_zu1cIKwdTvKg" title="Concentration risk percentage">10</span>% of accounts receivable. As of October 31, 2025, <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20241101__20251031__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--AccountsReceivablesMember__srt--TitleOfIndividualAxis__custom--CustomerOneMember_zs17EFAyZxTk" title="Concentration risk percentage">36</span>% of the Company’s accounts receivable were attributable to sales to one customer. No other customer comprised more than 10% of the accounts receivable balance as of April 30, 2026 or October 31, 2025.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span> </p> <p id="xdx_84C_eus-gaap--EarningsPerSharePolicyTextBlock_zQFaLTjToDG8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basic Loss Per Share</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company complies with accounting and disclosure requirements ASC Topic 260, “Earnings Per Share.” Basic net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share takes into consideration shares of common stock outstanding (computed under basic income or loss per share) and potentially dilutive shares of common stock that are not anti-dilutive. For the six months ended April 30, 2026 and 2025, the following number of potentially dilutive shares have been excluded from diluted net loss since such inclusion would be anti-dilutive:</span></p> <p id="xdx_897_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zLY2foc8QXFf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B0_zMimpd0A1FQb" style="display: none">SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED EARNINGS PER SHARE</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20251101__20260430_zN9gV2Y68RWd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">April 30, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_493_20241101__20250430_z32vJ95skjaa" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">April 30, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td></tr> <tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_z6U1sbHl4Zzg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: justify">Stock options outstanding</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">1,028,308</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">1,112,923</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zFVJVRnBzu1j" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Shares to be issued in connection with exercise of warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">149,727</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">215,881</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--TwoThousandTwentyTwoSeriesConvertibleNotesPayableCommonSharesMember_zU8dyDdptWm8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2022 Series Convertible Notes Payable - common shares</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,692</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,692</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--TwoThousandTwentyThreeSeriesConvertibleNotesPayableStockSettlementMember_zRmJTF6wXtC9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2023 Series Convertible Notes Payable – Stock Settled</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">34,142</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">31,984</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--TwoThousandTwentyThreeSeriesConvertibleNotesPayableStockSettledWarrantsIssuableMember_zh9LZ90qJAU3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2023 Series Convertible Notes Payable – Stock Settled - warrants issuable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,076</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,076</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--TwoThousandTwentyThreeSeriesBConvertibleNotesPayableStockSettledMember_zdiY2hxHZLAg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2023 Series B Convertible Notes Payable - Stock Settled</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">108,520</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">101,522</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--TwoThousandTwentyThreeSeriesBConvertibleNotesPayableStockSettledWarrantsIssuableMember_zptatoXNt2i8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2023 Series B Convertible Notes Payable - Stock Settled - warrants issuable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">39,881</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">39,881</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--TwoThousandTwentyFourSeriesSeniorSecuredConvertibleNotesPayableStockSettledMember_zMcQDh8zsl5j" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2024 Series Senior Secured Convertible Notes Payable – Stock Settled</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,333</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">39,583</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--TwoThousandTwentyFourSeriesSeniorSecuredConvertibleNotesPayableStockSettledWarrantsIssuableMember_zgoKzyq9SoTj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2024 Series Senior Secured Convertible Notes Payable – Stock Settled – warrants issuable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">289,583</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">289,583</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--TwoThousandTwentyFourPrefundedWarrantsMember_zfhLIbiwE3q" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2024 Pre-funded Warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,107,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,107,500</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--TwoThousandTwentyFivePrefundedWarrantsMember_z5ZdP11Zlgjc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2025 Pre-funded Warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">276,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">276,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--TwoThousandTwentyFiveSeriesSeniorSecuredConvertibleNotesPayableStockSettledMember_z40qN0Le85E5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2025 Series Senior Secured Convertible Notes Payable – Stock Settled</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,126,623</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,737,013</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--TwoThousandTwentyFiveSeriesSeniorSecuredConvertibleNotesPayableStockSettledWarrantsIssuableMember_zRW7f29QURyl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2025 Series Senior Secured Convertible Notes Payable – Stock Settled – warrants issuable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,488,637</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,215,909</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesAOneConvertiblePreferredStockMember_zSrtVvCPKQMf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Series A-1 Convertible Preferred Stock</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">645,325</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0897">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zSxhwD15OSgd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">7,313,347</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">6,178,547</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A6_z70WSyqO4xN8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_849_eus-gaap--InventoryPolicyTextBlock_z0dH8oDYXCZ4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Inventory</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_897_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zMJXYpdjdS61" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventories, consisting of raw materials and finished goods, are stated at the lower of cost (using the specific identification method) or net realizable value. Inventories consisted of the following at the balance sheet dates:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B3_zPjrCHMwj8pb" style="display: none">SCHEDULE OF INVENTORIES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20260430_z5I5uJYQeq6d" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">April 30, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20251031_zt1V6ZTmNm7i" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">October 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr id="xdx_403_eus-gaap--InventoryFinishedGoodsNetOfReserves_iI_maINzybn_zV63rUD2UlL3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left; padding-bottom: 1pt">Finished Goods</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">138,919</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">134,833</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--InventoryNet_iTI_mtINzybn_zuxWtP9UmcRa" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total inventory</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">138,919</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">134,833</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AA_zSJCb8iD8jS2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company periodically reviews the value of items in inventory and provides write-downs or write-offs of inventory based on its assessment of market conditions. During the three and six months ended April 30, 2026 and 2025, the Company recorded $<span id="xdx_90B_eus-gaap--AssetImpairmentCharges_dxL_c20260201__20260430_zk2cqPHbNhE2" title="Impairment expense::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0912">0 </span></span>and $<span id="xdx_903_eus-gaap--AssetImpairmentCharges_c20251101__20260430_z31obStaYcU1" title="Impairment expense">99,700</span>, and $<span id="xdx_906_eus-gaap--AssetImpairmentCharges_dxL_c20250201__20250430_zoRaIJ8FLn13" title="Impairment expense::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0916">0</span></span> and $<span id="xdx_902_eus-gaap--AssetImpairmentCharges_dxL_c20241101__20250430_zcoGKZqMgX2h" title="Impairment expense::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0918">0</span></span> in impairment expense, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84D_ecustom--PatentsPolicyTextBlock_zc2rz4NXSXB1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Patents</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs related to filing and pursuing patent applications (including direct application fees, and the legal and consulting expenses related to making such applications) are capitalized as incurred and will not be amortized until a patent is granted at which time they will be amortized. Capitalized patent costs recorded as of April 30, 2026 and October 31, 2025 were $<span id="xdx_909_ecustom--CapitalizedPatentCosts_iI_c20260430_zgAA1uKOUO41" title="Capitalized patent costs">163,827</span> and $<span id="xdx_907_ecustom--CapitalizedPatentCosts_iI_c20251031_zOZNQvQ0e4f" title="Capitalized patent costs">156,631</span> respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84D_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zWrjD6yPh5K8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Property and Equipment</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property, equipment, and leasehold improvements are recorded at historical cost. The cost of property and equipment is depreciated over the estimated useful lives, when placed in service (ranging from <span id="xdx_900_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20260430__srt--RangeAxis__srt--MinimumMember_z3ePsjnDKEQl" title="Property and equipment useful life">3</span>-<span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20260430__srt--RangeAxis__srt--MaximumMember_zXbfsOmUGjag" title="Property and equipment useful life">5</span> years), of the related assets utilizing the straight-line method of depreciation. The cost of leasehold improvements is depreciated (amortized) over the lesser of the length of the related leases or the estimated useful lives of the assets. Ordinary repairs and maintenance are expensed when incurred and major repairs are capitalized and expensed if they benefit future periods.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_zT4MNTGgT2e1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Intangible Assets and Impairment</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible assets that are subject to amortization are reviewed for potential impairment whenever events or circumstances indicate that carrying amounts may not be recoverable. Assets not subject to amortization are tested for impairment at least annually.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company periodically reviews its intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable. The Company recognizes an impairment loss when the sum of expected undiscounted future cash flows is less that the carrying amount of the asset. The amount of impairment is measured as the difference between the asset’s estimated fair value and its book value.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_849_eus-gaap--GoodwillAndIntangibleAssetsPolicyTextBlock_zIeyG2l9ksG9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Goodwill</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Goodwill is the excess of acquisition cost over the fair value of the net assets of acquired businesses. The Company does not amortize goodwill but assesses goodwill for impairment at least annually or when there has been a material change in circumstances, using the market approach.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_840_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zVth9LaSMuu4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock Based Compensation</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for expenses associated with shares issued for services using the fair value method following the guidance outlined in Section 718-10 of the FASB ASC for disclosure about stock-based compensation. This section requires a public entity to measure the cost of employee and non-employee services received in exchange for an award of equity instruments based on the grant date fair value of the award (with limited exceptions). That cost is recognized over the period during which the service is provided. No compensation cost is recognized for equity instruments for which service is not provided or rendered.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_846_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zqwcXZnU9Ckf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recent Accounting Standards</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2023, the FASB issued ASU 2023-09, Income Taxes: Improvements to Income Tax Disclosures, which applies to all public business entities. This standard is effective for annual reporting periods beginning after December 15, 2024, with early adoption permitted. The Company will adopt this standard for the period ending October 31, 2026.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In November 2024, the FASB issued ASU 2024-03, Disaggregation of Income Statement Expenses (DISE), which applies to all public business entities. This standard is effective for annual reporting periods beginning after December 15, 2026, with early adoption permitted.</span></p> <p id="xdx_851_zD8ago3wDwz9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zV5Qzmyp6Ral" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basis of Presentation</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The interim consolidated financial statements included herein have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and note disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) have been condensed or omitted pursuant to such rules and regulations, although the Company believes that the disclosures included herein are adequate to make the information presented not misleading. These interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended October 31, 2025, as filed with the SEC (“Form 10-K”). Unless otherwise noted in this Interim Report, there have been no material changes to the disclosures contained in the notes to the audited financial statements for the year ended October 31, 2025, contained in the Form 10-K.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Consolidated Balance Sheet as of October 31, 2025, was derived from the audited financial statements included in the Form 10-K. In management’s opinion, the unaudited interim Consolidated Balance Sheet, Statements of Operations, Statements of Changes in Shareholders’ Deficit and Statements of Cash Flows, contained herein, reflect all adjustments, consisting solely of normal recurring items, which are necessary for the fair presentation of the Company’s financial position, results of operations and cash flows on a basis consistent with that of the Company’s prior audited consolidated financial statements. The results of operations for the interim periods may not be indicative of results to be expected for the full fiscal year. Certain prior period amounts were reclassified to conform to the current presentation on the Consolidated Financial Statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying consolidated financial statements are presented in U.S. dollars in conformity with accounting principles generally accepted in the United States of America (“GAAP”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_841_eus-gaap--ConsolidationPolicyTextBlock_zsJHYHYVFpei" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basis of Consolidation</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The consolidated financial statements include the operations of the Company and its wholly owned subsidiary, InfiniVive MD, LLC (“InfiniVive”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84E_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zlIqYVKjl1Fg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Reclassifications</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain amounts in the prior period have been reclassified to conform with current period presentation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_849_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zCMi4om0n3c3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cash Equivalents</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the purposes of the Balance Sheets and Statements of Cash Flows, the Company considers all highly liquid debt instruments purchased with an original maturity of three months or less to be cash equivalents.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84E_eus-gaap--ConcentrationRiskCreditRisk_zzAv510yp4la" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Concentration of Credit Risk</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which at times, may exceed the Federal depository insurance coverage limits. The Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Concentrations</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the three and six months ended April 30, 2026 and 2025, <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20260201__20260430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--TitleOfIndividualAxis__custom--FormerChiefExecutiveOfficerAndPresidentMember_z51eW5yDHfNl" title="Concentration risk percentage">0</span>% and <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20251101__20260430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--TitleOfIndividualAxis__custom--FormerChiefExecutiveOfficerAndPresidentMember_zWlyAVqzdun5" title="Concentration risk percentage">0</span>%, and <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250201__20250430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--TitleOfIndividualAxis__custom--FormerChiefExecutiveOfficerAndPresidentMember_zaav4CFpfmPf" title="Concentration risk percentage">0</span>% and <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20241101__20250430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--TitleOfIndividualAxis__custom--FormerChiefExecutiveOfficerAndPresidentMember_zcmyFHLuly3" title="Concentration risk percentage">2</span>% respectively, of the Company’s total revenues were derived from sales to an entity controlled by the Company’s former Chief Executive Officer and President, Dr. Jack Zamora (“Dr. Zamora”) (Note 10). Dr. Zamora is also a <span id="xdx_908_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20260430__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--JackZamoraMember_zpszeoiQ30fc" title="Ownership percentage">29</span>% stockholder. During the three months ended April 30, 2026, <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20260201__20260430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerOneMember_zl4E5NOWd1Nh" title="Concentration risk percentage">25%</span> and <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20260201__20260430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerTwoMember_zGjaP4KnFfgb" title="Concentration risk percentage">12%</span> of the Company’s total revenue was attributable to product sales to two customers. During the three months ended April 30, 2025, two customers accounted for <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250201__20250430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerOneMember_zsDhG5EAHkw3" title="Concentration risk percentage">33%</span> and <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250201__20250430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerTwoMember_zXYTfEwUSjVf" title="Concentration risk percentage">24%</span> of the Company’s revenues. Other than the revenues derived through sales to the customers referenced herein, no customer accounted for greater than 10% of the Company’s gross sales for the three months ended April 30, 2026 or 2025. During the six months ended April 30, 2026, <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20251101__20260430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerOneMember_z75dmqqgnBCd" title="Concentration risk percentage">28</span>%, <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20251101__20260430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerTwoMember_z67KzXUgxCr6" title="Concentration risk percentage">13</span>% and <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20251101__20260430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerThreeMember_zlFj6Jg0Rhvk" title="Concentration risk percentage">11</span>% of the Company’s total revenue was attributable to product sales to three customers. During the six months ended April 30, 2025, two customers accounted for <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20241101__20250430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--TitleOfIndividualAxis__custom--CustomerOneMember_zGILEkppjq72" title="Concentration risk percentage">36</span>% and <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20241101__20250430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--TitleOfIndividualAxis__custom--CustomerTwoMember_zAI9InP8LCj1" title="Concentration risk percentage">22</span>% of the Company’s revenues. Other than the revenues derived through sales to the customers referenced herein, no customer accounted for greater than 10% of the Company’s gross sales for the six months ended April 30, 2026 or 2025.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of April 30, 2026, two customers accounted for <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20251101__20260430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--TitleOfIndividualAxis__custom--CustomerOneMember_zesyFydxEzTh" title="Concentration risk percentage">26</span>% and <span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20251101__20260430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--TitleOfIndividualAxis__custom--CustomerTwoMember_znEhjnCtkAb5" title="Concentration risk percentage">10</span>% of total accounts receivable, respectively. No other customer accounted for more than 10% of total accounts receivable. As of April 30, 2026, Dr. Zamora accounted for <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20251101__20260430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--TitleOfIndividualAxis__custom--FormerChiefExecutiveOfficerAndPresidentMember_zGQ3B6HeVhbf" title="Concentration risk percentage">0</span>% of accounts receivable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the three and six months ended April 30, 2026 and 2025, foreign purchasers accounted for <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20260201__20260430__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--ForeignVendorMember_zPE4KnpJGLci" title="Concentration risk percentage">86</span>% and <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20251101__20260430__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--ForeignVendorMember_z9ZQmCEMzqWe" title="Concentration risk percentage">50</span>%, and <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250201__20250430__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--ForeignVendorMember_z5u4SgQPeO6f" title="Concentration risk percentage">72</span>% and <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20241101__20250430__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--ForeignVendorMember_zj2e6fPrmusd" title="Concentration risk percentage">68</span>% of total revenues, respectively. All sales to foreign customers were conducted in US Dollars.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 0 0 0 0.02 0.29 0.25 0.12 0.33 0.24 0.28 0.13 0.11 0.36 0.22 0.26 0.10 0 0.86 0.50 0.72 0.68 <p id="xdx_843_eus-gaap--FairValueOfFinancialInstrumentsPolicy_z4jCrMyaN2yj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financial Instruments</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value of the Company’s assets and liabilities, which qualify as financial instruments under Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) 820, “Fair Value Measurements and Disclosures,” approximates the carrying amounts represented in the balance sheets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_841_eus-gaap--UseOfEstimates_zk60Z6n1p5dh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Use of Estimates</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_eus-gaap--RevenueRecognitionPolicyTextBlock_z5l9zdlL9N91" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Revenue Recognition</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of January 1, 2018, the Company adopted Revenue from Contracts with Customers (Topic 606) (“ASC 606”). The new guidance sets forth a new five-step revenue recognition model which replaces the prior revenue recognition guidance in its entirety and is intended to eliminate numerous industry-specific pieces of revenue recognition guidance that have historically existed in GAAP. The underlying principle of the new standard is that a business or other organization will recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects what it expects to receive in exchange for the goods or services. To determine the appropriate amount of revenue to be recognized for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following steps: (i) identify the contract(s) with the customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract and (v) recognize revenue when (or as) each performance obligation is satisfied. The Company adopted the standard using the modified retrospective method and the adoption did not have a material impact on the Company’s consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For each performance obligation identified in accordance with ASC 606, the Company determines at contract inception whether it satisfies the performance obligation over time (in accordance with paragraphs 606-10-25-27 through 25-29) or satisfies the performance obligation at a point in time (in accordance with paragraph 606-10-25-30). If an entity does not satisfy a performance obligation over time, the performance obligation is satisfied at a point in time.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Control is considered transferred over time if any one of the following criteria is met:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The customer simultaneously receives and consumes the benefits of the asset or service which the entity performs;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The entity’s performance creates or enhances an asset; or</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The entity’s performance creates or enhances an asset that has no alternative use to the entity and the entity has the right to payment for work completed to date.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For certain contracts to which the Company is party, it uses the recognition over time method to recognize revenue.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognizes revenue when performance obligations with the customer are satisfied. Product sales occur once control is transferred upon shipment to the customer at the time of the sale. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring goods and services. The Company’s revenue is primarily derived from the sources listed below:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Sale of research and development product</i></b>: <i>Sales of research and development product include the sale of stem cell medium</i>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Sale of therapeutic product: </i></b><i>Includes cell culture media to be used in therapeutic treatment, i.e. sales to Foreign Third-Party Clinics.</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Shipping: </i></b><i>Includes amounts charged to customers for shipping products. These amounts are included with the various types of revenue described in the table below.</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Fitore product sales online: </i></b><i>Includes internet sales, via the Fitore Nutrition website, of dietary supplements called Stemulife, Spectrum+, Easy Sleep and Thought Calmer. The Company stopped selling Fitore products in March 2025.</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>InfiniVive product sales: </i></b><i>InfiniVive, via call-in and online orders, sells exosomes and daily cosmetic serum</i>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Disaggregation of revenue</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_895_eus-gaap--DisaggregationOfRevenueTableTextBlock_zM1UdTeMVtp9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following tables summarize the Company’s revenue for the reporting periods, disaggregated by product or service type:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B0_zAQ9pmoPy8Dc" style="display: none">SCHEDULE OF DISAGGREGATION OF REVENUE</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20260201__20260430_zDLj8p4Ri7I8" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Three Months</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ended<br/> April 30, 2026</b></span></p></td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20250201__20250430_zWmKuVwjd169" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Three Months</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ended<br/> April 30, 2025</b></span></p></td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Revenues:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--ResearchAndDevelopmentProductsMember_zNP4HdPS0pvl" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 60%; text-align: left">Research and development products</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">164,797</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">122,328</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--AlloRxStemCellsToForeignThirdPartyClinicsMember_zD7flPdzMrM1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">AlloRx Stem Cells to Foreign Third-Party Clinics</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">101,780</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">365,825</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--InfiniViveProductsMember_zrJD6P6XBbsd" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">InfiniVive products</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">179,718</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">22,449</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--FitoreProductsMember_zRiZ4bTbCZDi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Fitore products</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0764">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">982</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zegnkYeVsa08" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">446,295</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">511,584</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following tables summarize the Company’s revenue for the reporting periods, disaggregated by product or service type:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20251101__20260430_zFMX7Oxrnm6f" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Six Months</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ended<br/> April 30, 2026</b></span></p></td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20241101__20250430_zlCDJQLyk1X7" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Six Months</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ended<br/> April 30, 2025</b></span></p></td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Revenues:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--ResearchAndDevelopmentProductsMember_zO8af2X19bjl" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 60%; text-align: left">Research and development products</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">248,517</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">239,898</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--AlloRxStemCellsToForeignThirdPartyClinicsMember_zPXtVwJxPSBa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">AlloRx Stem Cells to Foreign Third-Party Clinics</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">486,056</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">649,266</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--InfiniViveProductsMember_zAi9baANXn43" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">InfiniVive products</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">241,139</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">69,387</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--FitoreProductsMember_zljdCcCpN1Oa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Fitore products</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0779">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,907</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_z8Ho8H4ybmRi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">975,712</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">961,458</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A2_zYdqgxvcvh9k" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_895_eus-gaap--DisaggregationOfRevenueTableTextBlock_zM1UdTeMVtp9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following tables summarize the Company’s revenue for the reporting periods, disaggregated by product or service type:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B0_zAQ9pmoPy8Dc" style="display: none">SCHEDULE OF DISAGGREGATION OF REVENUE</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20260201__20260430_zDLj8p4Ri7I8" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Three Months</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ended<br/> April 30, 2026</b></span></p></td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20250201__20250430_zWmKuVwjd169" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Three Months</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ended<br/> April 30, 2025</b></span></p></td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Revenues:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--ResearchAndDevelopmentProductsMember_zNP4HdPS0pvl" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 60%; text-align: left">Research and development products</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">164,797</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">122,328</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--AlloRxStemCellsToForeignThirdPartyClinicsMember_zD7flPdzMrM1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">AlloRx Stem Cells to Foreign Third-Party Clinics</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">101,780</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">365,825</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--InfiniViveProductsMember_zrJD6P6XBbsd" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">InfiniVive products</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">179,718</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">22,449</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--FitoreProductsMember_zRiZ4bTbCZDi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Fitore products</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0764">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">982</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zegnkYeVsa08" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">446,295</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">511,584</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following tables summarize the Company’s revenue for the reporting periods, disaggregated by product or service type:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20251101__20260430_zFMX7Oxrnm6f" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Six Months</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ended<br/> April 30, 2026</b></span></p></td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20241101__20250430_zlCDJQLyk1X7" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Six Months</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ended<br/> April 30, 2025</b></span></p></td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Revenues:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--ResearchAndDevelopmentProductsMember_zO8af2X19bjl" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 60%; text-align: left">Research and development products</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">248,517</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">239,898</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--AlloRxStemCellsToForeignThirdPartyClinicsMember_zPXtVwJxPSBa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">AlloRx Stem Cells to Foreign Third-Party Clinics</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">486,056</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">649,266</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--InfiniViveProductsMember_zAi9baANXn43" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">InfiniVive products</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">241,139</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">69,387</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--FitoreProductsMember_zljdCcCpN1Oa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Fitore products</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0779">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,907</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_z8Ho8H4ybmRi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">975,712</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">961,458</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 164797 122328 101780 365825 179718 22449 982 446295 511584 248517 239898 486056 649266 241139 69387 2907 975712 961458 <p id="xdx_841_ecustom--DeferredRevenuePolicyTextBlock_zbhCAnfFzsz" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Deferred Revenue</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has recorded deferred revenue in connection with a Joint Operating Agreement (as subsequently amended, the “JOA”) executed between the Company and European Wellness/BIO PEP USA (“BIO PEP”). Pursuant to this JOA, which expired in accordance with its terms on July 31, 2023 and has not been renewed, the Company was obligated to use its best efforts to identify, develop and deliver various potential active pharmaceutical ingredients and to oversee the development of a recombinant cell line by a third-party service provider. The Company was also engaged to establish a Quality Management System to be utilized by BIO PEP in their pursuit of FDA authorizations. Prior to its expiration, our work under the JOA had been suspended since April 2023 pending discussions regarding amounts believed to be owed to us under that agreement for work already completed. If those discussions are unsuccessful, we may not be able to collect all of the amounts believed to be owed to us or the other amounts originally expected to be received by us under the agreement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company records as deferred revenue amounts for which the Company has been paid but for which it has not yet achieved and delivered related milestones or when the level of effort required to complete performance obligations under an arrangement cannot be reasonably estimated under the terms of the related agreement. Deferred revenue is classified as current or long-term based on when management estimates the revenue will be recognized. As of October 31, 2025 and April 30, 2026, the Company has net deferred $<span id="xdx_905_eus-gaap--DeferredRevenueCurrent_iI_c20260430_zZQsFAluD60a" title="Deferred revenue"><span id="xdx_90A_eus-gaap--DeferredRevenueCurrent_iI_c20251031_zcyat8uBNf94" title="Deferred revenue">525,387</span></span> in revenue, which is composed of $<span id="xdx_90A_eus-gaap--DeferredIncomeCurrent_iI_c20251031_ze1LjADjHaJi" title="Composed of deferred revenue"><span id="xdx_901_eus-gaap--DeferredIncomeCurrent_iI_c20260430_zhv9eR6BeUt6" title="Composed of deferred revenue">685,005</span></span> of deferred revenue, less $<span id="xdx_902_ecustom--PrepaidProjectCosts_iI_c20251031_z2gt09NYGyS6" title="Prepaid project cost"><span id="xdx_905_ecustom--PrepaidProjectCosts_iI_c20260430_zwMMtofz6e7h" title="Prepaid project cost">159,618</span></span> of prepaid project costs. The amount recorded as net deferred revenue will be recognized if and when the Company achieves and delivers the milestones under the terms of the agreement. The Company did not recognize any of this net deferred revenue during the three and six months ended April 30, 2026 and 2025.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_899_ecustom--ScheduleOfDeferredRevenueTableTextBlock_zpgKm7grYJ2k" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The table below summarizes Deferred Revenues as of April 30, 2026:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B2_zaVNPOu1CC2d" style="display: none">SUMMARY OF DEFERRED REVENUES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">October 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Project</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Income</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recognized</b></span></p></td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Net Revenue Deferred</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">April 30, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%; text-align: justify; padding-bottom: 1pt">Deferred Revenue</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--DeferredRevenue_iS_c20251101__20260430__us-gaap--RegulatoryLiabilityAxis__custom--DeferredRevenueMember_zxBXHIkfJVq6" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Deferred Revenue Beginning">525,387</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--OtherIncome_iN_di_c20251101__20260430__us-gaap--RegulatoryLiabilityAxis__custom--DeferredRevenueMember_zRgEPomJ3AKg" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Other Project Income Recognized"><span style="-sec-ix-hidden: xdx2ixbrl0803">-</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--DeferredRevenueRevenueRecognized1_c20251101__20260430__us-gaap--RegulatoryLiabilityAxis__custom--DeferredRevenueMember_zaN7zJ8OV5Y6" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Revenue Deferred"><span style="-sec-ix-hidden: xdx2ixbrl0805">-</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--DeferredRevenue_iE_c20251101__20260430__us-gaap--RegulatoryLiabilityAxis__custom--DeferredRevenueMember_zF4lLbxZk2Uk" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Deferred Revenue Ending">525,387</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--DeferredRevenue_iS_c20251101__20260430_zMTT1zM3g3ya" style="border-bottom: Black 2.5pt double; text-align: right" title="Deferred Revenue Beginning">525,387</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--OtherIncome_iN_di_c20251101__20260430_zlNBeC1xbswg" style="border-bottom: Black 2.5pt double; text-align: right" title="Other Project Income Recognized"><span style="-sec-ix-hidden: xdx2ixbrl0811">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--DeferredRevenueRevenueRecognized1_c20251101__20260430_zQMIuCQ27k8k" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue Deferred"><span style="-sec-ix-hidden: xdx2ixbrl0813">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--DeferredRevenue_iE_c20251101__20260430_zwcH4HNNcJni" style="border-bottom: Black 2.5pt double; text-align: right" title="Deferred Revenue Ending">525,387</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The table below summarizes Deferred Revenues as of October 31, 2025:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">October 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Project</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Income</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recognized</b></span></p></td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Net Revenue Deferred</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">October 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%; text-align: justify; padding-bottom: 1pt">Deferred Revenue</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--DeferredRevenue_iS_c20241101__20251031__us-gaap--RegulatoryLiabilityAxis__custom--DeferredRevenueMember_z4D9SmIJrtv9" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Deferred Revenue Beginning">525,387</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--OtherIncome_iN_di_c20241101__20251031__us-gaap--RegulatoryLiabilityAxis__custom--DeferredRevenueMember_zOsmcYG9B3ol" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Other Project Income Recognized"><span style="-sec-ix-hidden: xdx2ixbrl0819">-</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--DeferredRevenueRevenueRecognized1_c20241101__20251031__us-gaap--RegulatoryLiabilityAxis__custom--DeferredRevenueMember_zdefCLrDZgi7" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Revenue Deferred"><span style="-sec-ix-hidden: xdx2ixbrl0821">-</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--DeferredRevenue_iE_c20241101__20251031__us-gaap--RegulatoryLiabilityAxis__custom--DeferredRevenueMember_z7saJdk5gvS6" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Deferred Revenue Ending">525,387</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--DeferredRevenue_iS_c20241101__20251031_z7Oiisn0T9Sk" style="border-bottom: Black 2.5pt double; text-align: right" title="Deferred Revenue Beginning">525,387</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--OtherIncome_iN_di_c20241101__20251031_zHBfUuYHOWxb" style="border-bottom: Black 2.5pt double; text-align: right" title="Other Project Income Recognized"><span style="-sec-ix-hidden: xdx2ixbrl0827">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--DeferredRevenueRevenueRecognized1_c20241101__20251031_zHKrXPrArKd9" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue Deferred"><span style="-sec-ix-hidden: xdx2ixbrl0829">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--DeferredRevenue_iE_c20241101__20251031_zn7cEHakm7X6" style="border-bottom: Black 2.5pt double; text-align: right" title="Deferred Revenue Ending">525,387</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A9_zjB7A5ylbUA7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 525387 525387 685005 685005 159618 159618 <p id="xdx_899_ecustom--ScheduleOfDeferredRevenueTableTextBlock_zpgKm7grYJ2k" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The table below summarizes Deferred Revenues as of April 30, 2026:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B2_zaVNPOu1CC2d" style="display: none">SUMMARY OF DEFERRED REVENUES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">October 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Project</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Income</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recognized</b></span></p></td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Net Revenue Deferred</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">April 30, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%; text-align: justify; padding-bottom: 1pt">Deferred Revenue</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--DeferredRevenue_iS_c20251101__20260430__us-gaap--RegulatoryLiabilityAxis__custom--DeferredRevenueMember_zxBXHIkfJVq6" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Deferred Revenue Beginning">525,387</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--OtherIncome_iN_di_c20251101__20260430__us-gaap--RegulatoryLiabilityAxis__custom--DeferredRevenueMember_zRgEPomJ3AKg" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Other Project Income Recognized"><span style="-sec-ix-hidden: xdx2ixbrl0803">-</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--DeferredRevenueRevenueRecognized1_c20251101__20260430__us-gaap--RegulatoryLiabilityAxis__custom--DeferredRevenueMember_zaN7zJ8OV5Y6" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Revenue Deferred"><span style="-sec-ix-hidden: xdx2ixbrl0805">-</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--DeferredRevenue_iE_c20251101__20260430__us-gaap--RegulatoryLiabilityAxis__custom--DeferredRevenueMember_zF4lLbxZk2Uk" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Deferred Revenue Ending">525,387</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--DeferredRevenue_iS_c20251101__20260430_zMTT1zM3g3ya" style="border-bottom: Black 2.5pt double; text-align: right" title="Deferred Revenue Beginning">525,387</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--OtherIncome_iN_di_c20251101__20260430_zlNBeC1xbswg" style="border-bottom: Black 2.5pt double; text-align: right" title="Other Project Income Recognized"><span style="-sec-ix-hidden: xdx2ixbrl0811">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--DeferredRevenueRevenueRecognized1_c20251101__20260430_zQMIuCQ27k8k" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue Deferred"><span style="-sec-ix-hidden: xdx2ixbrl0813">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--DeferredRevenue_iE_c20251101__20260430_zwcH4HNNcJni" style="border-bottom: Black 2.5pt double; text-align: right" title="Deferred Revenue Ending">525,387</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The table below summarizes Deferred Revenues as of October 31, 2025:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">October 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Project</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Income</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recognized</b></span></p></td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Net Revenue Deferred</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">October 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%; text-align: justify; padding-bottom: 1pt">Deferred Revenue</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--DeferredRevenue_iS_c20241101__20251031__us-gaap--RegulatoryLiabilityAxis__custom--DeferredRevenueMember_z4D9SmIJrtv9" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Deferred Revenue Beginning">525,387</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--OtherIncome_iN_di_c20241101__20251031__us-gaap--RegulatoryLiabilityAxis__custom--DeferredRevenueMember_zOsmcYG9B3ol" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Other Project Income Recognized"><span style="-sec-ix-hidden: xdx2ixbrl0819">-</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--DeferredRevenueRevenueRecognized1_c20241101__20251031__us-gaap--RegulatoryLiabilityAxis__custom--DeferredRevenueMember_zdefCLrDZgi7" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Revenue Deferred"><span style="-sec-ix-hidden: xdx2ixbrl0821">-</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--DeferredRevenue_iE_c20241101__20251031__us-gaap--RegulatoryLiabilityAxis__custom--DeferredRevenueMember_z7saJdk5gvS6" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Deferred Revenue Ending">525,387</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--DeferredRevenue_iS_c20241101__20251031_z7Oiisn0T9Sk" style="border-bottom: Black 2.5pt double; text-align: right" title="Deferred Revenue Beginning">525,387</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--OtherIncome_iN_di_c20241101__20251031_zHBfUuYHOWxb" style="border-bottom: Black 2.5pt double; text-align: right" title="Other Project Income Recognized"><span style="-sec-ix-hidden: xdx2ixbrl0827">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--DeferredRevenueRevenueRecognized1_c20241101__20251031_zHKrXPrArKd9" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue Deferred"><span style="-sec-ix-hidden: xdx2ixbrl0829">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--DeferredRevenue_iE_c20241101__20251031_zn7cEHakm7X6" style="border-bottom: Black 2.5pt double; text-align: right" title="Deferred Revenue Ending">525,387</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 525387 525387 525387 525387 525387 525387 525387 525387 <p id="xdx_847_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zNLwO4SzF5n6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Accounts Receivable</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts receivable consists of amounts due from customers. The Company considers accounts more than 30 days old to be past due. The Company uses the current expected credit loss method for recognizing bad debts. When an account is deemed uncollectible, it is written off against the allowance. The Company generally does not require collateral for its accounts receivable. As of April 30, 2026 and October 31, 2025, total accounts receivable, including related party amounts of $<span id="xdx_90B_eus-gaap--AccountsReceivableNet_iI_c20260430__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zQEQRRDLG4N6" title="Accounts receivables">0</span> and $<span id="xdx_902_eus-gaap--AccountsReceivableNet_iI_c20251031__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zX8fpxUGIy2" title="Accounts receivables">2,250</span>, amounted to $<span id="xdx_90D_eus-gaap--AccountsReceivableNet_iI_c20260430__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_zxKygm9VO442" title="Accounts receivables">62,244</span> and $<span id="xdx_902_eus-gaap--AccountsReceivableNet_iI_c20251031__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_zhzfYDxKkXS9" title="Accounts receivables">82,776</span>, respectively, net of allowances. The Company monitors accounts receivable for collectability and when doubt as to the realization of amounts recorded arises, an allowance is recorded and/or accounts deemed to be uncollectible will be written off. As of April 30, 2026 and October 31, 2025, the allowance for credit losses was $<span id="xdx_90A_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_c20260430_zsSUM8PMeLrf" title="Allowance for doubtful accounts receivable">0</span> and $<span id="xdx_90E_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_c20251031_zy89EhsbyArj" title="Allowance for doubtful accounts receivable">0</span>, respectively. No bad debt expense was recognized during the six months ended April 30, 2026 and 2025.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of April 30, 2026, two customers accounted for <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20251101__20260430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--AccountsReceivablesMember__srt--TitleOfIndividualAxis__custom--CustomerOneMember_z1BGDZAYe5gd" title="Concentration risk percentage">26</span>% and <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20251101__20260430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--AccountsReceivablesMember__srt--TitleOfIndividualAxis__custom--CustomerTwoMember_zu1cIKwdTvKg" title="Concentration risk percentage">10</span>% of accounts receivable. As of October 31, 2025, <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20241101__20251031__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--AccountsReceivablesMember__srt--TitleOfIndividualAxis__custom--CustomerOneMember_zs17EFAyZxTk" title="Concentration risk percentage">36</span>% of the Company’s accounts receivable were attributable to sales to one customer. No other customer comprised more than 10% of the accounts receivable balance as of April 30, 2026 or October 31, 2025.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span> </p> 0 2250 62244 82776 0 0 0.26 0.10 0.36 <p id="xdx_84C_eus-gaap--EarningsPerSharePolicyTextBlock_zQFaLTjToDG8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basic Loss Per Share</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company complies with accounting and disclosure requirements ASC Topic 260, “Earnings Per Share.” Basic net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share takes into consideration shares of common stock outstanding (computed under basic income or loss per share) and potentially dilutive shares of common stock that are not anti-dilutive. For the six months ended April 30, 2026 and 2025, the following number of potentially dilutive shares have been excluded from diluted net loss since such inclusion would be anti-dilutive:</span></p> <p id="xdx_897_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zLY2foc8QXFf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B0_zMimpd0A1FQb" style="display: none">SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED EARNINGS PER SHARE</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20251101__20260430_zN9gV2Y68RWd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">April 30, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_493_20241101__20250430_z32vJ95skjaa" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">April 30, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td></tr> <tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_z6U1sbHl4Zzg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: justify">Stock options outstanding</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">1,028,308</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">1,112,923</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zFVJVRnBzu1j" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Shares to be issued in connection with exercise of warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">149,727</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">215,881</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--TwoThousandTwentyTwoSeriesConvertibleNotesPayableCommonSharesMember_zU8dyDdptWm8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2022 Series Convertible Notes Payable - common shares</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,692</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,692</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--TwoThousandTwentyThreeSeriesConvertibleNotesPayableStockSettlementMember_zRmJTF6wXtC9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2023 Series Convertible Notes Payable – Stock Settled</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">34,142</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">31,984</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--TwoThousandTwentyThreeSeriesConvertibleNotesPayableStockSettledWarrantsIssuableMember_zh9LZ90qJAU3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2023 Series Convertible Notes Payable – Stock Settled - warrants issuable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,076</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,076</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--TwoThousandTwentyThreeSeriesBConvertibleNotesPayableStockSettledMember_zdiY2hxHZLAg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2023 Series B Convertible Notes Payable - Stock Settled</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">108,520</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">101,522</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--TwoThousandTwentyThreeSeriesBConvertibleNotesPayableStockSettledWarrantsIssuableMember_zptatoXNt2i8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2023 Series B Convertible Notes Payable - Stock Settled - warrants issuable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">39,881</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">39,881</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--TwoThousandTwentyFourSeriesSeniorSecuredConvertibleNotesPayableStockSettledMember_zMcQDh8zsl5j" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2024 Series Senior Secured Convertible Notes Payable – Stock Settled</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,333</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">39,583</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--TwoThousandTwentyFourSeriesSeniorSecuredConvertibleNotesPayableStockSettledWarrantsIssuableMember_zgoKzyq9SoTj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2024 Series Senior Secured Convertible Notes Payable – Stock Settled – warrants issuable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">289,583</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">289,583</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--TwoThousandTwentyFourPrefundedWarrantsMember_zfhLIbiwE3q" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2024 Pre-funded Warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,107,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,107,500</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--TwoThousandTwentyFivePrefundedWarrantsMember_z5ZdP11Zlgjc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2025 Pre-funded Warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">276,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">276,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--TwoThousandTwentyFiveSeriesSeniorSecuredConvertibleNotesPayableStockSettledMember_z40qN0Le85E5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2025 Series Senior Secured Convertible Notes Payable – Stock Settled</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,126,623</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,737,013</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--TwoThousandTwentyFiveSeriesSeniorSecuredConvertibleNotesPayableStockSettledWarrantsIssuableMember_zRW7f29QURyl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2025 Series Senior Secured Convertible Notes Payable – Stock Settled – warrants issuable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,488,637</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,215,909</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesAOneConvertiblePreferredStockMember_zSrtVvCPKQMf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Series A-1 Convertible Preferred Stock</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">645,325</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0897">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zSxhwD15OSgd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">7,313,347</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">6,178,547</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A6_z70WSyqO4xN8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_897_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zLY2foc8QXFf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B0_zMimpd0A1FQb" style="display: none">SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED EARNINGS PER SHARE</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20251101__20260430_zN9gV2Y68RWd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">April 30, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_493_20241101__20250430_z32vJ95skjaa" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">April 30, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td></tr> <tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_z6U1sbHl4Zzg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: justify">Stock options outstanding</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">1,028,308</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">1,112,923</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zFVJVRnBzu1j" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Shares to be issued in connection with exercise of warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">149,727</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">215,881</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--TwoThousandTwentyTwoSeriesConvertibleNotesPayableCommonSharesMember_zU8dyDdptWm8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2022 Series Convertible Notes Payable - common shares</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,692</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,692</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--TwoThousandTwentyThreeSeriesConvertibleNotesPayableStockSettlementMember_zRmJTF6wXtC9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2023 Series Convertible Notes Payable – Stock Settled</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">34,142</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">31,984</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--TwoThousandTwentyThreeSeriesConvertibleNotesPayableStockSettledWarrantsIssuableMember_zh9LZ90qJAU3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2023 Series Convertible Notes Payable – Stock Settled - warrants issuable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,076</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,076</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--TwoThousandTwentyThreeSeriesBConvertibleNotesPayableStockSettledMember_zdiY2hxHZLAg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2023 Series B Convertible Notes Payable - Stock Settled</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">108,520</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">101,522</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--TwoThousandTwentyThreeSeriesBConvertibleNotesPayableStockSettledWarrantsIssuableMember_zptatoXNt2i8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2023 Series B Convertible Notes Payable - Stock Settled - warrants issuable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">39,881</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">39,881</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--TwoThousandTwentyFourSeriesSeniorSecuredConvertibleNotesPayableStockSettledMember_zMcQDh8zsl5j" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2024 Series Senior Secured Convertible Notes Payable – Stock Settled</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,333</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">39,583</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--TwoThousandTwentyFourSeriesSeniorSecuredConvertibleNotesPayableStockSettledWarrantsIssuableMember_zgoKzyq9SoTj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2024 Series Senior Secured Convertible Notes Payable – Stock Settled – warrants issuable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">289,583</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">289,583</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--TwoThousandTwentyFourPrefundedWarrantsMember_zfhLIbiwE3q" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2024 Pre-funded Warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,107,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,107,500</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--TwoThousandTwentyFivePrefundedWarrantsMember_z5ZdP11Zlgjc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2025 Pre-funded Warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">276,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">276,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--TwoThousandTwentyFiveSeriesSeniorSecuredConvertibleNotesPayableStockSettledMember_z40qN0Le85E5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2025 Series Senior Secured Convertible Notes Payable – Stock Settled</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,126,623</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,737,013</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--TwoThousandTwentyFiveSeriesSeniorSecuredConvertibleNotesPayableStockSettledWarrantsIssuableMember_zRW7f29QURyl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2025 Series Senior Secured Convertible Notes Payable – Stock Settled – warrants issuable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,488,637</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,215,909</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesAOneConvertiblePreferredStockMember_zSrtVvCPKQMf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Series A-1 Convertible Preferred Stock</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">645,325</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0897">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zSxhwD15OSgd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">7,313,347</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">6,178,547</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 1028308 1112923 149727 215881 7692 7692 34142 31984 3076 3076 108520 101522 39881 39881 8333 39583 289583 289583 1107500 1107500 276000 276000 2126623 1737013 1488637 1215909 645325 7313347 6178547 <p id="xdx_849_eus-gaap--InventoryPolicyTextBlock_z0dH8oDYXCZ4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Inventory</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_897_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zMJXYpdjdS61" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventories, consisting of raw materials and finished goods, are stated at the lower of cost (using the specific identification method) or net realizable value. Inventories consisted of the following at the balance sheet dates:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B3_zPjrCHMwj8pb" style="display: none">SCHEDULE OF INVENTORIES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20260430_z5I5uJYQeq6d" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">April 30, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20251031_zt1V6ZTmNm7i" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">October 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr id="xdx_403_eus-gaap--InventoryFinishedGoodsNetOfReserves_iI_maINzybn_zV63rUD2UlL3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left; padding-bottom: 1pt">Finished Goods</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">138,919</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">134,833</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--InventoryNet_iTI_mtINzybn_zuxWtP9UmcRa" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total inventory</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">138,919</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">134,833</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AA_zSJCb8iD8jS2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company periodically reviews the value of items in inventory and provides write-downs or write-offs of inventory based on its assessment of market conditions. During the three and six months ended April 30, 2026 and 2025, the Company recorded $<span id="xdx_90B_eus-gaap--AssetImpairmentCharges_dxL_c20260201__20260430_zk2cqPHbNhE2" title="Impairment expense::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0912">0 </span></span>and $<span id="xdx_903_eus-gaap--AssetImpairmentCharges_c20251101__20260430_z31obStaYcU1" title="Impairment expense">99,700</span>, and $<span id="xdx_906_eus-gaap--AssetImpairmentCharges_dxL_c20250201__20250430_zoRaIJ8FLn13" title="Impairment expense::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0916">0</span></span> and $<span id="xdx_902_eus-gaap--AssetImpairmentCharges_dxL_c20241101__20250430_zcoGKZqMgX2h" title="Impairment expense::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0918">0</span></span> in impairment expense, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_897_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zMJXYpdjdS61" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventories, consisting of raw materials and finished goods, are stated at the lower of cost (using the specific identification method) or net realizable value. Inventories consisted of the following at the balance sheet dates:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B3_zPjrCHMwj8pb" style="display: none">SCHEDULE OF INVENTORIES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20260430_z5I5uJYQeq6d" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">April 30, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20251031_zt1V6ZTmNm7i" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">October 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr id="xdx_403_eus-gaap--InventoryFinishedGoodsNetOfReserves_iI_maINzybn_zV63rUD2UlL3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left; padding-bottom: 1pt">Finished Goods</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">138,919</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">134,833</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--InventoryNet_iTI_mtINzybn_zuxWtP9UmcRa" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total inventory</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">138,919</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">134,833</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 138919 134833 138919 134833 99700 <p id="xdx_84D_ecustom--PatentsPolicyTextBlock_zc2rz4NXSXB1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Patents</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs related to filing and pursuing patent applications (including direct application fees, and the legal and consulting expenses related to making such applications) are capitalized as incurred and will not be amortized until a patent is granted at which time they will be amortized. Capitalized patent costs recorded as of April 30, 2026 and October 31, 2025 were $<span id="xdx_909_ecustom--CapitalizedPatentCosts_iI_c20260430_zgAA1uKOUO41" title="Capitalized patent costs">163,827</span> and $<span id="xdx_907_ecustom--CapitalizedPatentCosts_iI_c20251031_zOZNQvQ0e4f" title="Capitalized patent costs">156,631</span> respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 163827 156631 <p id="xdx_84D_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zWrjD6yPh5K8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Property and Equipment</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property, equipment, and leasehold improvements are recorded at historical cost. The cost of property and equipment is depreciated over the estimated useful lives, when placed in service (ranging from <span id="xdx_900_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20260430__srt--RangeAxis__srt--MinimumMember_z3ePsjnDKEQl" title="Property and equipment useful life">3</span>-<span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20260430__srt--RangeAxis__srt--MaximumMember_zXbfsOmUGjag" title="Property and equipment useful life">5</span> years), of the related assets utilizing the straight-line method of depreciation. The cost of leasehold improvements is depreciated (amortized) over the lesser of the length of the related leases or the estimated useful lives of the assets. Ordinary repairs and maintenance are expensed when incurred and major repairs are capitalized and expensed if they benefit future periods.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> P3Y P5Y <p id="xdx_847_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_zT4MNTGgT2e1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Intangible Assets and Impairment</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible assets that are subject to amortization are reviewed for potential impairment whenever events or circumstances indicate that carrying amounts may not be recoverable. Assets not subject to amortization are tested for impairment at least annually.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company periodically reviews its intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable. The Company recognizes an impairment loss when the sum of expected undiscounted future cash flows is less that the carrying amount of the asset. The amount of impairment is measured as the difference between the asset’s estimated fair value and its book value.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_849_eus-gaap--GoodwillAndIntangibleAssetsPolicyTextBlock_zIeyG2l9ksG9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Goodwill</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Goodwill is the excess of acquisition cost over the fair value of the net assets of acquired businesses. The Company does not amortize goodwill but assesses goodwill for impairment at least annually or when there has been a material change in circumstances, using the market approach.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_840_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zVth9LaSMuu4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock Based Compensation</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for expenses associated with shares issued for services using the fair value method following the guidance outlined in Section 718-10 of the FASB ASC for disclosure about stock-based compensation. This section requires a public entity to measure the cost of employee and non-employee services received in exchange for an award of equity instruments based on the grant date fair value of the award (with limited exceptions). That cost is recognized over the period during which the service is provided. No compensation cost is recognized for equity instruments for which service is not provided or rendered.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_846_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zqwcXZnU9Ckf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recent Accounting Standards</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2023, the FASB issued ASU 2023-09, Income Taxes: Improvements to Income Tax Disclosures, which applies to all public business entities. This standard is effective for annual reporting periods beginning after December 15, 2024, with early adoption permitted. The Company will adopt this standard for the period ending October 31, 2026.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In November 2024, the FASB issued ASU 2024-03, Disaggregation of Income Statement Expenses (DISE), which applies to all public business entities. This standard is effective for annual reporting periods beginning after December 15, 2026, with early adoption permitted.</span></p> <p id="xdx_803_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_zkYjnv8rrqG9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2 – <span id="xdx_82A_z3av8u1ntgh">GOING CONCERN</span> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying financial statements have been prepared in conformity with GAAP, which contemplate continuation of the Company as a going concern. The Company has incurred net losses of approximately $<span id="xdx_906_eus-gaap--NetIncomeLoss_iN_pn5n6_di_c20251101__20260430_zSrWjXRnan17" title="Net loss">2.7</span> million for the six months ended April 30, 2026. The Company had a working capital deficit of approximately $<span id="xdx_902_ecustom--WorkingCapitalDeficit_iNI_pn5n6_di_c20260430_z0yJOgGEbFOf" title="Working capital deficit">16.3</span> million as of April 30, 2026. In addition, the revenues of the Company do not provide adequate working capital for the Company to sustain its current and planned business operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These factors raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the financial statements are issued. In view of these matters, realization of certain of the assets in the accompanying balance sheets is dependent upon continued operations of the Company, which in turn is dependent upon the Company’s ability to meet its financial requirements, raise additional capital, and generate additional revenues and profit from operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management plans to address the going concern include but are not limited to raising additional capital through an attempted public and/or private offering of equity securities, as well potentially issuing additional debt instruments. The Company also has various initiatives underway to increase revenue generation through diversified offerings of products and services related to its stem cell technology and analytical capabilities. The goal of these initiatives is to achieve profitable operations as quickly as possible. Various strategic alliances that are ongoing and under development are also critical aspects of management’s overall growth and development strategy. There is no assurance that these initiatives will yield sufficient capital to maintain the Company’s operations. There is no assurance that the ongoing capital raising efforts will be successful. Should management fail to successfully raise additional capital and/or fully implement its strategic initiatives, it may be compelled to curtail part or all of its ongoing operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The financial statements do not include any adjustments relating to the recoverability of assets and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company has historically financed its operations primarily through various private placements of debt and equity securities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> -2700000 -16300000 <p id="xdx_80F_eus-gaap--FairValueMeasurementInputsDisclosureTextBlock_zpHVeYKSR6u1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 3 – <span id="xdx_82B_z6Cxcddjb5S9">FAIR VALUE MEASUREMENT</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC Topic 820, “Fair Value Measurements and Disclosures”, establishes a hierarchy for inputs used in measuring fair value for financial assets and liabilities that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions of what market participants would use in pricing the asset or liability based on the best information available in the circumstances. The hierarchy is broken down into three levels based on the reliability of the inputs as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">● Level 1: Quoted prices available in active markets for identical assets or liabilities;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">● Level 2: Quoted prices in active markets for similar assets and liabilities that are observable for the asset or liability; and</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">● Level 3: Unobservable pricing inputs that are generally less observable from objective sources, such as discounted cash or valuation models.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The financial assets and liabilities are classified in the Consolidated Balance Sheets based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the valuation of the fair value of assets and liabilities and their placement within the fair value hierarchy levels.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As disclosed in Note 7, the two tranches of 2023 Series Convertible Notes Payable - Stock Settled Derivative/Warrant Liability required identification and quantification of fair value. Similarly, the tranches of 2024 Series Senior Secured Convertible Notes – Stock Settled Derivative/Warrant Liability and the tranches of 2025 Series Senior Secured Convertible Notes – Stock Settled Derivative/Warrant Liability required identification and quantification of fair value. The derivative liabilities described below only relate to (i) the warrants included with the two tranches of the 2023 Series Convertible Notes Payable – Stock Settled debt, (ii) the warrants included with 2024 Series Senior Secured Convertible Note – Stock Settled debt and (iii) the warrants included with 2025 Series Senior Secured Convertible Note – Stock Settled debt. The estimated fair values as of the issuance date of these three tranches of notes are presented in Note 7.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_895_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_ze1Wz4FaAJwa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of April 30, 2026 and October 31, 2025, the estimated fair values of the Company’s financial liabilities are presented in the following table:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BF_ztHtXhfLocti" style="display: none">SCHEDULE OF FAIR VALUE ON FINANCIAL LIABILITIES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%"> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">April 30, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">2023 Series Convertible Notes Payable - Stock Settled - Derivative/Warrant Liability</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--DerivativeLiabilities_iI_c20260430__us-gaap--FinancialInstrumentAxis__custom--TwoThousandTwentyThreeSeriesConvertibleNotesPayableMember_z1QI3kc2TGa3" style="width: 16%; text-align: right" title="Financial liabilities, fair values">2,279</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2023 Series B Convertible Notes Payable – Stock Settled – Derivative/Warrant Liability</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--DerivativeLiabilities_iI_c20260430__us-gaap--FinancialInstrumentAxis__custom--TwoThousandTwentyThreeSeriesBConvertibleNotesPayableMember_zXi2TjBExWtg" style="text-align: right" title="Financial liabilities, fair values">29,556</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2024 Series Senior Secured Convertible Notes Payable – Stock Settled – Derivative/Warrant Liability</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--DerivativeLiabilities_iI_c20260430__us-gaap--FinancialInstrumentAxis__custom--TwoThousandTwentyFourSeniorSecuredConvertibleNotesPayableMember_zeEAuaIxrg0g" style="text-align: right" title="Financial liabilities, fair values">12,556</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">2025 Series Senior Secured Convertible Notes Payable – Stock Settled – Derivative/Warrant Liability</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--DerivativeLiabilities_iI_c20260430__us-gaap--FinancialInstrumentAxis__custom--TwoThousandTwentyFiveSeniorSecuredConvertibleNotesPayableMember_zXqhGtQKLfC2" style="border-bottom: Black 1pt solid; text-align: right" title="Financial liabilities, fair values">4,752,032</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--DerivativeLiabilities_iI_c20260430_zFhPVUU7jfQ2" style="border-bottom: Black 2.5pt double; text-align: right" title="Financial liabilities, fair values">4,796,423</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%"> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">October 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">2023 Series Convertible Notes Payable - Stock Settled - Derivative/Warrant Liability</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--DerivativeLiabilities_iI_c20251031__us-gaap--FinancialInstrumentAxis__custom--TwoThousandTwentyThreeSeriesConvertibleNotesPayableMember_z0VoCDRNvKG6" style="width: 16%; text-align: right" title="Financial liabilities, fair values">4,122</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2023 Series B Convertible Notes Payable – Stock Settled – Derivative/Warrant Liability</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--DerivativeLiabilities_iI_c20251031__us-gaap--FinancialInstrumentAxis__custom--TwoThousandTwentyThreeSeriesBConvertibleNotesPayableMember_zTjy14jHxvjd" style="text-align: right" title="Financial liabilities, fair values">53,442</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2024 Series Senior Secured Convertible Notes Payable – Stock Settled – Derivative/Warrant Liability</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--DerivativeLiabilities_iI_c20251031__us-gaap--FinancialInstrumentAxis__custom--TwoThousandTwentyFourSeniorSecuredConvertibleNotesPayableMember_zkqqE4K98o6a" style="text-align: right" title="Financial liabilities, fair values">66,032</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">2025 Series Senior Secured Convertible Notes Payable – Stock Settled – Derivative/Warrant Liability</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--DerivativeLiabilities_iI_c20251031__us-gaap--FinancialInstrumentAxis__custom--TwoThousandTwentyFiveSeniorSecuredConvertibleNotesPayableMember_zbFv4OLKNCW" style="border-bottom: Black 1pt solid; text-align: right" title="Financial liabilities, fair values">5,448,146</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--DerivativeLiabilities_iI_c20251031_z9QZe3zMlEF8" style="border-bottom: Black 2.5pt double; text-align: right" title="Financial liabilities, fair values">5,571,742</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table><div style="clear: both"></div> <p id="xdx_8A7_z9ps6JyvZp5j" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_892_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_zWsWMQeihp9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents a roll-forward of the fair value of the derivative liabilities associated with the Company’s warrants included with its 2025 Series Senior Secured Convertible Notes, its 2024 Series Senior Secured Convertible Notes Payable and its 2023 Series Convertible Notes Payable, categorized as Level 3:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BE_zGrjLiM3m55e" style="display: none">SCHEDULE OF FAIR VALUE DERIVATIVE LIABILITIES ON RECURRING BASIS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20251101__20260430_zYPdXmxyjCSk" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Six Months</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>April 30, 2026</b></span></p></td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20241101__20251031_zqLWZyka7H49" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>October 31, 2025</b></span></p></td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_40B_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iS_hus-gaap--FinancialInstrumentAxis__us-gaap--DerivativeMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z2KkLNKIgkq3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: justify">Beginning Balance</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">5,571,742</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">280,972</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues_hus-gaap--FinancialInstrumentAxis__us-gaap--DerivativeMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zEbRcSYqQ6Ye" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Additions</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0975">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,783,825</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements_hus-gaap--FinancialInstrumentAxis__us-gaap--DerivativeMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zM2aMjxruXz9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Subtractions</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(47,269</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0979">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings_hus-gaap--FinancialInstrumentAxis__us-gaap--DerivativeMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zhSOrlQaQvc2" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Total Unrealized Gains</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(728,050</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(493,055</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_402_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iE_hus-gaap--FinancialInstrumentAxis__us-gaap--DerivativeMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zOGmz6Nonkj9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Ending Balance</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,796,423</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,571,742</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AC_zDJUunAVJxSi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the three and six months ended April 30, 2026 and 2025, the unrealized (gain) or loss on the Derivative Warrant Liability associated with the two tranches of 2023 Series Convertible Notes Payable – Stock Settled was ($<span id="xdx_90E_eus-gaap--UnrealizedGainLossOnDerivatives_c20260201__20260430__us-gaap--FinancialInstrumentAxis__custom--TwoThousandTwentyThreeSeriesConvertibleNotesPayableMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember_zzOaCNKaxgaa" title="Unrealized (gain) loss derivative warrant liability">25,111</span>) and ($<span id="xdx_90F_eus-gaap--UnrealizedGainLossOnDerivatives_c20251101__20260430__us-gaap--FinancialInstrumentAxis__custom--TwoThousandTwentyThreeSeriesConvertibleNotesPayableMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember_zIlIF40K7YGa" title="Unrealized (gain) loss derivative warrant liability">25,729</span>), and $<span id="xdx_903_eus-gaap--UnrealizedGainLossOnDerivatives_c20250201__20250430__us-gaap--FinancialInstrumentAxis__custom--TwoThousandTwentyThreeSeriesConvertibleNotesPayableMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember_z1Zq4TLMhyj1" title="Unrealized (gain) loss derivative warrant liability">560</span> and $<span id="xdx_900_eus-gaap--UnrealizedGainLossOnDerivatives_c20241101__20250430__us-gaap--FinancialInstrumentAxis__custom--TwoThousandTwentyThreeSeriesConvertibleNotesPayableMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember_zerIw7mPlrcf" title="Unrealized (gain) loss derivative warrant liability">466</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the three and six months ended April 30, 2026 and 2025, the unrealized (gain) or loss on the Derivative Warrant Liability associated with the 2024 Series Senior Secured convertible notes payable – stock settled was (<span id="xdx_90F_eus-gaap--UnrealizedGainLossOnDerivatives_c20260201__20260430__us-gaap--FinancialInstrumentAxis__custom--TwoThousandTwentyFourSeniorSecuredConvertibleNotesPayableMember_z74RkgdUtHY5" title="Unrealized (gain) loss derivative warrant liability">$1,270</span>) and (<span id="xdx_90F_eus-gaap--UnrealizedGainLossOnDerivatives_c20251101__20260430__us-gaap--FinancialInstrumentAxis__custom--TwoThousandTwentyFourSeniorSecuredConvertibleNotesPayableMember_zc5Qlwt7ffub" title="Unrealized (gain) loss derivative warrant liability">$6,207</span>), and (<span id="xdx_90B_eus-gaap--UnrealizedGainLossOnDerivatives_c20250201__20250430__us-gaap--FinancialInstrumentAxis__custom--TwoThousandTwentyFourSeniorSecuredConvertibleNotesPayableMember_zIhmavk1PfZg" title="Unrealized (gain) loss derivative warrant liability">$6,421</span>) and ($<span id="xdx_90A_eus-gaap--UnrealizedGainLossOnDerivatives_c20241101__20250430__us-gaap--FinancialInstrumentAxis__custom--TwoThousandTwentyFourSeniorSecuredConvertibleNotesPayableMember_zHRyjrCPd0Y2" title="Unrealized (gain) loss derivative warrant liability">11,938</span>), respectively. On February 24, 2025, $<span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_c20250224__20250224__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember_zRAcQ84M9Zeh" title="Converible preferred stock value">468,750</span> of these notes were converted to Series A-1 Preferred Stock. As a result, $<span id="xdx_90B_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements_c20251101__20260430_zOb6vHItQ7Z9" title="Derivative warrant liability">47,269</span> of Derivative Warrant Liability was recognized and reclassified to Additional Paid-in Capital.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the three and six months ended April 30, 2026 and 2025, the unrealized (gain) or loss on the Derivative Warrant Liability associated with the 2025 Series Senior Secured convertible notes payable – stock settled was ($<span id="xdx_90B_eus-gaap--UnrealizedGainLossOnDerivatives_c20260201__20260430__us-gaap--FinancialInstrumentAxis__custom--TwoThousandTwentyFiveSeniorSecuredConvertibleNotesPayableMember_zHOiqt5bBJr5" title="Unrealized (gain) loss derivative warrant liability">413,965</span>) and $(<span id="xdx_90B_eus-gaap--UnrealizedGainLossOnDerivatives_c20251101__20260430__us-gaap--FinancialInstrumentAxis__custom--TwoThousandTwentyFiveSeniorSecuredConvertibleNotesPayableMember_zsBNW4RffwF8" title="Unrealized (gain) loss derivative warrant liability">696,114</span>), and $<span id="xdx_90F_eus-gaap--UnrealizedGainLossOnDerivatives_c20250201__20250430__us-gaap--FinancialInstrumentAxis__custom--TwoThousandTwentyFiveSeniorSecuredConvertibleNotesPayableMember_zbfIVFNVAkab" title="Unrealized (gain) loss derivative warrant liability">6,375</span> and $<span id="xdx_905_eus-gaap--UnrealizedGainLossOnDerivatives_c20241101__20250430__us-gaap--FinancialInstrumentAxis__custom--TwoThousandTwentyFiveSeniorSecuredConvertibleNotesPayableMember_z1d7QbXj3uH1" title="Unrealized (gain) loss derivative warrant liability">6,375</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_897_ecustom--ScheduleOfFairValueDerivativeLiabilitiesOnWarrantsGrantedTableTextBlock_zHttGnm8ACU2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value of the warrants granted in connection with the 2023 Series Convertible Notes Payable, the 2024 Series Senior Secured Convertible Notes Payable - Stock Settled and the 2025 Series Senior Secured Convertible Notes Payable – Stock Settled during the periods presented was estimated using the Black-Scholes option-pricing model with the following assumptions at April 30, 2026 and October 31, 2025:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BA_zq8TF6KMZ2k4" style="display: none">SCHEDULE OF FAIR VALUE DERIVATIVE LIABILITIES ON WARRANTS GRANTED</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">April 30, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">October 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20260430__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zEmfDnHlJpja" title="Derivative measurement input">3.79</span>%-<span id="xdx_90D_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20260430__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_zH9WKwih2sn1" title="Derivative measurement input">4.02</span></span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20251031__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zc09o4EozdP8" title="Derivative measurement input">3.61</span>%-<span id="xdx_90A_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20251031__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_z97cFPRxhJr5" title="Derivative measurement input">4.36</span></span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: justify">Dividend yield</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_900_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20260430__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendPaymentMember_z5JAYNu5qJo5" title="Derivative measurement input">0.00</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_906_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20251031__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendPaymentMember_zO7m1HDkxhm9" title="Derivative measurement input">0.00</span></td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Volatility factor</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20260430__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__srt--RangeAxis__srt--MinimumMember_zPT88CWkCFw3" title="Derivative measurement input">128.19</span>%-<span id="xdx_90A_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20260430__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__srt--RangeAxis__srt--MaximumMember_zDKf2h9PedR5" title="Derivative measurement input">132.3</span></span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20251031__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__srt--RangeAxis__srt--MinimumMember_zECOwhtrZSs7" title="Derivative measurement input">129.58</span>%-<span id="xdx_901_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20251031__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__srt--RangeAxis__srt--MaximumMember_z3XxG6xvAuTd" title="Derivative measurement input">136.33</span></span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Weighted average expected life (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_ecustom--DerivativeLiabilityMeasurementWeightedAverageExpectedLife_dtY_c20251101__20260430__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember_zAJMk3SZhG5a" title="Weighted average expected life (years)">1.0</span> - <span id="xdx_906_ecustom--DerivativeLiabilityMeasurementWeightedAverageExpectedLife_dtY_c20251101__20260430__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember_zY8g4xFB62nc" title="Weighted average expected life (years)">2.0</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_ecustom--DerivativeLiabilityMeasurementWeightedAverageExpectedLife_dtY_c20241101__20251031__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember_zZ6Z3Y8X2ET9" title="Weighted average expected life (years)">1.5</span> – <span id="xdx_906_ecustom--DerivativeLiabilityMeasurementWeightedAverageExpectedLife_dtY_c20241101__20251031__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember_zf6v9fTSmam1" title="Weighted average expected life (years)">2.5</span></span></td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8A1_zarAMchFWYGg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Estimated Fair Value of Financial Assets and Liabilities Not Measured at Fair Value</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s financial instruments consist primarily of cash, accounts receivable, accounts payable, and Convertible Notes Payable. The carrying values of cash, accounts receivable and accounts payable are representative of their fair values due to their short-term maturities. The carrying amount of the Company’s Convertible Notes Payable approximates fair value as they bear interest over the term of the loans.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_895_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_ze1Wz4FaAJwa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of April 30, 2026 and October 31, 2025, the estimated fair values of the Company’s financial liabilities are presented in the following table:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BF_ztHtXhfLocti" style="display: none">SCHEDULE OF FAIR VALUE ON FINANCIAL LIABILITIES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%"> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">April 30, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">2023 Series Convertible Notes Payable - Stock Settled - Derivative/Warrant Liability</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--DerivativeLiabilities_iI_c20260430__us-gaap--FinancialInstrumentAxis__custom--TwoThousandTwentyThreeSeriesConvertibleNotesPayableMember_z1QI3kc2TGa3" style="width: 16%; text-align: right" title="Financial liabilities, fair values">2,279</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2023 Series B Convertible Notes Payable – Stock Settled – Derivative/Warrant Liability</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--DerivativeLiabilities_iI_c20260430__us-gaap--FinancialInstrumentAxis__custom--TwoThousandTwentyThreeSeriesBConvertibleNotesPayableMember_zXi2TjBExWtg" style="text-align: right" title="Financial liabilities, fair values">29,556</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2024 Series Senior Secured Convertible Notes Payable – Stock Settled – Derivative/Warrant Liability</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--DerivativeLiabilities_iI_c20260430__us-gaap--FinancialInstrumentAxis__custom--TwoThousandTwentyFourSeniorSecuredConvertibleNotesPayableMember_zeEAuaIxrg0g" style="text-align: right" title="Financial liabilities, fair values">12,556</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">2025 Series Senior Secured Convertible Notes Payable – Stock Settled – Derivative/Warrant Liability</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--DerivativeLiabilities_iI_c20260430__us-gaap--FinancialInstrumentAxis__custom--TwoThousandTwentyFiveSeniorSecuredConvertibleNotesPayableMember_zXqhGtQKLfC2" style="border-bottom: Black 1pt solid; text-align: right" title="Financial liabilities, fair values">4,752,032</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--DerivativeLiabilities_iI_c20260430_zFhPVUU7jfQ2" style="border-bottom: Black 2.5pt double; text-align: right" title="Financial liabilities, fair values">4,796,423</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%"> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">October 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">2023 Series Convertible Notes Payable - Stock Settled - Derivative/Warrant Liability</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--DerivativeLiabilities_iI_c20251031__us-gaap--FinancialInstrumentAxis__custom--TwoThousandTwentyThreeSeriesConvertibleNotesPayableMember_z0VoCDRNvKG6" style="width: 16%; text-align: right" title="Financial liabilities, fair values">4,122</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2023 Series B Convertible Notes Payable – Stock Settled – Derivative/Warrant Liability</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--DerivativeLiabilities_iI_c20251031__us-gaap--FinancialInstrumentAxis__custom--TwoThousandTwentyThreeSeriesBConvertibleNotesPayableMember_zTjy14jHxvjd" style="text-align: right" title="Financial liabilities, fair values">53,442</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2024 Series Senior Secured Convertible Notes Payable – Stock Settled – Derivative/Warrant Liability</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--DerivativeLiabilities_iI_c20251031__us-gaap--FinancialInstrumentAxis__custom--TwoThousandTwentyFourSeniorSecuredConvertibleNotesPayableMember_zkqqE4K98o6a" style="text-align: right" title="Financial liabilities, fair values">66,032</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">2025 Series Senior Secured Convertible Notes Payable – Stock Settled – Derivative/Warrant Liability</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--DerivativeLiabilities_iI_c20251031__us-gaap--FinancialInstrumentAxis__custom--TwoThousandTwentyFiveSeniorSecuredConvertibleNotesPayableMember_zbFv4OLKNCW" style="border-bottom: Black 1pt solid; text-align: right" title="Financial liabilities, fair values">5,448,146</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--DerivativeLiabilities_iI_c20251031_z9QZe3zMlEF8" style="border-bottom: Black 2.5pt double; text-align: right" title="Financial liabilities, fair values">5,571,742</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table><div style="clear: both"></div> 2279 29556 12556 4752032 4796423 4122 53442 66032 5448146 5571742 <p id="xdx_892_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_zWsWMQeihp9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents a roll-forward of the fair value of the derivative liabilities associated with the Company’s warrants included with its 2025 Series Senior Secured Convertible Notes, its 2024 Series Senior Secured Convertible Notes Payable and its 2023 Series Convertible Notes Payable, categorized as Level 3:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BE_zGrjLiM3m55e" style="display: none">SCHEDULE OF FAIR VALUE DERIVATIVE LIABILITIES ON RECURRING BASIS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20251101__20260430_zYPdXmxyjCSk" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Six Months</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>April 30, 2026</b></span></p></td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20241101__20251031_zqLWZyka7H49" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>October 31, 2025</b></span></p></td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_40B_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iS_hus-gaap--FinancialInstrumentAxis__us-gaap--DerivativeMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z2KkLNKIgkq3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: justify">Beginning Balance</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">5,571,742</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">280,972</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues_hus-gaap--FinancialInstrumentAxis__us-gaap--DerivativeMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zEbRcSYqQ6Ye" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Additions</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0975">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,783,825</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements_hus-gaap--FinancialInstrumentAxis__us-gaap--DerivativeMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zM2aMjxruXz9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Subtractions</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(47,269</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0979">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings_hus-gaap--FinancialInstrumentAxis__us-gaap--DerivativeMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zhSOrlQaQvc2" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Total Unrealized Gains</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(728,050</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(493,055</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_402_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iE_hus-gaap--FinancialInstrumentAxis__us-gaap--DerivativeMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zOGmz6Nonkj9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Ending Balance</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,796,423</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,571,742</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 5571742 280972 5783825 -47269 -728050 -493055 4796423 5571742 25111 25729 560 466 1270 6207 6421 11938 468750 47269 413965 696114 6375 6375 <p id="xdx_897_ecustom--ScheduleOfFairValueDerivativeLiabilitiesOnWarrantsGrantedTableTextBlock_zHttGnm8ACU2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value of the warrants granted in connection with the 2023 Series Convertible Notes Payable, the 2024 Series Senior Secured Convertible Notes Payable - Stock Settled and the 2025 Series Senior Secured Convertible Notes Payable – Stock Settled during the periods presented was estimated using the Black-Scholes option-pricing model with the following assumptions at April 30, 2026 and October 31, 2025:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BA_zq8TF6KMZ2k4" style="display: none">SCHEDULE OF FAIR VALUE DERIVATIVE LIABILITIES ON WARRANTS GRANTED</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">April 30, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">October 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20260430__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zEmfDnHlJpja" title="Derivative measurement input">3.79</span>%-<span id="xdx_90D_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20260430__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_zH9WKwih2sn1" title="Derivative measurement input">4.02</span></span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20251031__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zc09o4EozdP8" title="Derivative measurement input">3.61</span>%-<span id="xdx_90A_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20251031__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_z97cFPRxhJr5" title="Derivative measurement input">4.36</span></span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: justify">Dividend yield</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_900_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20260430__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendPaymentMember_z5JAYNu5qJo5" title="Derivative measurement input">0.00</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_906_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20251031__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendPaymentMember_zO7m1HDkxhm9" title="Derivative measurement input">0.00</span></td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Volatility factor</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20260430__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__srt--RangeAxis__srt--MinimumMember_zPT88CWkCFw3" title="Derivative measurement input">128.19</span>%-<span id="xdx_90A_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20260430__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__srt--RangeAxis__srt--MaximumMember_zDKf2h9PedR5" title="Derivative measurement input">132.3</span></span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20251031__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__srt--RangeAxis__srt--MinimumMember_zECOwhtrZSs7" title="Derivative measurement input">129.58</span>%-<span id="xdx_901_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20251031__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__srt--RangeAxis__srt--MaximumMember_z3XxG6xvAuTd" title="Derivative measurement input">136.33</span></span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Weighted average expected life (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_ecustom--DerivativeLiabilityMeasurementWeightedAverageExpectedLife_dtY_c20251101__20260430__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember_zAJMk3SZhG5a" title="Weighted average expected life (years)">1.0</span> - <span id="xdx_906_ecustom--DerivativeLiabilityMeasurementWeightedAverageExpectedLife_dtY_c20251101__20260430__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember_zY8g4xFB62nc" title="Weighted average expected life (years)">2.0</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_ecustom--DerivativeLiabilityMeasurementWeightedAverageExpectedLife_dtY_c20241101__20251031__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember_zZ6Z3Y8X2ET9" title="Weighted average expected life (years)">1.5</span> – <span id="xdx_906_ecustom--DerivativeLiabilityMeasurementWeightedAverageExpectedLife_dtY_c20241101__20251031__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember_zf6v9fTSmam1" title="Weighted average expected life (years)">2.5</span></span></td><td style="text-align: left"> </td></tr> </table> 3.79 4.02 3.61 4.36 0.00 0.00 128.19 132.3 129.58 136.33 P1Y P2Y P1Y6M P2Y6M <p id="xdx_80D_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zvhvkPLj1jS4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 4 – <span id="xdx_82C_zRoHIDL23XKh">PROPERTY AND EQUIPMENT</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89F_eus-gaap--PropertyPlantAndEquipmentTextBlock_zlz9zptnJ4Qb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following is a summary of property and equipment, less accumulated depreciation at the balance sheet dates:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BB_zOdOm943zgmg" style="display: none">SCHEDULE OF PROPERTY AND EQUIPMENT</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20260430_z7UrPBkvbgVj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">April 30, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20251031_zi2vfe9NP6fg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">October 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_408_eus-gaap--LeaseholdImprovementsGross_iI_maPPAEGzbzm_zpMa3UvKdfqa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Leasehold improvements</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">12,840</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">12,840</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentOther_iI_maPPAEGzbzm_zmuzPjAnmVs5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Property and equipment</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,085,900</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,052,095</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--PropertyPlantAndEquipmentGross_iTI_mtPPAEGzbzm_maPPAENzNBC_zGgHILcsnHac" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Total cost</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,098,740</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,064,935</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzNBC_zdVwoYC6xdo2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Less accumulated depreciation</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(1,038,810</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(1,022,767</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_402_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzNBC_zPYBRJNOPail" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Net property and equipment</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">59,930</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">42,168</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AC_zykPenDYVDf7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation expense for the three and six months ended April 30, 2026 and 2025 was $<span id="xdx_909_eus-gaap--Depreciation_c20260201__20260430_zqxOyAUrsQP6" title="Depreciation expense">7,039</span> and $<span id="xdx_903_eus-gaap--Depreciation_c20251101__20260430_zgMi7Y8otu8f" title="Depreciation expense">16,043</span>, and $<span id="xdx_90C_eus-gaap--Depreciation_c20250201__20250430_z3veqnmc6aD4" title="Depreciation expense">24,534</span> and $<span id="xdx_902_eus-gaap--Depreciation_c20241101__20250430_zgs5fsEJ4TTl" title="Depreciation expense">61,968</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89F_eus-gaap--PropertyPlantAndEquipmentTextBlock_zlz9zptnJ4Qb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following is a summary of property and equipment, less accumulated depreciation at the balance sheet dates:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BB_zOdOm943zgmg" style="display: none">SCHEDULE OF PROPERTY AND EQUIPMENT</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20260430_z7UrPBkvbgVj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">April 30, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20251031_zi2vfe9NP6fg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">October 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_408_eus-gaap--LeaseholdImprovementsGross_iI_maPPAEGzbzm_zpMa3UvKdfqa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Leasehold improvements</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">12,840</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">12,840</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentOther_iI_maPPAEGzbzm_zmuzPjAnmVs5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Property and equipment</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,085,900</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,052,095</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--PropertyPlantAndEquipmentGross_iTI_mtPPAEGzbzm_maPPAENzNBC_zGgHILcsnHac" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Total cost</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,098,740</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,064,935</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzNBC_zdVwoYC6xdo2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Less accumulated depreciation</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(1,038,810</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(1,022,767</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_402_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzNBC_zPYBRJNOPail" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Net property and equipment</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">59,930</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">42,168</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 12840 12840 1085900 1052095 1098740 1064935 1038810 1022767 59930 42168 7039 16043 24534 61968 <p id="xdx_806_eus-gaap--IntangibleAssetsDisclosureTextBlock_z5sPiqZRyJka" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 5 – <span id="xdx_821_zsjo4NKw55hl">INTANGIBLE ASSETS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_890_eus-gaap--ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_zFAIEqLiCAug" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table sets forth the carrying amounts of intangible assets and goodwill including accumulated amortization as of April 30, 2026:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B7_zZjx1luiZCn1" style="display: none">SCHEDULE OF INTANGIBLE ASSETS AND GOODWILL</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Useful Life</b></span></p></td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Cost</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold">Impairment</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Accumulated</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Amortization</b></span></p></td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Net Carrying</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Value</b></span></p></td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 37%; text-align: left">Trademarks and tradenames</td><td style="width: 2%"> </td> <td style="width: 9%; text-align: center"><span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_iI_dtY_c20260430__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zQ6O0n9IthS1" title="Intangible assets, remaining useful life">10.25</span> years</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20260430__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_z040VT2z6LHb" style="width: 9%; text-align: right" title="Cost">693,330</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_c20260430__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zQDicHOmOD12" style="width: 9%; text-align: right" title="Impairment">(418,512</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20260430__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zYVhZoFDNQaa" style="width: 9%; text-align: right" title="Accumulated Amortization">(136,398</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20260430__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zFl5f3OgPpTc" style="width: 9%; text-align: right" title="Net Carrying Value">138,420</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Patents, know-how and unpatented technology</td><td> </td> <td style="text-align: center"><span id="xdx_909_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_iI_dtY_c20260430__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsKnowHowAndUnpatentedTechnologyMember_zx2tVR77nDOj" title="Intangible assets, remaining useful life">10.25</span> years</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20260430__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsKnowHowAndUnpatentedTechnologyMember_zpHiukGhL5v1" style="text-align: right" title="Cost">710,060</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_c20260430__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsKnowHowAndUnpatentedTechnologyMember_zCNBZiz1i0M6" style="text-align: right" title="Impairment">(388,259</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20260430__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsKnowHowAndUnpatentedTechnologyMember_zIgv1ig1NWHi" style="text-align: right" title="Accumulated Amortization">(147,851</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20260430__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsKnowHowAndUnpatentedTechnologyMember_zHT4b4UgzVCf" style="text-align: right" title="Net Carrying Value">173,950</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Customer relationships</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: center; padding-bottom: 1pt"><span id="xdx_909_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_iI_dtY_c20260430__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zgtpJzCl0PZe" title="Intangible assets, remaining useful life">0</span> years</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20260430__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_z4M42rY2zSVj" style="border-bottom: Black 1pt solid; text-align: right" title="Cost">114,536</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_c20260430__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zdWgcFOjtwad" style="border-bottom: Black 1pt solid; text-align: right" title="Impairment">(17,108</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20260430__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_z0IX9oafB6G7" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated Amortization">(97,428</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20260430__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zNEi5yLTBTIi" style="border-bottom: Black 1pt solid; text-align: right" title="Net Carrying Value"><span style="-sec-ix-hidden: xdx2ixbrl1104">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20260430_zkDEHpytSeAd" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets, cost">1,517,926</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_c20260430_z7OgSxBD8fbi" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets, impairment">(823,879</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20260430_zy22iRWeVl23" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets. accumulated amortization">(381,677</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20260430_zbghGCWAkh75" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets, net carrying value">312,370</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Useful Life</b></span></p></td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Cost</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Impairment</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Net Carrying</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Value</b></span></p></td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 38%; text-align: justify; padding-bottom: 2.5pt">Goodwill</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="width: 12%; text-align: right; padding-bottom: 2.5pt"><span id="xdx_90F_ecustom--GoodwillEstimatedRemainingUsefulLives_c20251101__20260430__us-gaap--FairValueByAssetClassAxis__us-gaap--GoodwillMember_zGEFuWyjY7A" title="Goodwill, remaining useful life">Indefinite</span></td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--GoodwillGross_iI_c20260430__us-gaap--FairValueByAssetClassAxis__us-gaap--GoodwillMember_zqPiIwLQG1P3" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right" title="Goodwill, cost">4,523,040</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--GoodwillImpairedAccumulatedImpairmentLoss_iNI_di_c20260430__us-gaap--FairValueByAssetClassAxis__us-gaap--GoodwillMember_zGd2qTg3KqGe" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right" title="Goodwill, impairment">(1,351,459</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--Goodwill_iI_c20260430__us-gaap--FairValueByAssetClassAxis__us-gaap--GoodwillMember_zi3KFmeMhjF2" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right" title="Goodwill, net carrying value">3,171,581</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table sets forth the carrying amounts of intangible assets and goodwill including accumulated amortization as of October 31, 2025:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Useful Life</b></span></p></td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Cost</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold">Impairment</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Accumulated</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Amortization</b></span></p></td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Net Carrying</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Value</b></span></p></td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 37%; text-align: justify">Trademarks and tradenames</td><td style="width: 2%"> </td> <td style="width: 9%; text-align: center"><span id="xdx_90A_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_iI_dtY_c20251031__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zWnjHRHTlnm9" title="Intangible assets, remaining useful life">10.75</span> years</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20251031__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zOgGKBqhVpue" style="width: 9%; text-align: right" title="Cost">693,330</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_c20251031__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zXpMV3HAzny6" style="width: 9%; text-align: right" title="Impairment">(418,512</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20251031__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zG5z82ZArCg5" style="width: 9%; text-align: right" title="Accumulated Amortization">(129,646</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20251031__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zJXtJibOLEb6" style="width: 9%; text-align: right" title="Net Carrying Value">145,172</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Patents, know-how and unpatented technology</td><td> </td> <td style="text-align: center"><span id="xdx_903_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_iI_dtY_c20251031__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsKnowHowAndUnpatentedTechnologyMember_zFQoETwT6L8b" title="Intangible assets, remaining useful life">10.75</span> years</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20251031__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsKnowHowAndUnpatentedTechnologyMember_z5ra2PMbMo7k" style="text-align: right" title="Cost">710,060</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_c20251031__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsKnowHowAndUnpatentedTechnologyMember_zhamUpGmugDa" style="text-align: right" title="Impairment">(388,259</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20251031__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsKnowHowAndUnpatentedTechnologyMember_ziTuX9wZqanl" style="text-align: right" title="Accumulated Amortization">(139,365</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20251031__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsKnowHowAndUnpatentedTechnologyMember_znP5onn9Hlc9" style="text-align: right" title="Net Carrying Value">182,436</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1pt">Customer relationships</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: center; padding-bottom: 1pt"><span id="xdx_90A_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_iI_dtY_c20251031__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zeIYEDMCF7Gi" title="Intangible assets, remaining useful life">0</span> years</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20251031__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_ziilXDBlcKGb" style="border-bottom: Black 1pt solid; text-align: right" title="Cost">114,536</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_c20251031__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zKHWu1dMRZek" style="border-bottom: Black 1pt solid; text-align: right" title="Impairment">(17,108</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20251031__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zJNTnVIpwNoh" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated Amortization">(97,428</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20251031__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zs22DC8V7u93" style="border-bottom: Black 1pt solid; text-align: right" title="Net Carrying Value"><span style="-sec-ix-hidden: xdx2ixbrl1150">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20251031_zG701oHA5nr5" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets, cost">1,517,926</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_c20251031_zG484rX1jU1b" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets, impairment">(823,879</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20251031_zdilHUg574E4" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets. accumulated amortization">(366,439</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_986_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20251031_zb2kljaG3Hr6" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets, net carrying value">327,608</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Useful Life</b></span></p></td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Cost</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Impairment</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Net Carrying</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Value</b></span></p></td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 38%; text-align: justify; padding-bottom: 2.5pt">Goodwill</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="width: 12%; text-align: right; padding-bottom: 2.5pt"><span id="xdx_90F_ecustom--GoodwillEstimatedRemainingUsefulLives_c20241101__20251031__us-gaap--FairValueByAssetClassAxis__us-gaap--GoodwillMember_zOG2sZn2Gznj" title="Goodwill, remaining useful life">Indefinite</span></td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--GoodwillGross_iI_c20251031__us-gaap--FairValueByAssetClassAxis__us-gaap--GoodwillMember_zOsKjgiOCxdh" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right" title="Goodwill, cost">4,523,040</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--GoodwillImpairedAccumulatedImpairmentLoss_iNI_di_c20251031__us-gaap--FairValueByAssetClassAxis__us-gaap--GoodwillMember_zeYeQlUSyPE2" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right" title="Goodwill, impairment">(1,351,459</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--Goodwill_iI_c20251031__us-gaap--FairValueByAssetClassAxis__us-gaap--GoodwillMember_zkIN0VNmAyVc" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right" title="Goodwill, net carrying value">3,171,581</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AE_zvqacWTWcgP4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span> </p> <p id="xdx_890_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zQ3ShkzkPbsl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The table below presents anticipated future amortization expense related to the Company’s intangible assets for each of the succeeding five fiscal years ending October 31:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B4_zPhs9O0bX3V5" style="display: none">SCHEDULE OF FUTURE AMORTIZATION EXPENSE</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: center"> </td><td style="text-align: center"> </td> <td style="text-align: center"> </td><td id="xdx_492_20260430_zNqo1p3e5XZe" style="text-align: center"> </td><td style="text-align: center"> </td></tr> <tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_iI_maFLIANz9tV_zfwE3rMtQ3s7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: justify">2026 (six months remaining)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">15,237</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_maFLIANz9tV_zdBCiOp6BM61" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">2027</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">30,475</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_maFLIANz9tV_zAqT9qFX01Jh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">2028</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">30,475</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_maFLIANz9tV_zjPa0olEsQva" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">2029</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">30,475</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_maFLIANz9tV_z86uyQOV7Mfj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">2030</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">30,475</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_ecustom--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour_iI_maFLIANz9tV_zKix50pQ3Q1k" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Thereafter</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">175,233</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtFLIANz9tV_z8pNLoUrIEX" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">312,370</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A3_zrH6ht4qX4Pg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the three and six months ended April 30, 2026 and 2025, the Company recorded amortization expense of $<span id="xdx_90F_eus-gaap--AmortizationOfIntangibleAssets_c20260201__20260430_zL4XPZoKn12b" title="Amortization of intangible assets">7,619</span> and $<span id="xdx_908_eus-gaap--AmortizationOfIntangibleAssets_c20250201__20250430_zf6rU4wQJDX" title="Amortization of intangible assets">15,238</span>, and $<span id="xdx_90D_eus-gaap--AmortizationOfIntangibleAssets_c20251101__20260430_zRkftVAqatL6" title="Amortization of intangible assets">7,619</span> and $<span id="xdx_907_eus-gaap--AmortizationOfIntangibleAssets_c20241101__20250430_zOeUwdmuIf2" title="Amortization of intangible assets">15,238</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_890_eus-gaap--ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_zFAIEqLiCAug" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table sets forth the carrying amounts of intangible assets and goodwill including accumulated amortization as of April 30, 2026:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B7_zZjx1luiZCn1" style="display: none">SCHEDULE OF INTANGIBLE ASSETS AND GOODWILL</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Useful Life</b></span></p></td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Cost</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold">Impairment</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Accumulated</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Amortization</b></span></p></td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Net Carrying</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Value</b></span></p></td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 37%; text-align: left">Trademarks and tradenames</td><td style="width: 2%"> </td> <td style="width: 9%; text-align: center"><span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_iI_dtY_c20260430__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zQ6O0n9IthS1" title="Intangible assets, remaining useful life">10.25</span> years</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20260430__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_z040VT2z6LHb" style="width: 9%; text-align: right" title="Cost">693,330</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_c20260430__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zQDicHOmOD12" style="width: 9%; text-align: right" title="Impairment">(418,512</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20260430__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zYVhZoFDNQaa" style="width: 9%; text-align: right" title="Accumulated Amortization">(136,398</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20260430__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zFl5f3OgPpTc" style="width: 9%; text-align: right" title="Net Carrying Value">138,420</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Patents, know-how and unpatented technology</td><td> </td> <td style="text-align: center"><span id="xdx_909_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_iI_dtY_c20260430__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsKnowHowAndUnpatentedTechnologyMember_zx2tVR77nDOj" title="Intangible assets, remaining useful life">10.25</span> years</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20260430__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsKnowHowAndUnpatentedTechnologyMember_zpHiukGhL5v1" style="text-align: right" title="Cost">710,060</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_c20260430__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsKnowHowAndUnpatentedTechnologyMember_zCNBZiz1i0M6" style="text-align: right" title="Impairment">(388,259</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20260430__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsKnowHowAndUnpatentedTechnologyMember_zIgv1ig1NWHi" style="text-align: right" title="Accumulated Amortization">(147,851</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20260430__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsKnowHowAndUnpatentedTechnologyMember_zHT4b4UgzVCf" style="text-align: right" title="Net Carrying Value">173,950</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Customer relationships</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: center; padding-bottom: 1pt"><span id="xdx_909_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_iI_dtY_c20260430__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zgtpJzCl0PZe" title="Intangible assets, remaining useful life">0</span> years</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20260430__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_z4M42rY2zSVj" style="border-bottom: Black 1pt solid; text-align: right" title="Cost">114,536</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_c20260430__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zdWgcFOjtwad" style="border-bottom: Black 1pt solid; text-align: right" title="Impairment">(17,108</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20260430__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_z0IX9oafB6G7" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated Amortization">(97,428</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20260430__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zNEi5yLTBTIi" style="border-bottom: Black 1pt solid; text-align: right" title="Net Carrying Value"><span style="-sec-ix-hidden: xdx2ixbrl1104">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20260430_zkDEHpytSeAd" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets, cost">1,517,926</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_c20260430_z7OgSxBD8fbi" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets, impairment">(823,879</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20260430_zy22iRWeVl23" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets. accumulated amortization">(381,677</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20260430_zbghGCWAkh75" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets, net carrying value">312,370</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Useful Life</b></span></p></td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Cost</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Impairment</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Net Carrying</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Value</b></span></p></td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 38%; text-align: justify; padding-bottom: 2.5pt">Goodwill</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="width: 12%; text-align: right; padding-bottom: 2.5pt"><span id="xdx_90F_ecustom--GoodwillEstimatedRemainingUsefulLives_c20251101__20260430__us-gaap--FairValueByAssetClassAxis__us-gaap--GoodwillMember_zGEFuWyjY7A" title="Goodwill, remaining useful life">Indefinite</span></td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--GoodwillGross_iI_c20260430__us-gaap--FairValueByAssetClassAxis__us-gaap--GoodwillMember_zqPiIwLQG1P3" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right" title="Goodwill, cost">4,523,040</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--GoodwillImpairedAccumulatedImpairmentLoss_iNI_di_c20260430__us-gaap--FairValueByAssetClassAxis__us-gaap--GoodwillMember_zGd2qTg3KqGe" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right" title="Goodwill, impairment">(1,351,459</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--Goodwill_iI_c20260430__us-gaap--FairValueByAssetClassAxis__us-gaap--GoodwillMember_zi3KFmeMhjF2" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right" title="Goodwill, net carrying value">3,171,581</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table sets forth the carrying amounts of intangible assets and goodwill including accumulated amortization as of October 31, 2025:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Useful Life</b></span></p></td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Cost</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold">Impairment</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Accumulated</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Amortization</b></span></p></td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Net Carrying</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Value</b></span></p></td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 37%; text-align: justify">Trademarks and tradenames</td><td style="width: 2%"> </td> <td style="width: 9%; text-align: center"><span id="xdx_90A_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_iI_dtY_c20251031__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zWnjHRHTlnm9" title="Intangible assets, remaining useful life">10.75</span> years</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20251031__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zOgGKBqhVpue" style="width: 9%; text-align: right" title="Cost">693,330</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_c20251031__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zXpMV3HAzny6" style="width: 9%; text-align: right" title="Impairment">(418,512</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20251031__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zG5z82ZArCg5" style="width: 9%; text-align: right" title="Accumulated Amortization">(129,646</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20251031__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zJXtJibOLEb6" style="width: 9%; text-align: right" title="Net Carrying Value">145,172</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Patents, know-how and unpatented technology</td><td> </td> <td style="text-align: center"><span id="xdx_903_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_iI_dtY_c20251031__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsKnowHowAndUnpatentedTechnologyMember_zFQoETwT6L8b" title="Intangible assets, remaining useful life">10.75</span> years</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20251031__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsKnowHowAndUnpatentedTechnologyMember_z5ra2PMbMo7k" style="text-align: right" title="Cost">710,060</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_c20251031__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsKnowHowAndUnpatentedTechnologyMember_zhamUpGmugDa" style="text-align: right" title="Impairment">(388,259</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20251031__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsKnowHowAndUnpatentedTechnologyMember_ziTuX9wZqanl" style="text-align: right" title="Accumulated Amortization">(139,365</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20251031__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsKnowHowAndUnpatentedTechnologyMember_znP5onn9Hlc9" style="text-align: right" title="Net Carrying Value">182,436</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1pt">Customer relationships</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: center; padding-bottom: 1pt"><span id="xdx_90A_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_iI_dtY_c20251031__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zeIYEDMCF7Gi" title="Intangible assets, remaining useful life">0</span> years</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20251031__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_ziilXDBlcKGb" style="border-bottom: Black 1pt solid; text-align: right" title="Cost">114,536</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_c20251031__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zKHWu1dMRZek" style="border-bottom: Black 1pt solid; text-align: right" title="Impairment">(17,108</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20251031__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zJNTnVIpwNoh" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated Amortization">(97,428</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20251031__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zs22DC8V7u93" style="border-bottom: Black 1pt solid; text-align: right" title="Net Carrying Value"><span style="-sec-ix-hidden: xdx2ixbrl1150">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20251031_zG701oHA5nr5" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets, cost">1,517,926</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_c20251031_zG484rX1jU1b" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets, impairment">(823,879</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20251031_zdilHUg574E4" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets. accumulated amortization">(366,439</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_986_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20251031_zb2kljaG3Hr6" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets, net carrying value">327,608</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Useful Life</b></span></p></td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Cost</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Impairment</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Net Carrying</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Value</b></span></p></td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 38%; text-align: justify; padding-bottom: 2.5pt">Goodwill</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="width: 12%; text-align: right; padding-bottom: 2.5pt"><span id="xdx_90F_ecustom--GoodwillEstimatedRemainingUsefulLives_c20241101__20251031__us-gaap--FairValueByAssetClassAxis__us-gaap--GoodwillMember_zOG2sZn2Gznj" title="Goodwill, remaining useful life">Indefinite</span></td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--GoodwillGross_iI_c20251031__us-gaap--FairValueByAssetClassAxis__us-gaap--GoodwillMember_zOsKjgiOCxdh" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right" title="Goodwill, cost">4,523,040</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--GoodwillImpairedAccumulatedImpairmentLoss_iNI_di_c20251031__us-gaap--FairValueByAssetClassAxis__us-gaap--GoodwillMember_zeYeQlUSyPE2" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right" title="Goodwill, impairment">(1,351,459</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--Goodwill_iI_c20251031__us-gaap--FairValueByAssetClassAxis__us-gaap--GoodwillMember_zkIN0VNmAyVc" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right" title="Goodwill, net carrying value">3,171,581</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> P10Y3M 693330 -418512 -136398 138420 P10Y3M 710060 -388259 -147851 173950 P0Y 114536 -17108 -97428 1517926 -823879 -381677 312370 Indefinite 4523040 1351459 3171581 P10Y9M 693330 -418512 -129646 145172 P10Y9M 710060 -388259 -139365 182436 P0Y 114536 -17108 -97428 1517926 -823879 -366439 327608 Indefinite 4523040 1351459 3171581 <p id="xdx_890_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zQ3ShkzkPbsl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The table below presents anticipated future amortization expense related to the Company’s intangible assets for each of the succeeding five fiscal years ending October 31:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B4_zPhs9O0bX3V5" style="display: none">SCHEDULE OF FUTURE AMORTIZATION EXPENSE</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: center"> </td><td style="text-align: center"> </td> <td style="text-align: center"> </td><td id="xdx_492_20260430_zNqo1p3e5XZe" style="text-align: center"> </td><td style="text-align: center"> </td></tr> <tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_iI_maFLIANz9tV_zfwE3rMtQ3s7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: justify">2026 (six months remaining)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">15,237</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_maFLIANz9tV_zdBCiOp6BM61" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">2027</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">30,475</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_maFLIANz9tV_zAqT9qFX01Jh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">2028</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">30,475</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_maFLIANz9tV_zjPa0olEsQva" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">2029</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">30,475</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_maFLIANz9tV_z86uyQOV7Mfj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">2030</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">30,475</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_ecustom--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour_iI_maFLIANz9tV_zKix50pQ3Q1k" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Thereafter</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">175,233</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtFLIANz9tV_z8pNLoUrIEX" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">312,370</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 15237 30475 30475 30475 30475 175233 312370 7619 15238 7619 15238 <p id="xdx_802_eus-gaap--LesseeOperatingLeasesTextBlock_zidXc3Op7bQk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 6 – <span id="xdx_828_z1b8paSnKQxf">LEASE OBLIGATIONS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for its leases in accordance with ASU No. 2016-02, <i>Leases (Topic 842) (“ASC 842”).</i> ASC 842 requires lessees to (i) recognize a right of use asset (“ROU asset”) and a lease liability that is measured at the present value of the remaining lease payments on the Consolidated Balance Sheets, (ii) recognize a single lease cost, calculated over the lease term on a straight-line basis and (iii) classify lease related cash payments within operating and financing activities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s operating lease consists of a lease for office space. The Company’s finance lease activities consist of leases for equipment. Leases with an initial term of 12 months or less are not recorded on the balance sheet. The office lease contains an option to a renewal period of <span id="xdx_90C_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dc_c20260430_zYy5uxEvNhP8" title="Lessee operating lease renewal term">five years</span> at then-current market rates. The equipment leases are non-renewable as the Company owns the equipment at the end of the lease period, for a nominal amount.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_893_ecustom--ScheduleOfBalanceSheetInformationRelatedToLeasesTableTextBlock_zAzcXxraEFI6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table shows the classification and location of the Company’s leases in the Consolidated Balance Sheets:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B2_zTYCDm5g4l4f" style="display: none">SCHEDULE OF BALANCE SHEET RELATED TO LEASES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Leases</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Balance Sheet Location</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20260430_zvuSDPJ2BEs4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">April 30, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20251031_zRlNO0HjynGe" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">October 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Assets</td><td> </td> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-style: italic">Noncurrent:</td><td> </td> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--OperatingLeaseRightOfUseAsset_iI_maOAFLRzIPG_zisldrUxs70a" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 31%; padding-bottom: 1pt">Operating</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="width: 31%; text-align: left; padding-bottom: 1pt">Right-of-use asset – operating lease</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 14%; text-align: right">294,526</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 14%; text-align: right">360,681</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_408_ecustom--OperatingAndFinanceLeaseRightofUseAsset_iTI_mtOAFLRzIPG_zZL3EpNZ72o4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total Lease Assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">294,526</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">360,681</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Liabilities</td><td> </td> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-style: italic">Current:</td><td> </td> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--OperatingLeaseLiabilityCurrent_iI_maOAFLLznu4_zifVj6UAppl2" style="vertical-align: bottom; background-color: White"> <td>Operating</td><td> </td> <td style="text-align: left">Operating lease liabilities</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">111,327</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">136,813</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--FinanceLeaseLiabilityCurrent_iI_maOAFLLznu4_zxc80BbBek1g" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Finance</td><td> </td> <td style="text-align: left">Finance lease liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">860</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,043</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-style: italic">Noncurrent:</td><td> </td> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_maOAFLLznu4_zP3b7dLw5S45" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Operating</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left; padding-bottom: 1pt">Operating lease liabilities</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">183,199</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">223,868</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--OperatingAndFinanceLeaseLiability_iTI_mtOAFLLznu4_zgi5NP3jYrAg" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total Lease Liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">295,386</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">365,724</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AA_z1ydBzp3pSfa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> </p> <p id="xdx_89A_ecustom--ScheduleOfOperationsInformationRelatedToLeasesTableTextBlock_zhZskeUnTWzg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table shows the classification and location of the Company’s lease costs in the Consolidated Statements of Operations:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BD_zcWc63XAHF79" style="display: none">SCHEDULE OF OPERATIONS RELATED TO LEASES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20251101__20260430_zb9RDH1smLh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20241101__20250430_zhpT6kU3i4wk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Statements of Operations</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Six Months Ended April 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Location</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_400_eus-gaap--OperatingLeaseCost_maLCzq6o_zppd0c0VlLE2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 31%; text-align: left">Operating lease expense</td><td style="width: 2%"> </td> <td style="width: 31%; text-align: left">General and administrative expense</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">83,004</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">110,273</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Finance lease expense:</td><td> </td> <td style="text-align: right"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--FinanceLeaseInterestExpense_maLCzq6o_zjzFE8m18x97" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Interest on lease liability</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left; padding-bottom: 1pt">Interest expense</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">97</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">452</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--LeaseCost_iT_mtLCzq6o_zYLf4NxPOVr7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total Lease expense</td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: right; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">83,101</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">110,725</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AF_zrkCIDE3FJ65" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_897_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zgmmtKpwlSje" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Minimum contractual obligations for the Company’s leases (undiscounted) as of April 30, 2026 were as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B1_zuNeYOqklEr" style="display: none">SCHEDULE OF MINIMUM CONTRACTUAL OBLIGATIONS OF LEASES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Operating</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Finance</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Fiscal year 2026 (six months remaining)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_c20260430_zoniIf2E2gaf" style="width: 16%; text-align: right" title="Operating lease, Fiscal year 2026 (six months remaining)">83,935</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_c20260430_zPz6T5bwSQdl" style="width: 16%; text-align: right" title="Finance lease, Fiscal year 2026 (six months remaining)">870</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Fiscal year 2027</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_c20260430_zShcQmYSSRvi" style="text-align: right" title="Operating lease, Fiscal year 2027">84,609</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iI_c20260430_zX4HuaTfiPCh" style="text-align: right" title="Finance lease, Fiscal year 2027"><span style="-sec-ix-hidden: xdx2ixbrl1235">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Fiscal year 2028</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_c20260430_zRM6vHdq1ODb" style="text-align: right" title="Operating lease, Fiscal year 2028">67,734</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iI_c20260430_zIficai5eEG" style="text-align: right" title="Finance lease, Fiscal year 2028"><span style="-sec-ix-hidden: xdx2ixbrl1239">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Fiscal year 2029</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_c20260430_zmcbo9NqZic8" style="text-align: right" title="Operating lease, Fiscal year 2029">67,734</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearThree_iI_c20260430_zOGoMzEtBvgd" style="text-align: right" title="Finance lease, Fiscal year 2029"><span style="-sec-ix-hidden: xdx2ixbrl1243">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Thereafter</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree_iI_c20260430_znomq98JI2I" style="border-bottom: Black 1pt solid; text-align: right" title="Operating lease, Thereafter">45,156</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_ecustom--FinanceLeaseLiabilityPaymentsDueAfterYearThree_iI_c20260430_zH1UjmdDFAJi" style="border-bottom: Black 1pt solid; text-align: right" title="Finance lease, Thereafter"><span style="-sec-ix-hidden: xdx2ixbrl1247">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total Lease Payments</td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_c20260430_zmAuiolhYD63" style="text-align: right" title="Operating lease, Total Lease Payments">349,168</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--FinanceLeaseLiabilityPaymentsDue_iI_c20260430_zZGrI37d81mc" style="text-align: right" title="Finance lease, Total Lease Payments">870</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Less Imputed interest</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_c20260430_zVdVWtmOmMH1" style="border-bottom: Black 1pt solid; text-align: right" title="Operating lease, Less Imputed interest">(54,642</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--FinanceLeaseLiabilityUndiscountedExcessAmount_iNI_di_c20260430_z5BQuNQKbzf" style="border-bottom: Black 1pt solid; text-align: right" title="Finance lease, Less Imputed interest">(10</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total lease liability</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--OperatingLeaseLiability_iI_c20260430_zAn2XQbeUdb3" style="border-bottom: Black 2.5pt double; text-align: right" title="Operating lease, Total lease liability">294,526</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--FinanceLeaseLiability_iI_c20260430_z1dKH9ZkOuEe" style="border-bottom: Black 2.5pt double; text-align: right" title="Finance lease, Total lease liability">860</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A8_zjUCDhpHsXKj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_891_ecustom--ScheduleOfOtherInformationTableTextBlock_zhbo4TrE07la" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table shows the weighted average remaining lease term and the weighted average discount rate for the Company’s leases as of the dates indicated:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B8_z5ICRcx7He84" style="display: none">SCHEDULE OF OTHER INFORMATION RELATED TO LEASES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">April 30, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">October 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Operating Leases</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Finance Leases</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Operating Leases</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Finance Leases</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%; text-align: left">Weighted-average remaining lease term (in years)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_90B_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20260430_zNb1vfLXwTj2" title="Weighted-average remaining lease term (in years), operating leases">2.0</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_90F_eus-gaap--FinanceLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20260430_zkhgeJEHSvng" title="Weighted-average remaining lease term (in years), finance leases">0.25</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_902_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20251031_zsay4GJVBmNk" title="Weighted-average remaining lease term (in years), operating leases">3.9</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_905_eus-gaap--FinanceLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20251031_zNXKK5QuqFG1" title="Weighted-average remaining lease term (in years), finance leases">0.54</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted-average discount rate ⁽¹⁾</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20260430_fKDEp_zQDP3BNDrGNf" title="Weighted-average discount rate, operating lease">10.00</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--FinanceLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20260430_fKDEp_zBAAA6mJuX52" title="Weighted-average discount rate, finance leases">6.78</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20251031_fKDEp_zqrIBQcdJZRl" title="Weighted-average discount rate, operating lease">10.00</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_eus-gaap--FinanceLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20251031_fKDEp_zBLpbmGZrU5f" title="Weighted-average discount rate, finance leases">6.69</span></td><td style="text-align: left">%</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup id="xdx_F0B_zS96IkpTTK8a">(1)</sup></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F12_ziph7KNojPlf" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The discount rate used for the operating lease is based on the Company’s incremental borrowing rate at lease commencement and may be adjusted if modification to lease terms or lease reassessments occur. The discount rate used for finance leases is based on the rates implicit in the leases.</span></td></tr> </table> <p id="xdx_8AE_zep3wzLy1xe2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89B_eus-gaap--ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_zs9KtByz8741" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table includes other quantitative information for the Company’s leases for the periods indicated:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BE_zfX7hRYlHxoi" style="display: none">SCHEDULE OF CASH FLOW INFORMATION RELATED TO LEASES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20251101__20260430_zgDoIMriReNf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20241101__20250430_z3JnHSCenuRi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Six Months Ended April 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Cash paid for amounts included in measurement of lease liabilities:</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr id="xdx_406_eus-gaap--OperatingLeasePayments_zt3VFYfV6XHc" style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: left">Cash payments for operating leases</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">82,824</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">81,515</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--FinanceLeasePrincipalPayments_zv9g2Ajx0cBg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Cash payments for finance leases</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">4,280</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">7,253</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8AE_zD0QxPOv7Tf1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recorded amortization of the operating lease right-of-use asset of $<span id="xdx_90A_eus-gaap--OperatingLeaseRightOfUseAssetAmortizationExpense_c20260201__20260430_zTxRmnw0x3Il" title="Amortization of operating lease right-of-use asset">33,489</span> and $<span id="xdx_902_eus-gaap--OperatingLeaseRightOfUseAssetAmortizationExpense_c20251101__20260430_z6M7b7Y2eQuj" title="Amortization of operating lease right-of-use asset">66,155</span>, and $<span id="xdx_901_eus-gaap--OperatingLeaseRightOfUseAssetAmortizationExpense_c20250201__20250430_zdRX9mzleHP1" title="Amortization of operating lease right-of-use asset">29,681</span> and $<span id="xdx_904_eus-gaap--OperatingLeaseRightOfUseAssetAmortizationExpense_c20241101__20250430_zdFLXuZVg742" title="Amortization of operating lease right-of-use asset">60,961</span> for the three and six months ended April 30, 2026 and 2025, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> P5Y <p id="xdx_893_ecustom--ScheduleOfBalanceSheetInformationRelatedToLeasesTableTextBlock_zAzcXxraEFI6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table shows the classification and location of the Company’s leases in the Consolidated Balance Sheets:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B2_zTYCDm5g4l4f" style="display: none">SCHEDULE OF BALANCE SHEET RELATED TO LEASES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Leases</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Balance Sheet Location</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20260430_zvuSDPJ2BEs4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">April 30, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20251031_zRlNO0HjynGe" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">October 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Assets</td><td> </td> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-style: italic">Noncurrent:</td><td> </td> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--OperatingLeaseRightOfUseAsset_iI_maOAFLRzIPG_zisldrUxs70a" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 31%; padding-bottom: 1pt">Operating</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="width: 31%; text-align: left; padding-bottom: 1pt">Right-of-use asset – operating lease</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 14%; text-align: right">294,526</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 14%; text-align: right">360,681</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_408_ecustom--OperatingAndFinanceLeaseRightofUseAsset_iTI_mtOAFLRzIPG_zZL3EpNZ72o4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total Lease Assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">294,526</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">360,681</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Liabilities</td><td> </td> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-style: italic">Current:</td><td> </td> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--OperatingLeaseLiabilityCurrent_iI_maOAFLLznu4_zifVj6UAppl2" style="vertical-align: bottom; background-color: White"> <td>Operating</td><td> </td> <td style="text-align: left">Operating lease liabilities</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">111,327</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">136,813</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--FinanceLeaseLiabilityCurrent_iI_maOAFLLznu4_zxc80BbBek1g" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Finance</td><td> </td> <td style="text-align: left">Finance lease liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">860</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,043</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-style: italic">Noncurrent:</td><td> </td> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_maOAFLLznu4_zP3b7dLw5S45" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Operating</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left; padding-bottom: 1pt">Operating lease liabilities</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">183,199</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">223,868</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--OperatingAndFinanceLeaseLiability_iTI_mtOAFLLznu4_zgi5NP3jYrAg" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total Lease Liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">295,386</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">365,724</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 294526 360681 294526 360681 111327 136813 860 5043 183199 223868 295386 365724 <p id="xdx_89A_ecustom--ScheduleOfOperationsInformationRelatedToLeasesTableTextBlock_zhZskeUnTWzg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table shows the classification and location of the Company’s lease costs in the Consolidated Statements of Operations:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BD_zcWc63XAHF79" style="display: none">SCHEDULE OF OPERATIONS RELATED TO LEASES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20251101__20260430_zb9RDH1smLh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20241101__20250430_zhpT6kU3i4wk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Statements of Operations</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Six Months Ended April 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Location</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_400_eus-gaap--OperatingLeaseCost_maLCzq6o_zppd0c0VlLE2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 31%; text-align: left">Operating lease expense</td><td style="width: 2%"> </td> <td style="width: 31%; text-align: left">General and administrative expense</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">83,004</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">110,273</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Finance lease expense:</td><td> </td> <td style="text-align: right"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--FinanceLeaseInterestExpense_maLCzq6o_zjzFE8m18x97" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Interest on lease liability</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left; padding-bottom: 1pt">Interest expense</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">97</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">452</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--LeaseCost_iT_mtLCzq6o_zYLf4NxPOVr7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total Lease expense</td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: right; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">83,101</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">110,725</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 83004 110273 97 452 83101 110725 <p id="xdx_897_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zgmmtKpwlSje" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Minimum contractual obligations for the Company’s leases (undiscounted) as of April 30, 2026 were as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B1_zuNeYOqklEr" style="display: none">SCHEDULE OF MINIMUM CONTRACTUAL OBLIGATIONS OF LEASES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Operating</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Finance</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Fiscal year 2026 (six months remaining)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_c20260430_zoniIf2E2gaf" style="width: 16%; text-align: right" title="Operating lease, Fiscal year 2026 (six months remaining)">83,935</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_c20260430_zPz6T5bwSQdl" style="width: 16%; text-align: right" title="Finance lease, Fiscal year 2026 (six months remaining)">870</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Fiscal year 2027</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_c20260430_zShcQmYSSRvi" style="text-align: right" title="Operating lease, Fiscal year 2027">84,609</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iI_c20260430_zX4HuaTfiPCh" style="text-align: right" title="Finance lease, Fiscal year 2027"><span style="-sec-ix-hidden: xdx2ixbrl1235">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Fiscal year 2028</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_c20260430_zRM6vHdq1ODb" style="text-align: right" title="Operating lease, Fiscal year 2028">67,734</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iI_c20260430_zIficai5eEG" style="text-align: right" title="Finance lease, Fiscal year 2028"><span style="-sec-ix-hidden: xdx2ixbrl1239">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Fiscal year 2029</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_c20260430_zmcbo9NqZic8" style="text-align: right" title="Operating lease, Fiscal year 2029">67,734</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearThree_iI_c20260430_zOGoMzEtBvgd" style="text-align: right" title="Finance lease, Fiscal year 2029"><span style="-sec-ix-hidden: xdx2ixbrl1243">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Thereafter</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree_iI_c20260430_znomq98JI2I" style="border-bottom: Black 1pt solid; text-align: right" title="Operating lease, Thereafter">45,156</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_ecustom--FinanceLeaseLiabilityPaymentsDueAfterYearThree_iI_c20260430_zH1UjmdDFAJi" style="border-bottom: Black 1pt solid; text-align: right" title="Finance lease, Thereafter"><span style="-sec-ix-hidden: xdx2ixbrl1247">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total Lease Payments</td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_c20260430_zmAuiolhYD63" style="text-align: right" title="Operating lease, Total Lease Payments">349,168</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--FinanceLeaseLiabilityPaymentsDue_iI_c20260430_zZGrI37d81mc" style="text-align: right" title="Finance lease, Total Lease Payments">870</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Less Imputed interest</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_c20260430_zVdVWtmOmMH1" style="border-bottom: Black 1pt solid; text-align: right" title="Operating lease, Less Imputed interest">(54,642</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--FinanceLeaseLiabilityUndiscountedExcessAmount_iNI_di_c20260430_z5BQuNQKbzf" style="border-bottom: Black 1pt solid; text-align: right" title="Finance lease, Less Imputed interest">(10</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total lease liability</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--OperatingLeaseLiability_iI_c20260430_zAn2XQbeUdb3" style="border-bottom: Black 2.5pt double; text-align: right" title="Operating lease, Total lease liability">294,526</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--FinanceLeaseLiability_iI_c20260430_z1dKH9ZkOuEe" style="border-bottom: Black 2.5pt double; text-align: right" title="Finance lease, Total lease liability">860</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 83935 870 84609 67734 67734 45156 349168 870 54642 10 294526 860 <p id="xdx_891_ecustom--ScheduleOfOtherInformationTableTextBlock_zhbo4TrE07la" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table shows the weighted average remaining lease term and the weighted average discount rate for the Company’s leases as of the dates indicated:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B8_z5ICRcx7He84" style="display: none">SCHEDULE OF OTHER INFORMATION RELATED TO LEASES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">April 30, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">October 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Operating Leases</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Finance Leases</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Operating Leases</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Finance Leases</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%; text-align: left">Weighted-average remaining lease term (in years)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_90B_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20260430_zNb1vfLXwTj2" title="Weighted-average remaining lease term (in years), operating leases">2.0</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_90F_eus-gaap--FinanceLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20260430_zkhgeJEHSvng" title="Weighted-average remaining lease term (in years), finance leases">0.25</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_902_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20251031_zsay4GJVBmNk" title="Weighted-average remaining lease term (in years), operating leases">3.9</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_905_eus-gaap--FinanceLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20251031_zNXKK5QuqFG1" title="Weighted-average remaining lease term (in years), finance leases">0.54</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted-average discount rate ⁽¹⁾</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20260430_fKDEp_zQDP3BNDrGNf" title="Weighted-average discount rate, operating lease">10.00</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--FinanceLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20260430_fKDEp_zBAAA6mJuX52" title="Weighted-average discount rate, finance leases">6.78</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20251031_fKDEp_zqrIBQcdJZRl" title="Weighted-average discount rate, operating lease">10.00</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_eus-gaap--FinanceLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20251031_fKDEp_zBLpbmGZrU5f" title="Weighted-average discount rate, finance leases">6.69</span></td><td style="text-align: left">%</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup id="xdx_F0B_zS96IkpTTK8a">(1)</sup></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F12_ziph7KNojPlf" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The discount rate used for the operating lease is based on the Company’s incremental borrowing rate at lease commencement and may be adjusted if modification to lease terms or lease reassessments occur. The discount rate used for finance leases is based on the rates implicit in the leases.</span></td></tr> </table> P2Y P0Y3M P3Y10M24D P0Y6M14D 0.1000 0.0678 0.1000 0.0669 <p id="xdx_89B_eus-gaap--ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_zs9KtByz8741" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table includes other quantitative information for the Company’s leases for the periods indicated:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BE_zfX7hRYlHxoi" style="display: none">SCHEDULE OF CASH FLOW INFORMATION RELATED TO LEASES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20251101__20260430_zgDoIMriReNf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20241101__20250430_z3JnHSCenuRi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Six Months Ended April 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Cash paid for amounts included in measurement of lease liabilities:</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr id="xdx_406_eus-gaap--OperatingLeasePayments_zt3VFYfV6XHc" style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: left">Cash payments for operating leases</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">82,824</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">81,515</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--FinanceLeasePrincipalPayments_zv9g2Ajx0cBg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Cash payments for finance leases</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">4,280</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">7,253</td><td style="text-align: left"> </td></tr> </table> 82824 81515 4280 7253 33489 66155 29681 60961 <p id="xdx_803_eus-gaap--DebtDisclosureTextBlock_zjb8rYVM9Rx8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 7 – <span id="xdx_825_zAx0Q1fQ9pF3">DEBT</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_892_eus-gaap--ScheduleOfDebtInstrumentsTextBlock_zTyMCXZsaotb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The table below presents outstanding debt instruments as of April 30, 2026 and October 31, 2025:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B9_zuwaxQQ7iVN9" style="display: none">SCHEDULE OF OUTSTANDING DEBT INSTRUMENTS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20260430_zXNP5Kxghvt5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">April 30, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20251031_zf9sfJdnu2K1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">October 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; font-style: italic; text-align: left">Short Term</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--ConvertibleSeriesSeniorSecureShortTermNotesPayableOne_iNI_di_msSTBz8gR_zYFDvMslhlZ1" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 60%; text-align: left">2024 Senior secured convertible notes payable</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">125,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">593,750</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_ecustom--ConvertibleSeriesSeniorSecureShortTermNotesPayableTwo_iNI_di_msSTBz8gR_z88U52o6pwi2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">2025 Senior secured convertible notes payable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><p style="margin: 0">8,187,500</p></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1304">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_406_ecustom--DiscountConvertibleSeriesSeniorSecureShortTermNotesPayable_iI_maSTBz8gR_zA467Gs81RZ2" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Discount 2025 Senior secured convertible notes payable</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><p style="margin: 0">(1,590,876</p></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><p style="margin: 0"><span style="-sec-ix-hidden: xdx2ixbrl1307">-</span></p></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--ShortTermBorrowings_iTI_maDLASCzQh4_mtSTBz8gR_zUT2wYS4gBHk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; font-style: italic; text-align: left">Total Short-Term Debt</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,721,624</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">593,750</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; font-style: italic; text-align: left">Long Term</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--UnsecuredDebtCurrent_iI_maLTDNzb5m_zF7FlqYzwAk7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Unsecured 6% note payable – related party</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">767,288</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">767,288</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_ecustom--UnsecuredNotePayableRelatedPartyNoncurrentOne_iI_maLTDNzb5m_zNfiZKKZCih9" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Unsecured 4% note payable – related party</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,221,958</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,221,958</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--ConvertibleLongTermNotesPayable_iI_maLTDNzb5m_zKVmsb3TPP2h" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">2022 Series convertible notes</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">200,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">200,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_ecustom--ConvertibleLongTermNotesPayableStockSettled_iI_maLTDNzb5m_zOT84e9el3J4" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">2023 Series convertible notes – stock settled</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">405,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">405,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_ecustom--ConvertibleLongTermNotesPayableSeriesDiscount_iNI_di_msLTDNzb5m_zCNHv5t3fTu1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Discount 2023 Series convertible notes</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(30,171</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(37,834</td><td style="text-align: left">)</td></tr> <tr id="xdx_401_ecustom--ConvertibleSeriesBLongTermNotesPayableStockSettled_iI_maLTDNzb5m_zyzs2sIbyCP7" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">2023 Series B convertible notes – stock settled</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,312,600</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,312,600</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_ecustom--ConvertibleSeriesBLongTermNotesPayableSeriesDiscount_iNI_di_msLTDNzb5m_zQuzTqTlyfMh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Discount 2023 Series B convertible notes</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(590,079</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(676,304</td><td style="text-align: left">)</td></tr> <tr id="xdx_40E_ecustom--SeniorSecuredConvertibleLongTermNotesPayable_iI_maLTDNzb5m_zVn6WiZO4sba" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">2025 Senior secured convertible notes payable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1333">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,187,500</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_ecustom--SeniorSecuredConvertibleLongTermNotesPayableDiscount_iNI_di_msLTDNzb5m_zf2hcheNOFEd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Discount 2025 Senior secured convertible notes payable</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1336">-</span></td><td style="padding-bottom: 1pt; text-align: left"></td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(2,388,419</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40E_eus-gaap--LongTermDebtNoncurrent_iTI_mtLTDNzb5m_maDLASCzQh4_zEm4plK0LmE6" style="vertical-align: bottom; background-color: White"> <td style="font-style: italic; text-align: left; padding-bottom: 1pt">Total Long-Term Debt</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">3,286,596</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">8,991,789</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--DebtLongtermAndShorttermCombinedAmount_iTI_mtDLASCzQh4_zLkyf8ckCeYl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-style: italic; text-align: left; padding-bottom: 2.5pt">Total Debt</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">10,008,220</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">9,585,539</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AD_zQt6WMQox9Bd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_895_eus-gaap--ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_z0ZPr1xnoqkk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The table below presents the future maturities of outstanding debt obligations as of April 30, 2026:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BC_zfHsOpqkWJzl" style="display: none">SCHEDULE OF FUTURE MATURITIES OUTSTANDING DEBT OBLIGATIONS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: center"> </td><td style="text-align: center"> </td> <td style="text-align: center"> </td><td id="xdx_496_20260430_zyWzqousEqXi" style="text-align: center"> </td><td style="text-align: center"> </td></tr> <tr id="xdx_40F_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_iI_maLTDz6x0_zM2izD568994" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">Fiscal year 2026</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">125,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_maLTDz6x0_zbFUd7xDqFx" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Fiscal year 2027</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,387,500</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_maLTDz6x0_zxBLbHoclfa8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Fiscal year 2028</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,717,600</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_iI_maLTDz6x0_zCn8kktad9G9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Fiscal year 2029</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1353">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_iI_maLTDz6x0_zNHwSBvpDg7c" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Fiscal year 2030</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1355">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_iI_maLTDz6x0_zbRsY60So1x1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Fiscal year 2031</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,989,246</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--LongTermDebt_iTI_mtLTDz6x0_zgabJkW54a2c" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">12,219,346</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A1_zLeDiHWkYx8l" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Unsecured 6% Note Payable - Related Party</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest expense on this note was $<span id="xdx_906_eus-gaap--InterestExpense_c20260201__20260430__us-gaap--LongtermDebtTypeAxis__custom--UnsecuredSixPercentageNotePayableRelatedPartyDebtMember_zRCwxhiVa5Gl" title="Interest expense">11,225</span> and $<span id="xdx_907_eus-gaap--InterestExpense_c20250201__20250430__us-gaap--LongtermDebtTypeAxis__custom--UnsecuredSixPercentageNotePayableRelatedPartyDebtMember_z1Y9SGTrsmSe" title="Interest expense">22,829</span>, and $<span id="xdx_903_eus-gaap--InterestExpense_c20251101__20260430__us-gaap--LongtermDebtTypeAxis__custom--UnsecuredSixPercentageNotePayableRelatedPartyDebtMember_zl2yb432f4x8" title="Interest expense">11,226</span> and $<span id="xdx_90B_eus-gaap--InterestExpense_c20241101__20250430__us-gaap--LongtermDebtTypeAxis__custom--UnsecuredSixPercentageNotePayableRelatedPartyDebtMember_zXs6BnPuy5P7" title="Interest expense">22,829</span>, for the three and six months ended April 30, 2026 and 2025, respectively. During the six months ended April 30, 2026, the Company paid down the interest on this note by $<span id="xdx_903_eus-gaap--InterestPaid_c20251101__20260430__us-gaap--LongtermDebtTypeAxis__custom--UnsecuredSixPercentageNotePayableRelatedPartyDebtMember_z7s8N1TEsBtf" title="Interest paid down">51,923</span>. Accrued interest on this note was $<span id="xdx_907_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20260430__us-gaap--LongtermDebtTypeAxis__custom--UnsecuredSixPercentageNotePayableRelatedPartyDebtMember_zloQtZCv9q9g" title="Accrued interest">201,219</span> and $<span id="xdx_900_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20251031__us-gaap--LongtermDebtTypeAxis__custom--UnsecuredSixPercentageNotePayableRelatedPartyDebtMember_zAv1dEwpuZp2" title="Accrued interest">230,313</span> as of April 30, 2026 and October 31, 2025, respectively. This note is unsecured. The original maturity date of this note was <span id="xdx_907_eus-gaap--DebtInstrumentMaturityDate_dd_c20251101__20260430__us-gaap--LongtermDebtTypeAxis__custom--UnsecuredSixPercentageNotePayableRelatedPartyDebtMember_zciNcW9tjtR7" title="Debt instrument, maturity date">December 31, 2025</span>. As of December 31, 2025, the Company and the related party signed an amendment to this note to extend the maturity date to December 31, 2030. In addition to the change to the maturity date, the Company agreed to pay the lender $<span id="xdx_90D_eus-gaap--RepaymentsOfLinesOfCredit_c20251101__20260430__us-gaap--LongtermDebtTypeAxis__custom--UnsecuredSixPercentageNotePayableRelatedPartyDebtMember_zg8QJaelfmPj" title="Repayments of accrued interest to lender">150,000</span> per year, with such payments to be applied to accrued interest on this note.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Unsecured 4% Note Payable - Related Party</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest expense on this note was $<span id="xdx_901_eus-gaap--InterestExpense_c20260201__20260430__us-gaap--LongtermDebtTypeAxis__custom--UnsecuredFourPercentageNotePayableRelatedPartyDebtMember_z7hIiWriwoBk" title="Interest expense">11,918</span> and $<span id="xdx_905_eus-gaap--InterestExpense_c20250201__20250430__us-gaap--LongtermDebtTypeAxis__custom--UnsecuredFourPercentageNotePayableRelatedPartyDebtMember_ztNR4VCgwe63" title="Interest expense">24,238</span>, and $<span id="xdx_908_eus-gaap--InterestExpense_c20251101__20260430__us-gaap--LongtermDebtTypeAxis__custom--UnsecuredFourPercentageNotePayableRelatedPartyDebtMember_zdUGcBXj2pt8" title="Interest expense">11,918</span> and $<span id="xdx_905_eus-gaap--InterestExpense_c20241101__20250430__us-gaap--LongtermDebtTypeAxis__custom--UnsecuredFourPercentageNotePayableRelatedPartyDebtMember_z6LiyVQ9KRA1" title="Interest expense">24,238</span>, for the three and six months ended April 30, 2026, and 2025, respectively. Accrued interest on this note was $<span id="xdx_90F_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20260430__us-gaap--LongtermDebtTypeAxis__custom--UnsecuredFourPercentageNotePayableRelatedPartyDebtMember_zl3h2wNjKxGi" title="Accrued interest">268,764</span> and $<span id="xdx_902_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20251031__us-gaap--LongtermDebtTypeAxis__custom--UnsecuredFourPercentageNotePayableRelatedPartyDebtMember_zxZATOlhBUv2" title="Accrued interest">244,526</span> as of April 30, 2026 and October 31, 2025, respectively. This note is unsecured. The original maturity date of this note was <span id="xdx_904_eus-gaap--DebtInstrumentMaturityDate_dd_c20251101__20260430__us-gaap--LongtermDebtTypeAxis__custom--UnsecuredFourPercentageNotePayableRelatedPartyDebtMember_zMOkVxKKzSS4" title="Debt instrument, maturity date">December 31, 2025</span> As of December 31, 2025, the Company and the related party signed an amendment to this note to extend the maturity date to December 31, 2030.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>2022 Series Convertible Notes</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During June and July, 2022, the Company issued a total of $<span id="xdx_906_eus-gaap--ProceedsFromConvertibleDebt_c20220601__20220630__us-gaap--LongtermDebtTypeAxis__custom--TwoThousandTwentyTwoSeriesConvertibleNotesMember_zV9kldO45Uj" title="Proceeds from convertible debt"><span id="xdx_90D_eus-gaap--ProceedsFromConvertibleDebt_c20220701__20220731__us-gaap--LongtermDebtTypeAxis__custom--TwoThousandTwentyTwoSeriesConvertibleNotesMember_ztJ4egK0o1L2" title="Proceeds from convertible debt">200,000</span></span> in 2022 Series Convertible notes to two unrelated parties. These notes are unsecured, earn interest at a rate of <span id="xdx_907_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220630__us-gaap--LongtermDebtTypeAxis__custom--TwoThousandTwentyTwoSeriesConvertibleNotesMember_zGjRdcYzNwGg" title="Interest rate"><span id="xdx_901_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220731__us-gaap--LongtermDebtTypeAxis__custom--TwoThousandTwentyTwoSeriesConvertibleNotesMember_zaRnevI3n05c" title="Interest rate">5</span></span>% per annum and mature in June and July of 2027. These notes are payable solely in common stock of the Company and are convertible (i) upon the closing of a Qualified Financing of at least $<span id="xdx_904_eus-gaap--ConvertibleNotesPayable_iI_c20220630__us-gaap--LongtermDebtTypeAxis__custom--TwoThousandTwentyTwoSeriesConvertibleNotesMember_zVM5lFHlIJ4d" title="Convertible notes payable"><span id="xdx_908_eus-gaap--ConvertibleNotesPayable_iI_c20220731__us-gaap--LongtermDebtTypeAxis__custom--TwoThousandTwentyTwoSeriesConvertibleNotesMember_z6Fr76GhckHb" title="Convertible notes payable">5,000,000</span></span>, (ii) upon the closing of a change in control, (iii) at the option of the holder of the notes or (iv) at maturity. During the three and six months ended April 30, 2026 and 2025, the Company recorded $<span id="xdx_909_eus-gaap--InterestExpense_c20260201__20260430__us-gaap--LongtermDebtTypeAxis__custom--TwoThousandTwentyTwoSeriesConvertibleNotesMember_zdShQBJiFsXa" title="Interest expense">2,438</span> and $<span id="xdx_906_eus-gaap--InterestExpense_c20250201__20250430__us-gaap--LongtermDebtTypeAxis__custom--TwoThousandTwentyTwoSeriesConvertibleNotesMember_znwBSOYLEVs4" title="Interest expense">4,959</span>, and $<span id="xdx_908_eus-gaap--InterestExpense_c20251101__20260430__us-gaap--LongtermDebtTypeAxis__custom--TwoThousandTwentyTwoSeriesConvertibleNotesMember_zEXdLqlkhEvb" title="Interest expense">2,438</span> and $<span id="xdx_906_eus-gaap--InterestExpense_c20241101__20250430__us-gaap--LongtermDebtTypeAxis__custom--TwoThousandTwentyTwoSeriesConvertibleNotesMember_zhjpKTuDPpg3" title="Interest expense">4,959</span> in interest expense on these notes, respectively. As of April 30, 2026 and October 31, 2025, the Company had accrued $<span id="xdx_902_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20260430__us-gaap--LongtermDebtTypeAxis__custom--TwoThousandTwentyTwoSeriesConvertibleNotesMember_zBggODbU8JK5" title="Accrued interest">38,192</span> and $<span id="xdx_90A_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20251031__us-gaap--LongtermDebtTypeAxis__custom--TwoThousandTwentyTwoSeriesConvertibleNotesMember_zCVDqZ8l4fT2" title="Accrued interest">33,233</span>, respectively, in interest on these notes.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>2023 Series Convertible Notes – Stock Settled</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 6, 2023, the Company sold $<span id="xdx_906_eus-gaap--ProceedsFromConvertibleDebt_c20230105__20230106__us-gaap--LongtermDebtTypeAxis__custom--TwoThousandTwentyThreeSeriesConvertibleNotesStockSettledMember_zsh1nF9VmmTg" title="Proceeds from issuance of convertible notes">405,000</span> of its <span id="xdx_903_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230106__us-gaap--LongtermDebtTypeAxis__custom--TwoThousandTwentyThreeSeriesConvertibleNotesStockSettledMember_zscQc3I8fu4k" title="Interest rate">8</span>%, unsecured 2023 Series Convertible Notes - Stock Settled (the “January 2023 Notes”) and common stock purchase warrants (“January 2023 Warrants”) to five investors.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On various dates during March and April 2023, the Company sold $<span id="xdx_909_eus-gaap--ProceedsFromConvertibleDebt_c20230301__20230331__us-gaap--LongtermDebtTypeAxis__custom--TwoThousandTwentyThreeSeriesConvertibleNotesStockSettledMember_z96wmBkzuBui" title="Proceeds from issuance of convertible notes"><span id="xdx_903_eus-gaap--ProceedsFromConvertibleDebt_c20230401__20230430__us-gaap--LongtermDebtTypeAxis__custom--TwoThousandTwentyThreeSeriesConvertibleNotesStockSettledMember_zOwY4v78im42" title="Proceeds from issuance of convertible notes">787,600</span></span> of its <span id="xdx_903_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230331__us-gaap--LongtermDebtTypeAxis__custom--TwoThousandTwentyThreeSeriesConvertibleNotesStockSettledMember_zxa58ABMhgIl" title="Interest rate"><span id="xdx_907_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230430__us-gaap--LongtermDebtTypeAxis__custom--TwoThousandTwentyThreeSeriesConvertibleNotesStockSettledMember_z9D78BXeT2F3" title="Interest rate">8</span></span>%, unsecured 2023 Series B Convertible Notes - Stock Settled (the “March 2023 Notes”) and common stock purchase warrants (“March 2023 Warrants”) to six investors.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On various dates during June and July 2023, the Company sold $<span id="xdx_903_eus-gaap--ProceedsFromConvertibleDebt_c20230601__20230630__us-gaap--LongtermDebtTypeAxis__custom--TwoThousandTwentyThreeSeriesConvertibleNotesStockSettledMember_ziNCWTZTu3oc" title="Proceeds from issuance of convertible notes"><span id="xdx_905_eus-gaap--ProceedsFromConvertibleDebt_c20230701__20230731__us-gaap--LongtermDebtTypeAxis__custom--TwoThousandTwentyThreeSeriesConvertibleNotesStockSettledMember_zlXLtsDfxYHd" title="Proceeds from issuance of convertible notes">525,000</span></span> of its <span id="xdx_900_eus-gaap--DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_pid_dp_uPure_c20230601__20230630__us-gaap--LongtermDebtTypeAxis__custom--TwoThousandTwentyThreeSeriesConvertibleNotesStockSettledMember_ztjw9XRc8Nqb" title="Debt instrument, convertible, threshold percentage of stock price trigger"><span id="xdx_90B_eus-gaap--DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_pid_dp_uPure_c20230701__20230731__us-gaap--LongtermDebtTypeAxis__custom--TwoThousandTwentyThreeSeriesConvertibleNotesStockSettledMember_znTsdF5lk4Zi" title="Interest rate">8</span></span>%, unsecured 2023 Series B Convertible Notes - Stock Settled (the “June 2023 Notes”) and common stock purchase warrants (“June 2023 Warrants”) to three investors.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The sale and purchase were made through a Convertible Note and Warrant Purchase Agreement (“Purchase Agreement”) entered into with each investor. The Company followed the guidance of Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) ASC 480 “Distinguishing Liabilities from Equity” to account for the stock settled debt and ASC 815 “Derivatives and Hedging” to account for the derivative related to the notes and also to determine the number of warrants to be issued at the time of the issuance of the January 2023 Notes, March 2023 Notes, or the June 2023 Notes.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each of the January 2023 Notes, March 2023 Notes, and June 2023 Notes bear interest at the rate of eight per cent per annum and are payable solely in shares of the Company’s common stock. Each of the January 2023 Notes, March 2023 Notes, and June 2023 Notes may be converted at any time at the option of the holder and are payable in full at the earliest of (i) the completion of a “Qualified Financing,” as defined below, (ii) a change in control, (iii) in the event of default, or (iv) the maturity date, which is five years from the date of issuance. A Qualified Financing is defined in the Purchase Agreement as any financing completed after the date of issuance of either the January 2023 Notes, March 2023 Notes, or June 2023 Notes involving the sale of the Company’s equity securities primarily for capital raising purposes resulting in gross proceeds to the Company of at least $<span id="xdx_903_eus-gaap--ProceedsFromConvertibleDebt_pn6n6_c20251101__20260430__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zU8oIORJ3Eul" title="Proceeds from issuance of convertible notes">5</span> million. Upon completion of a Qualified Financing, each of the January 2023 Notes, March 2023 Notes, and June 2023 Notes is convertible into the securities issued in such financing (the “Qualified Financing Securities”) in an amount determined by dividing (i) the outstanding principal on the January 2023 Notes, March 2023 Notes, or June 2023 Notes plus all accrued interest by (ii) the lessor of (x) the “Discounted Qualified Financing Price” and (y) the “Capped Price.” In the event of a change in control or default, voluntary conversion or upon maturity, each of the January 2023 Notes, March 2023 Notes, and June 2023 Notes is convertible into that number of shares of the Company’s common stock that equals (i) the outstanding principal amount of each of the January 2023 Notes, March 2023 Notes, and June 2023 Notes plus any accrued but unpaid interest, divided by (ii) the Capped Price.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Discounted Qualified Financing Price is defined as the per share price at which the shares of the Qualified Financing Securities are sold in such Qualified Financing as determined for accounting purposes under GAAP, multiplied by <span id="xdx_902_eus-gaap--DebtInstrumentConvertibleStockPriceTrigger_c20251101__20260430_zl82xnv2w0mg" title="Conversion price trigger">0.75</span>. The Capped Price is the per share price implied by a fully-diluted (on an as-converted to common stock basis), pre-money valuation of $<span id="xdx_906_ecustom--PremoneyValuationAmount_iI_c20260430_zmdtZXMYueO8" title="Pre-money valuation amount">200,000,000</span> for the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each January 2023 Warrant issuable by the Company pursuant to the Purchase Agreement entitles the holder to purchase that number of fully paid and nonassessable shares of the Company’s common stock determined (A) in the case following a Qualified Financing, by dividing (i) the sum of the aggregate outstanding principal amount of the January 2023 Note plus all accrued and unpaid interest thereon at the time of conversion multiplied by <span id="xdx_90C_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20230131_zPLNM9mDuc1b" title="Conversion price">0.25</span> by (ii) the quotient of the Discounted Qualified Financing Price divided by <span id="xdx_90D_eus-gaap--DebtInstrumentConvertibleStockPriceTrigger_c20230101__20230131_zz2R5l8iS3Uk" title="Conversion price trigger">0.75</span>, or (B) in connection with a Change of Control, by dividing (i) the sum of the aggregate outstanding principal amount of the January 2023 Note plus all accrued and unpaid interest thereon at the time of the January 2023 Note’s conversion, by (ii) the Capped Price, subject to adjustment as set forth in the January 2023 Warrant. In each case, the January 2023 Warrants are exercisable at a price of $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230131_zWvIO2frHhwd" title="Exercise price">16.25</span> per share (as adjusted for the July 2023, <span id="xdx_90C_eus-gaap--StockholdersEquityReverseStockSplit_c20230101__20230131_z9moXOGQiKE8" title="Reverse stock split, description">1 to 26 reverse stock split</span>) for a period of <span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20230131_z6qi2HsLidhe" title="Warrants term">five years</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each March 2023 Warrant and June 2023 Warrant issuable by the Company pursuant to the Purchase Agreement entitles the holder to purchase that number of fully paid and nonassessable shares of the Company’s common stock determined (A) in the case following a Qualified Financing, by dividing (i) the sum of the aggregate outstanding principal amount of the March 2023 Note plus all accrued and unpaid interest thereon at the time of conversion by (ii) the quotient of the Discounted Qualified Financing Price divided by <span id="xdx_909_eus-gaap--DebtInstrumentConvertibleStockPriceTrigger_c20230301__20230331_zPP13hpsMidk" title="Conversion price trigger"><span id="xdx_90C_eus-gaap--DebtInstrumentConvertibleStockPriceTrigger_c20230601__20230630_z5nNdFGmqJvd" title="Conversion price trigger">0.75</span></span>, or (B) in connection with a Change of Control, by dividing (i) the sum of the aggregate outstanding principal amount of the March 2023 Note or June 2023 Note plus all accrued and unpaid interest thereon at the time of the March 2023 Note’s or June 2023 Note’s conversion, by (ii) the Capped Price, subject to adjustment as set forth in the March 2023 Warrant or June 2023 Warrant. In each case, the March 2023 Warrants and June 2023 Warrants are exercisable at a price of $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230331_zb6lpbA6Gs2j" title="Exercise price"><span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230630_z0NrYIrcKix4" title="Exercise price">16.25</span></span> per share for a period of <span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20230331_zcm6PdMWFeV" title="Warrants term"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20230630_zMD3lhRLCYc9" title="Warrants term">five years</span></span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Participation Rights</span>. Each of the January 2023 Notes, March 2023 Notes, and June 2023 Notes entitle the holder to purchase in a Qualified Financing an amount of Qualified Financing Securities (as defined above) up to <span id="xdx_903_ecustom--DebtInstrumentQualifiedFinancingSecuritiesPercentage_iI_pid_dp_uPure_c20260430_zyhZofHk9xx" title="Qualified financing securities percentage">200</span>% of the aggregate principal amount of either the January 2023 Note, March 2023 Note, or June 2023 Notes, respectively, subscribed for by such holder in this Offering.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company contemplated ASC 815-15-25-1 related to the valuation of the embedded conversion feature contained in the January 2023 Notes, March 2023 Notes and June 2023 Notes. The Company determined, per the guidance, the embedded conversion feature did not meet the criteria to be classified as a derivative.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company assessed the January 2023 Warrants, March 2023 Warrants, and June 2023 first under ASC 480. Based on the attributes of the January 2023 Warrants, March 2023 Warrants, and June 2023 Warrants, the Company determined that each are outside of the scope of ASC 480 and proceeded to assess each under ASC 815 to determine if any are considered indexed to the Company’s own common stock. Because the inputs which affect the number of shares to be issued upon exercise of the January 2023 Warrants, March 2023 Warrants, and June 2023 Warrants are not the inputs per 815-40-15-7E, none are deemed to be indexed to the Company’s own stock and have been recorded as liabilities under ASC 815 (Note 3) at the fair market value. At issuance, the Company recorded a warrant liability related to the January 2023 Warrants of $<span id="xdx_906_ecustom--DerivativeWarrantLiability_iI_c20230430__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyThreeWarrantsMember_zxqxihvv6zo5" title="Derivative warrant liability">73,213</span>, which amount is remeasured at fair market value at the end of each reporting period. The warrant liability of $<span id="xdx_905_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_c20230131__us-gaap--FinancialInstrumentAxis__custom--JanuaryTwoThousandTwentyThreeNotesAndJanuaryTwoThousandTwentyThreeWarrantsMember_zhwLdNFbr6l" title="Derivative warrant liability non current">73,213</span> resulted in the recognition of a debt discount of $<span id="xdx_908_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20230131__us-gaap--FinancialInstrumentAxis__custom--JanuaryTwoThousandTwentyThreeNotesAndJanuaryTwoThousandTwentyThreeWarrantsMember_zDv304eSPHf7" title="Debt discount">73,213</span> at issuance of the January 2023 Notes and January 2023 Warrants. Further, at issuance of the March 2023 Warrants, the Company recorded a warrant liability of $<span id="xdx_90B_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_c20230331__us-gaap--ClassOfWarrantOrRightAxis__custom--MarchTwoThousandTwentyThreeWarrantsMember_zPqwUCuWqSg" title="Derivative warrant liability non current">568,574</span>, which is remeasured at fair market value at the end of each reporting period. The warrant liability of $<span id="xdx_907_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_c20230331__us-gaap--FinancialInstrumentAxis__custom--MarchTwoThousandTwentyThreeNotesAndMarchTwoThousandTwentyThreeWarrantsMember_zwS0QA2oula9" title="Warrant liability">568,574</span> resulted in the recognition of a debt discount of $<span id="xdx_903_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20230331__us-gaap--FinancialInstrumentAxis__custom--MarchTwoThousandTwentyThreeNotesAndMarchTwoThousandTwentyThreeWarrantsMember_zB3pXrrwC8X" title="Debt discount">568,574</span> at issuance of the March 2023 Notes and March 2023 Warrants. Lastly, at issuance of the June 2023 Warrants, the Company recorded a warrant liability of $<span id="xdx_908_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_c20230630__us-gaap--ClassOfWarrantOrRightAxis__custom--JuneTwoThousandTwentyThreeWarrantsMember_zGNhwQ0pglEf" title="Derivative warrant liability non current">354,810</span>, which is remeasured at fair market value at the end of each reporting period. The warrant liability of $<span id="xdx_908_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_c20230630__us-gaap--FinancialInstrumentAxis__custom--JuneTwoThousandTwentyThreeNotesAndJuneTwoThousandTwentyThreeWarrantsMember_zPbjxjnks3Ei" title="Warrant liability">354,180</span> resulted in the recognition of a debt discount of $<span id="xdx_902_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20230630__us-gaap--FinancialInstrumentAxis__custom--JuneTwoThousandTwentyThreeNotesAndJuneTwoThousandTwentyThreeWarrantsMember_zruuQq3lgCJk" title="Debt discount">354,180</span> at issuance of the June 2023 Notes and June 2023 Warrants.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The $<span id="xdx_908_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20260430__us-gaap--DebtInstrumentAxis__custom--JanuaryTwoThousandTwentyThreeNotesMember_zYgggkqa8m8a" title="Debt discount">73,213</span> discount associated with the January 2023 Warrants is accreted over five years utilizing the effective interest method. The effective interest rate for the three and six months ended April 30, 2026 and 2025 is <span id="xdx_906_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20260430__us-gaap--DebtInstrumentAxis__custom--JanuaryTwoThousandTwentyThreeNotesMember_ziq0qkoLKk8i" title="Effective interest rate">13.0</span>% and <span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20250430__us-gaap--DebtInstrumentAxis__custom--JanuaryTwoThousandTwentyThreeNotesMember_zzeaXpdFyjTj" title="Effective interest rate">13.0</span>%, and <span id="xdx_901_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20260430__us-gaap--DebtInstrumentAxis__custom--JanuaryTwoThousandTwentyThreeNotesMember_zJ6iMSEluRqc" title="Effective interest rate">13.0</span>% and <span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20250430__us-gaap--DebtInstrumentAxis__custom--JanuaryTwoThousandTwentyThreeNotesMember_zK3KNsPvObcj" title="Effective interest rate">13.0</span>%, respectively. During the three and six months ended April 30, 2026 and 2025, the Company recorded accretion expense of $<span id="xdx_900_eus-gaap--AccretionExpense_c20260201__20260430__us-gaap--DebtInstrumentAxis__custom--JanuaryTwoThousandTwentyThreeNotesMember_zKI5T56HK0u2" title="Accretion expense">3,830</span> and $<span id="xdx_900_eus-gaap--AccretionExpense_c20251101__20260430__us-gaap--DebtInstrumentAxis__custom--JanuaryTwoThousandTwentyThreeNotesMember_zK3iD0WicA9e" title="Accretion expense">7,663</span>, and $<span id="xdx_90E_eus-gaap--AccretionExpense_c20250201__20250430__us-gaap--DebtInstrumentAxis__custom--JanuaryTwoThousandTwentyThreeNotesMember_zjqWbrWRGEJ" title="Accretion expense">3,371</span> and $<span id="xdx_905_eus-gaap--AccretionExpense_c20241101__20250430__us-gaap--DebtInstrumentAxis__custom--JanuaryTwoThousandTwentyThreeNotesMember_zJq3QKv1cnX7" title="Accretion expense">6,745</span>, respectively, and a (gain) or loss on the fair value of the warrant liability of <span id="xdx_909_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_c20260201__20260430__us-gaap--DebtInstrumentAxis__custom--JanuaryTwoThousandTwentyThreeNotesMember_zPwGM53hgFn5" title="Gain loss on fair value of warrant liability">($1,798)</span> and <span id="xdx_901_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_c20250201__20250430__us-gaap--DebtInstrumentAxis__custom--JanuaryTwoThousandTwentyThreeNotesMember_z8VXnBgiLKE1" title="Gain loss on fair value of warrant liability">($1,843)</span>, and $<span id="xdx_907_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_c20251101__20260430__us-gaap--DebtInstrumentAxis__custom--JanuaryTwoThousandTwentyThreeNotesMember_z7KTiw4iM8Zg" title="Fair value of the warrant liability">25</span> and $<span id="xdx_901_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_c20241101__20250430__us-gaap--DebtInstrumentAxis__custom--JanuaryTwoThousandTwentyThreeNotesMember_zbQsBQnF8Isg" title="Fair value of the warrant liability">33</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The $<span id="xdx_90F_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20260430__us-gaap--DebtInstrumentAxis__custom--MarchTwoThousandTwentyThreeNotesMember_zNe5PFqqobDd" title="Debt discount">568,574</span> discount associated with the March 2023 Warrants is accreted over five years utilizing the effective interest method. The effective interest rate for the three and six months ended April 30, 2026 and 2025 is <span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20260430__us-gaap--DebtInstrumentAxis__custom--MarchTwoThousandTwentyThreeNotesMember_zyHs31xECAye" title="Effective interest rate">44.6</span>% and <span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20250430__us-gaap--DebtInstrumentAxis__custom--MarchTwoThousandTwentyThreeNotesMember_z1E4oql1OtDc" title="Effective interest rate">44.6</span>%, and <span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20260430__us-gaap--DebtInstrumentAxis__custom--MarchTwoThousandTwentyThreeNotesMember_zRoVXKp3RiB9" title="Effective interest rate">44.6</span>% and <span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20250430__us-gaap--DebtInstrumentAxis__custom--MarchTwoThousandTwentyThreeNotesMember_z5jL4T0nM7B6" title="Effective interest rate">44.6</span>%, respectively. During the three and six months ended April 30, 2026 and 2025, the Company recorded accretion expense of $<span id="xdx_90F_eus-gaap--AccretionExpense_c20260201__20260430__us-gaap--DebtInstrumentAxis__custom--MarchTwoThousandTwentyThreeNotesMember_zHdI7dsKZMOb" title="Accretion expense">28,169</span> and $<span id="xdx_901_eus-gaap--AccretionExpense_c20251101__20260430__us-gaap--DebtInstrumentAxis__custom--MarchTwoThousandTwentyThreeNotesMember_zHwPaw3RuLad" title="Accretion expense">54,345</span>, and $<span id="xdx_903_eus-gaap--AccretionExpense_c20250201__20250430__us-gaap--DebtInstrumentAxis__custom--MarchTwoThousandTwentyThreeNotesMember_zvh2b8PSrHh" title="Accretion expense">18,457</span> and $<span id="xdx_907_eus-gaap--AccretionExpense_c20241101__20250430__us-gaap--DebtInstrumentAxis__custom--MarchTwoThousandTwentyThreeNotesMember_z4gg7rRvXFik" title="Accretion expense">35,610</span>, respectively, and a (gain) or loss on the fair value of the warrant liability of <span id="xdx_907_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_c20260201__20260430__us-gaap--DebtInstrumentAxis__custom--MarchTwoThousandTwentyThreeNotesMember_zC0G7b64NSp4" title="Gain loss on fair value of warrant liability">($13,988)</span> and <span id="xdx_90E_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_c20250201__20250430__us-gaap--DebtInstrumentAxis__custom--MarchTwoThousandTwentyThreeNotesMember_zwd1mlkUkBf3" title="Gain loss on fair value of warrant liability">($14,332)</span>, and $<span id="xdx_90C_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_c20251101__20260430__us-gaap--DebtInstrumentAxis__custom--MarchTwoThousandTwentyThreeNotesMember_zGuFsS6dmc1d" title="Gain loss on fair value of warrant liability">192</span> and $<span id="xdx_909_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_c20241101__20250430__us-gaap--DebtInstrumentAxis__custom--MarchTwoThousandTwentyThreeNotesMember_zQyLan7WhE82" title="Gain loss on fair value of warrant liability">259</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The $<span id="xdx_90D_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20260430__us-gaap--DebtInstrumentAxis__custom--JuneTwoThousandTwentyThreeNotesMember_zHWy18FIPCsh">354,810</span> discount associated with the June 2023 Warrants is accreted over five years utilizing the effective interest method. The effective interest rate for the three and six months ended April 30, 2026 and 2025 is <span id="xdx_905_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20260430__us-gaap--DebtInstrumentAxis__custom--JuneTwoThousandTwentyThreeNotesMember_zmEM15sWUey2">39.5</span>% and <span id="xdx_903_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20250430__us-gaap--DebtInstrumentAxis__custom--JuneTwoThousandTwentyThreeNotesMember_zGM8lolrt545">39.5</span>%, and <span id="xdx_905_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20260430__us-gaap--DebtInstrumentAxis__custom--JuneTwoThousandTwentyThreeNotesMember_zJdcILk9HEE8">39.5</span>% and <span id="xdx_903_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20250430__us-gaap--DebtInstrumentAxis__custom--JuneTwoThousandTwentyThreeNotesMember_zcsKzVpueole">39.5</span>%, respectively. During the three and six months ended April 30, 2026 and 2025, the Company recorded accretion expense of $<span id="xdx_909_eus-gaap--AccretionExpense_c20260201__20260430__us-gaap--DebtInstrumentAxis__custom--JuneTwoThousandTwentyThreeNotesMember_z0IrrnCkJFta">16,431</span> and $<span id="xdx_900_eus-gaap--AccretionExpense_c20251101__20260430__us-gaap--DebtInstrumentAxis__custom--JuneTwoThousandTwentyThreeNotesMember_zOiH0Rn8S2ne">31,881</span>, and $<span id="xdx_901_eus-gaap--AccretionExpense_c20250201__20250430__us-gaap--DebtInstrumentAxis__custom--JuneTwoThousandTwentyThreeNotesMember_zzULMtwaabV2">11,282</span> and $<span id="xdx_903_eus-gaap--AccretionExpense_c20241101__20250430__us-gaap--DebtInstrumentAxis__custom--JuneTwoThousandTwentyThreeNotesMember_zFJ6FK1g8nqh">21,891</span>, respectively, and a (gain) or loss on the fair value of the warrant liability of <span id="xdx_905_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_c20260201__20260430__us-gaap--DebtInstrumentAxis__custom--JuneTwoThousandTwentyThreeNotesMember_zhDHcj54blx6" title="Gain loss on fair value of warrant liability">($9,324)</span> and <span id="xdx_902_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_c20250201__20250430__us-gaap--DebtInstrumentAxis__custom--JuneTwoThousandTwentyThreeNotesMember_z55Rxo74OOl8" title="Gain loss on fair value of warrant liability">($9,554)</span>, and $<span id="xdx_902_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_c20251101__20260430__us-gaap--DebtInstrumentAxis__custom--JuneTwoThousandTwentyThreeNotesMember_zBdBqS87FyAe" title="Gain loss on fair value of warrant liability">128</span> and $<span id="xdx_906_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_c20241101__20250430__us-gaap--DebtInstrumentAxis__custom--JuneTwoThousandTwentyThreeNotesMember_zVganUqySlR" title="Gain loss on fair value of warrant liability">173</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the three and six months ended April, 2026 and 2025 the Company recorded $<span id="xdx_907_eus-gaap--InterestExpenseDebt_c20260201__20260430__us-gaap--DebtInstrumentAxis__custom--JanuaryTwoThousandTwentyThreeNotesMember_zy4F2SIjZzs9" title="Interest expense, debt">7,900</span> and $<span id="xdx_909_eus-gaap--InterestExpenseDebt_c20250201__20250430__us-gaap--DebtInstrumentAxis__custom--JanuaryTwoThousandTwentyThreeNotesMember_zBOyvHxnraFl" title="Interest expense, debt">16,067</span>, and $<span id="xdx_901_eus-gaap--InterestExpenseDebt_c20251101__20260430__us-gaap--DebtInstrumentAxis__custom--JanuaryTwoThousandTwentyThreeNotesMember_zXW7esdfmM13" title="Interest expense, debt">7,900</span> and $<span id="xdx_90B_eus-gaap--InterestExpenseDebt_c20241101__20250430__us-gaap--DebtInstrumentAxis__custom--JanuaryTwoThousandTwentyThreeNotesMember_zQLKPZ8QxHI3" title="Interest expense, debt">16,067</span>, respectively, in interest expense on the January 2023 Notes. During the three and six months ended April 30, 2026 and 2025, the Company recorded $<span id="xdx_909_eus-gaap--InterestExpenseDebt_c20260201__20260430__us-gaap--DebtInstrumentAxis__custom--MarchTwoThousandTwentyThreeNotesMember_zDUN9ucKNYW7" title="Interest expense, debt">15,364</span> and $<span id="xdx_903_eus-gaap--InterestExpenseDebt_c20250201__20250430__us-gaap--DebtInstrumentAxis__custom--MarchTwoThousandTwentyThreeNotesMember_zwT9kJcdzbv5" title="Interest expense, debt">31,245</span>, and $<span id="xdx_902_eus-gaap--InterestExpenseDebt_c20251101__20260430__us-gaap--DebtInstrumentAxis__custom--MarchTwoThousandTwentyThreeNotesMember_zpCBUlwtS4Db" title="Interest expense, debt">15,364</span> and $<span id="xdx_904_eus-gaap--InterestExpenseDebt_c20241101__20250430__us-gaap--DebtInstrumentAxis__custom--MarchTwoThousandTwentyThreeNotesMember_zk8CIlZPogwd" title="Interest expense, debt">31,245</span>, respectively, in interest expense on the March 2023 Notes. During the three and six months ended April 30, 2026 and 2025, the Company recorded $<span id="xdx_90E_eus-gaap--InterestExpenseDebt_c20260201__20260430__us-gaap--DebtInstrumentAxis__custom--JuneTwoThousandTwentyThreeNotesMember_z0A0F2kDc61j" title="Interest expense, debt">10,241</span> and $<span id="xdx_90A_eus-gaap--InterestExpenseDebt_c20250201__20250430__us-gaap--DebtInstrumentAxis__custom--JuneTwoThousandTwentyThreeNotesMember_z2g1JznBrMd3" title="Interest expense, debt">20,827</span>, and $<span id="xdx_90B_eus-gaap--InterestExpenseDebt_c20251101__20260430__us-gaap--DebtInstrumentAxis__custom--JuneTwoThousandTwentyThreeNotesMember_zVGGY6y9KAj6" title="Interest expense, debt">10,241</span> and $<span id="xdx_90B_eus-gaap--InterestExpenseDebt_c20241101__20250430__us-gaap--DebtInstrumentAxis__custom--JuneTwoThousandTwentyThreeNotesMember_z5rAN0HfvBZ4" title="Interest expense, debt">20,827</span>, respectively, in interest expense on the June 2023 Notes.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of April 30, 2026 and October 31, 2025, the Company had accrued $<span id="xdx_900_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20260430__us-gaap--DebtInstrumentAxis__custom--JanuaryTwoThousandTwentyThreeNotesMember_zexVyOLLC1lj" title="Accrued interest">107,196</span> and $<span id="xdx_90C_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20251031__us-gaap--DebtInstrumentAxis__custom--JanuaryTwoThousandTwentyThreeNotesMember_zV7H7TEA4mdh" title="Accrued interest">91,129</span>, respectively, in interest on the January 2023 Notes. As of April 30, 2026 and October 31, 2025, the Company had accrued $<span id="xdx_902_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20260430__us-gaap--DebtInstrumentAxis__custom--MarchTwoThousandTwentyThreeNotesMember_zKYHH52MYe1l" title="Accrued interest">194,748</span> and $<span id="xdx_907_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20251031__us-gaap--DebtInstrumentAxis__custom--MarchTwoThousandTwentyThreeNotesMember_zRxf9DXO9O52" title="Accrued interest">163,503</span>, respectively, in interest on the March 2023 Notes. As of April 30, 2026 and October 31, 2025, the Company had accrued $<span id="xdx_908_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20260430__us-gaap--DebtInstrumentAxis__custom--JuneTwoThousandTwentyThreeNotesMember_zlYH4YV4YuVa" title="Accrued interest">120,493</span> and $<span id="xdx_901_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20251031__us-gaap--DebtInstrumentAxis__custom--JuneTwoThousandTwentyThreeNotesMember_zT5Obk7gJ7T4" title="Accrued interest">99,666</span>, respectively, in interest on the June 2023 Notes.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>2024 Series Senior Secured Convertible Notes – Stock Settled</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 16, 2023 and January 10, 2024, the Company entered into securities purchase agreements (the “January Purchase Agreements”) with an accredited investor, pursuant to which the Company issued and sold to the investor, in a private placement, (i) senior secured convertible notes (the “January Series 2024 Notes”) in the principal amount of $<span id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_iI_c20231116__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourSeniorSecuredConvertibleNotesMember_zqDrHu9z4xO3" title="Principal amount">2,500,000</span> and $<span id="xdx_904_eus-gaap--DebtInstrumentFaceAmount_iI_c20240110__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourSeniorSecuredConvertibleNotesMember_zelFmf3MDy82" title="Principal amount">1,250,000</span>, respectively, for a purchase price of $<span id="xdx_90C_eus-gaap--ProceedsFromConvertibleDebt_c20231116__20231116__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourSeniorSecuredConvertibleNotesMember_z9Vlqg5tdTka" title="Purchase price">2,000,000</span> and $<span id="xdx_90B_eus-gaap--ProceedsFromConvertibleDebt_c20240110__20240110__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourSeniorSecuredConvertibleNotesMember_zQ8IHHawJy7b" title="Purchase price">1,000,000</span>, respectively, (reflecting a <span id="xdx_90B_ecustom--DebtInstrumentDiscountRate_pid_dp_c20231116__20231116__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourSeniorSecuredConvertibleNotesMember_zKEDF8Ha0wT2" title="Original issue discount rate"><span id="xdx_90E_ecustom--DebtInstrumentDiscountRate_pid_dp_uPure_c20240110__20240110__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourSeniorSecuredConvertibleNotesMember_zLvegULD2tJk" title="Original issue discount rate">20</span></span>% original issue discount), and warrants to purchase shares of common stock of the Company (the “January Series 2024 Warrants”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 11, 2024, the Company entered into a securities purchase agreement (the “April Purchase Agreement”) with an accredited investor, pursuant to which the Company issued and sold to the investor, in a private placement, (i) senior secured convertible notes (the “April Series 2024 Notes”) in the principal amount of $<span id="xdx_907_eus-gaap--DebtInstrumentFaceAmount_iI_c20240411__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourSeniorSecuredConvertibleNotesMember_zPVHMlXBUOka" title="Principal amount">218,750</span> for a purchase price of $<span id="xdx_906_eus-gaap--ProceedsFromConvertibleDebt_c20240411__20240411__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourSeniorSecuredConvertibleNotesMember_zlS3n8vscyk9" title="Purchase price">175,000</span> (reflecting a <span id="xdx_90A_ecustom--DebtInstrumentDiscountRate_dp_uPure_c20240411__20240411__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourSeniorSecuredConvertibleNotesMember_zfgao0dSlTNi" title="Discount rate">20</span>% original issue discount), and warrants to purchase shares of common stock of the Company (the “April Series 2024 Warrants”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 13, 2024, the Company entered into securities purchase agreements (the “May Purchase Agreement”) with accredited investors, pursuant to which the Company issued and sold to the investors, in a private placement, (i) senior secured convertible notes (the “May Series 2024 Notes”) in the principal amount of $<span id="xdx_903_eus-gaap--DebtInstrumentFaceAmount_iI_c20240513__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourSeniorSecuredConvertibleNotesMember_z9mpCchEzMLc" title="Principal amount">375,000</span> for a purchase price of $<span id="xdx_90C_eus-gaap--ProceedsFromConvertibleDebt_c20240513__20240513__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourSeniorSecuredConvertibleNotesMember_zvn1VaVe59dl" title="Purchase price">300,000</span> (reflecting a <span id="xdx_907_ecustom--DebtInstrumentDiscountRate_dp_uPure_c20240513__20240513__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourSeniorSecuredConvertibleNotesMember_zsNjg8j2ZZMj" title="Discount rate">20</span>% original issue discount), and warrants to purchase shares of common stock of the Company (the “May Series 2024 Warrants”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 21, 2024, the Company entered into a letter agreement (the “Target Extension Agreement”) with Target Capital 16 LLC (“Target”). Pursuant to the Target Extension Agreement, the maturity date of the January Series 2024 Notes of the Company held by Target, in the aggregate original principal amount of $<span id="xdx_906_eus-gaap--DebtInstrumentFaceAmount_iI_c20240621__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourSeniorSecuredConvertibleNotesMember_zYRwliGYg3L3" title="Principal amount">3,750,000</span>, was extended by 60 days, to October 16, 2024 (the “Original Final Maturity Date”), provided that, if the Company (A) will have been diligently pursuing the consummation of a Liquidity Event (as defined in the Notes) through such date (as evidenced by the filing of a registration statement under the Securities Act of 1933, as amended (the “Securities Act”), or the Securities Exchange Act of 1934, as amended) and (y) will have delivered an extension notice, then the Original Final Maturity Date will be extended to November 16, 2024 (the “Extended Final Maturity Date”), and (B) will have consummated a Liquidity Event on or before the Original Final Maturity Date or Extended Final Maturity Date, then the Extended Final Maturity Date will be extended by 180 days from the date of such consummation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 16, 2024, the Company entered into a second letter agreement (the “Target Consolidation Agreement”) with Target. Pursuant to the Target Consolidation Agreement, in consideration of an additional $<span id="xdx_902_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20240716__20240716__us-gaap--TypeOfArrangementAxis__custom--TargetConsolidationAgreementMember_zBFFLwjn0Y38" title="Additional paid">300,000</span> paid by Target to the Company, the outstanding January Series 2024 Notes, each as amended by the Target Extension Agreement, were consolidated, amended and restated into a new note (the “July Series 2024 Notes”) under the Purchase Agreement. The July Series 2024 Note has a subscription amount of $<span id="xdx_90B_ecustom--DebtInstrumentSubscriptionAmount_iI_c20240716__us-gaap--TypeOfArrangementAxis__custom--TargetConsolidationAgreementMember_zhjxdgR5jql" title="Subscription amount">3,300,000</span>, an original issue discount of $<span id="xdx_904_eus-gaap--AmortizationOfDebtDiscountPremium_c20240716__20240716__us-gaap--TypeOfArrangementAxis__custom--TargetConsolidationAgreementMember_zhjGtkJcLsZ3" title="Original issue discount">825,000</span>, and an original principal amount of $<span id="xdx_906_eus-gaap--DebtInstrumentRepurchasedFaceAmount_iI_c20240716__us-gaap--TypeOfArrangementAxis__custom--TargetConsolidationAgreementMember_zFDwFADtXjrd" title="Original principal amount">4,125,000</span>, and otherwise has the same material terms as the Outstanding Notes.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The January Series 2024 Notes, April Series 2024 Notes, May Series 2024 Notes, and July Series 2024 Notes are collectively the “Series 2024 Notes.” The January Series 2024 Warrants, April Series 2024 Warrants, and May Series 2024 Warrants are collectively the “Series 2024 Warrants.” No Series 2024 Warrants were issued with the July Series 2024 Notes.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest on the Series 2024 Notes will accrue commencing on the earlier of the maturity date or upon an event of default, at the annual rate of 20%, due the first day of each calendar month following such date. The January Series 2024 Notes will mature at the earlier of (i) six months from the issuance date (the “Original Maturity Date”) and (ii) the occurrence of a Liquidity Event (as defined in the January Series 2024 Notes), provided that the Company may extend the maturity date for an additional three months (the “January Extension Period”). The April Series 2024 Notes will mature at the earlier of (i) May 16, 2024 and (ii) the occurrence of a Liquidity Event (as defined in the April Series 2024 Notes), provided that the Company may extend the maturity date for an additional three months (the “April Extension Period”). The May Series 2024 Notes will mature at the earlier of (i) May 16, 2024 and (ii) the occurrence of a Liquidity Event (as defined in the May Series 2024 Notes), provided that the Company may extend the maturity date for an additional three months (the “May Extension Period”). The July Series 2024 Notes will mature on October 16, 2024 (the “Original Final Maturity Date”), provided that, if the Company (A) will have been diligently pursuing the consummation of a Liquidity Event (as defined in the Notes) through such date (as evidenced by the filing of a registration statement under the Securities Act of 1933, as amended (the “Securities Act”), or the Securities Exchange Act of 1934, as amended) and (y) will have delivered an extension notice, then the Original Final Maturity Date will be extended to November 16, 2024 (the “Extended Final Maturity Date”), and (B) will have consummated a Liquidity Event on or before the Original Final Maturity Date or Extended Final Maturity Date, then the Extended Final Maturity Date will be extended by 180 days from the date of such consummation. The Series 2024 Notes are secured by all of the Company’s assets pursuant to a security agreement between the Company and the investors. <span id="xdx_90E_eus-gaap--DebtConversionDescription_c20251101__20260430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourSeniorSecuredConvertibleNotesMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesTwoThousandTwentyFourWarrantsMember_zzrmPeKsOHOl" title="Debt conversion, description">The Series 2024 Notes will be convertible, at the option of the investors, into common stock commencing on the maturity date, at a conversion price equal to the product of (x) the Liquidity Event Price (as defined in the Series 2024 Notes) and (y) 0.70 (or 0.60 if the Company has extended the maturity date), provided however, that if no Liquidity Event has occurred by the maturity date then the conversion price will be the amount obtained by dividing (i) $95,000,000 by (ii) the number of shares of common stock outstanding on such date calculated on a fully-diluted basis. In addition, the Company will have the right to effect conversion of the Series 2024 Notes if, at the time (a) a Liquidity Event has occurred and (b) the underlying shares are registered for resale.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_ecustom--WarrantExercisableRelatedToLiquidityEventDescription_c20251101__20260430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourSeniorSecuredConvertibleNotesMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesTwoThousandTwentyFourWarrantsMember_z5n07ktplvR3" title="Warrant exercisable and liquidity event description">The Series 2024 Warrants will be exercisable into the number the shares of common stock obtained by dividing 100% of the original principal amount of the Series 2024 Notes by (ii) the Liquidity Event Price (as defined in the Series 2024 Notes); provided, however, that if no Liquidity Event has occurred by the maturity date, then such percentage will be 150%. The Series 2024 Warrants will be exercisable for a period of five years and have an exercise price equal to the Liquidity Event Price provided however, that if no Liquidity Event has occurred by the maturity date then the exercise price will be the amount obtained by dividing (i) $95,000,000 by (ii) the number of shares of common stock outstanding on such date calculated on a fully-diluted basis.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company followed the guidance of Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) ASC 480 “Distinguishing Liabilities from Equity” to account for the stock settled debt, ASC 470 “Debt,” and ASC 815 “Derivatives and Hedging” to account for Series 2024 Notes and Series 2024 Warrants.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company contemplated ASC 815-15-25-1 related to the valuation of the embedded conversion feature contained in the Series 2024 Notes. The Company determined, per the guidance, the embedded conversion feature did not meet the criteria to be classified as a derivative.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company assessed the Series 2024 Warrants first under ASC 480. Based on the attributes of the Series 2024 Warrants, the Company determined that each are outside of the scope of ASC 480 and proceeded to assess each under ASC 815 to determine if any are considered indexed to the Company’s own common stock. Because the inputs which affect the number of shares to be issued upon exercise of the Series 2024 Warrants are not the inputs per 815-40-15-7E, none are deemed to be indexed to the Company’s own stock and have been recorded as liabilities under ASC 815 (Note 3) at the fair market value. Because the scenario under which the Series 2024 Notes are analyzed assumes a Liquidity Event, the scenarios under which to analyze the Series 2024 Warrants should also contain a Liquidity Event. As such, the assumed exercise price is $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourSeniorSecuredConvertibleNotesMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesTwoThousandTwentyFourWarrantsMember_zFcMXrsLBUra" title="Warrant exercise price">15.00</span>, and the Company would issue <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20251101__20260430__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesTwoThousandTwentyFourWarrantsMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourJanuarySeniorSecuredConvertibleNotesMember_zcWRYG37vANb" title="Stock option exercised">250,000</span> shares upon exercise of the January Series 2024 Warrants, <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20251101__20260430__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesTwoThousandTwentyFourWarrantsMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourAprilSeniorSecuredConvertibleNotesMember_zCHSBF7LMZwe">14,583</span> shares upon exercise of the April Series 2024 Warrants, and <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20251101__20260430__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesTwoThousandTwentyFourWarrantsMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourMaySeniorSecuredConvertibleNotesMember_zcuqMAxRbyAc">25,000</span> shares upon exercise of the May Series 2024 Warrants. At issuance, the Company recorded a warrant liability of $<span id="xdx_900_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_c20260430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourJanuarySeniorSecuredConvertibleNotesMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesTwoThousandTwentyFourWarrantsMember_zFym2IW5Bjjh" title="Derivative liability">2,732,304</span> related to the January Series 2024 Warrants, $<span id="xdx_903_ecustom--DerivativeWarrantLiability_iI_c20260430__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesTwoThousandTwentyFourWarrantsMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourAprilSeniorSecuredConvertibleNotesMember_zfFg7wvRpJa9" title="Derivative warrant liability">157,733</span> related to the April Series 2024 Warrants, and $<span id="xdx_90B_ecustom--DerivativeWarrantLiability_iI_c20260430__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesTwoThousandTwentyFourWarrantsMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourMaySeniorSecuredConvertibleNotesMember_zq7lofG6XM1i" title="Derivative warrant liability">269,752</span> related to the May Series 2024 Warrants, all of which are remeasured at fair market value at the end of each reporting period. The combination of the original issuance discount of $<span id="xdx_908_ecustom--OriginalIssuanceDiscount_c20251101__20260430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourJanuarySeniorSecuredConvertibleNotesMember_zSPTKhyKdLbe" title="Original issuance discount">750,000</span> and the warrant liability of $<span id="xdx_909_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_c20260430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourJanuarySeniorSecuredConvertibleNotesMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesTwoThousandTwentyFourWarrantsMember_zcbxsitJEL9k">2,732,304</span> resulted in the recognition of a debt discount of $<span id="xdx_90E_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20260430__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesTwoThousandTwentyFourWarrantsMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourJanuarySeniorSecuredConvertibleNotesMember_zUDmWFiXdmwb" title="Debt discount">3,482,304</span> at issuance of the January Series 2024 Notes and January Series 2024 Warrants. Similarly, the combination of the original issuance discount of $<span id="xdx_90B_eus-gaap--AmortizationOfFinancingCostsAndDiscounts_c20251101__20260430__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesTwoThousandTwentyFourWarrantsMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourAprilSeniorSecuredConvertibleNotesMember_zFsuAA2lZFb5" title="Original issuance discount">43,750</span> and the warrant liability of $<span id="xdx_906_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_c20260430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourAprilSeniorSecuredConvertibleNotesMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesTwoThousandTwentyFourWarrantsMember_zXR0R6BV31k6" title="Warrant liability">157,733</span> resulted in the recognition of a debt discount of $<span id="xdx_90D_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20260430__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesTwoThousandTwentyFourWarrantsMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourAprilSeniorSecuredConvertibleNotesMember_zQjQHiraz3md" title="Debt discount">201,483</span> at issuance of the April Series 2024 Notes and April Series 2024 Warrants. Finally, the combination of the original issuance discount of $<span id="xdx_90F_eus-gaap--AmortizationOfFinancingCostsAndDiscounts_c20251101__20260430__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesTwoThousandTwentyFourWarrantsMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourMaySeniorSecuredConvertibleNotesMember_zieJ0Z3RWP3h" title="Original issuance discount">75,000</span> and the warrant liability of $<span id="xdx_900_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_c20260430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourMaySeniorSecuredConvertibleNotesMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesTwoThousandTwentyFourWarrantsMember_zm54Ev0t15nl" title="Warrant liability">269,752</span> resulted in the recognition of a debt discount of $<span id="xdx_908_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20260430__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesTwoThousandTwentyFourWarrantsMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourMaySeniorSecuredConvertibleNotesMember_zWBO9uLiW1J8" title="Debt discount">344,752</span> at issuance of the May Series 2024 Notes and May Series 2024 Warrants.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The combination of the original issuance discount of $<span id="xdx_90D_ecustom--OriginalIssuanceDiscount_c20251101__20260430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourJanuarySeriesNotesMember_zXsGyinuSuj2" title="Original issuance discount">750,000</span> associated with the collected proceeds compared to the principal value of the January Series 2024 Notes and the $<span id="xdx_900_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20260430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourJanuarySeriesNotesMember_z7IiG1N7qLPa">2,732,304</span> discount associated with the January Series 2024 Warrants results in a net discount of $<span id="xdx_903_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumNet_iI_c20260430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourJanuarySeriesNotesMember_zQB1MFFh1lA">3,482,304</span> that is accreted over six months utilizing the effective interest method. The effective interest rate for the three and six months ended April 30, 2026 and 2025, is <span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20260430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourNovemberSeniorSecuredConvertibleNotesMember_zY30SRg23dO1" title="Effective interest rate">659</span>% and <span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20250430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourNovemberSeniorSecuredConvertibleNotesMember_zNVFLXCj5HEh" title="Effective interest rate">659</span>%, and <span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20260430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourNovemberSeniorSecuredConvertibleNotesMember_zUEkCnNOaIaj" title="Effective interest rate">659</span>% and <span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20250430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourNovemberSeniorSecuredConvertibleNotesMember_zFYn5Dkzqxa8" title="Effective interest rate">659</span>%, respectively, for the November issuance and <span id="xdx_906_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20260430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourJanuarySeriesNotesMember_z3goXLo1iVrg" title="Effective interest rate">624</span>% and <span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20250430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourJanuarySeriesNotesMember_zHTic281Agy" title="Effective interest rate">624</span>%, and <span id="xdx_903_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20260430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourJanuarySeriesNotesMember_z403ySwpgLS8" title="Effective interest rate">624</span>% and <span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20250430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourJanuarySeriesNotesMember_z2HDHYJOLB2l" title="Effective interest rate">624</span>%, respectively, for the January issuance. During the three and six months ended April 30, 2026 and 2025, the Company recorded accretion expense of $<span id="xdx_903_eus-gaap--AccretionExpense_c20260201__20260430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourJanuarySeriesNotesMember_zOQxmK6fOy41" title="Accretion expense">0</span> and $<span id="xdx_90D_eus-gaap--AccretionExpense_c20250201__20250430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourJanuarySeriesNotesMember_zTSwwtuCceu" title="Accretion expense">0</span>, and $<span id="xdx_907_eus-gaap--AccretionExpense_c20251101__20260430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourJanuarySeriesNotesMember_zahQ0lN6O1tb" title="Accretion expense">0</span> and $<span id="xdx_90B_eus-gaap--AccretionExpense_c20241101__20250430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourJanuarySeriesNotesMember_z0G86tHUyKpf" title="Accretion expense">0</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to ASC 480, the Company assessed the January Series 2024 Notes and the July Series 2024 Notes comparing the present value of the cash flows of both notes at the January Series 2024 Notes effective interest rate. Because the difference between the present value of the January Series 2024 Notes and July Series 2024 Notes cash flows was greater than 10%, the two sets of notes were deemed to be substantially different and, as such, the extinguishment of January Series 2024 Notes were recorded as a gain in the statement of operations. Immediately prior to the extinguishment, the Company recorded a gain on the fair value of the warrant liability of $<span id="xdx_909_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_c20251101__20260430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourJanuarySeniorSecuredConvertibleNotesMember_zUI9Jo9otCe9" title="Fair value of the warrant liability">1,713,320</span>. On the day of the extinguishment, the Company recorded additional proceeds of $<span id="xdx_908_ecustom--AdditionalProceedsOfExtinguishment_c20251101__20260430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourJanuarySeniorSecuredConvertibleNotesMember_zlGcy75KiiTb" title="Additional proceeds of extinguishment">300,000</span>, additional original issuance discount of $<span id="xdx_905_eus-gaap--AmortizationOfFinancingCostsAndDiscounts_c20251101__20260430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourJanuarySeniorSecuredConvertibleNotesMember_zhTNcfgvjZz6" title="Original issuance discount">75,000</span>, the extinguishment of the original warrant liability of $<span id="xdx_907_ecustom--AdditionalFairValueOfWarrantLiability_c20251101__20260430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourJanuarySeniorSecuredConvertibleNotesMember_zJjA3VDQLwf4" title="Original warrant liability">990,719</span>, and a gain on the transaction of $<span id="xdx_90D_eus-gaap--GainsLossesOnExtinguishmentOfDebt_c20251101__20260430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourJanuarySeniorSecuredConvertibleNotesMember_zfTIaDNJusjd" title="Gain loss on extinguishment of debt">740,724</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The combination of the original issuance discount of $<span id="xdx_906_eus-gaap--AmortizationOfFinancingCostsAndDiscounts_c20251101__20260430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourAprilSeniorSecuredConvertibleNotesMember_zD7qYn9kniN4">43,750</span> associated with the collected proceeds compared to the principal value of the April Series 2024 Notes and the $<span id="xdx_90A_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20260430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourAprilSeniorSecuredConvertibleNotesMember_z1lGWvcBngC1">157,733</span> discount associated with the April Series 2024 Warrants results in a net discount of $<span id="xdx_90A_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumNet_iI_c20260430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourAprilSeniorSecuredConvertibleNotesMember_zsUh4xrZbmJc">201,483</span> that is accreted through the first day of the April Extension Period utilizing the effective interest method. The effective interest rate for the three and six months ended April 30, 2026 and 2025 is over <span id="xdx_905_ecustom--InterestRateEffectivePercentageDescription_c20260201__20260430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourAprilSeniorSecuredConvertibleNotesMember_zOJVF011coYg" title="Interest rate effective percentage description"><span id="xdx_907_ecustom--InterestRateEffectivePercentageDescription_c20250201__20250430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourAprilSeniorSecuredConvertibleNotesMember_zEY2UCocYSDk" title="Interest rate effective percentage description"><span id="xdx_90B_ecustom--InterestRateEffectivePercentageDescription_c20251101__20260430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourAprilSeniorSecuredConvertibleNotesMember_z3vXDW7Dju7l" title="Interest rate effective percentage description"><span id="xdx_903_ecustom--InterestRateEffectivePercentageDescription_c20241101__20250430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourAprilSeniorSecuredConvertibleNotesMember_z2R9G9OA4qsk" title="Interest rate effective percentage description">5,000</span></span></span></span>%. During the three and six months ended April 30, 2026 and 2025, the Company recorded accretion expense of $<span id="xdx_90C_eus-gaap--AccretionExpense_c20260201__20260430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourAprilSeniorSecuredConvertibleNotesMember_zxYuV4HsxL7h">0</span> and $<span id="xdx_90D_eus-gaap--AccretionExpense_c20250201__20250430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourAprilSeniorSecuredConvertibleNotesMember_zXYwMlXT8o53">0</span>, and $<span id="xdx_90F_eus-gaap--AccretionExpense_c20251101__20260430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourAprilSeniorSecuredConvertibleNotesMember_zNlWmsaQ1rYk">0</span> and $<span id="xdx_904_eus-gaap--AccretionExpense_c20241101__20250430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourAprilSeniorSecuredConvertibleNotesMember_zxNIa0BCo9U8">0</span>, respectively, and a gain on the fair value of the warrant liability of $<span id="xdx_90E_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_c20260201__20260430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourAprilSeniorSecuredConvertibleNotesMember_zvfOtEYOTqqi">450</span> and $<span id="xdx_903_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_c20250201__20250430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourAprilSeniorSecuredConvertibleNotesMember_zhf3WDr5NQOc">2,269</span>, and $<span id="xdx_90C_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_c20251101__20260430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourAprilSeniorSecuredConvertibleNotesMember_zqiY0mYL2Xu2">2,365</span> and $<span id="xdx_90A_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_c20241101__20250430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourAprilSeniorSecuredConvertibleNotesMember_zjUnKpeKaVa6">4,398</span> respectively. On February 24, 2026, the holder of the April Series 2024 Notes converted their note with a face amount of $<span id="xdx_906_eus-gaap--DebtInstrumentFaceAmount_iI_c20260224__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourAprilSeniorSecuredConvertibleNotesMember_zPAZnod4EA61" title="Face amount">218,750</span> to the Company’s Series A-1 Preferred stock. The remaining balance of the warrant liability of $<span id="xdx_903_eus-gaap--DerivativeLiabilities_iI_c20260224__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourAprilSeniorSecuredConvertibleNotesMember_zqGaAa7sbbg8" title="Derivative warrant liability">22,059</span> was reclassified to Additional Paid-in Capital. Since the notes were converted at a discounted price, the Company recognized a $<span id="xdx_90E_eus-gaap--GainsLossesOnExtinguishmentOfDebt_c20260224__20260224__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourAprilSeniorSecuredConvertibleNotesMember_zzoaSb831UMg" title="Gain loss on extinguishment of debt">145,850</span> loss on extinguishment of debt.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The combination of the original issuance discount of $<span id="xdx_901_eus-gaap--AmortizationOfFinancingCostsAndDiscounts_c20251101__20260430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourMaySeniorSecuredConvertibleNotesMember_znITvhHoBIN8">75,000</span> associated with the collected proceeds compared to the principal value of the May Series 2024 Notes and the $<span id="xdx_907_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20260430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourMaySeniorSecuredConvertibleNotesMember_zRpwlUv7Bvl6">269,752</span> discount associated with the May Series 2024 Warrants results in a net discount of $<span id="xdx_90B_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumNet_iI_c20260430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourMaySeniorSecuredConvertibleNotesMember_zSbNVojbG5B1">344,752</span> that is accreted through the first day of the May Extension Period utilizing the effective interest method. The effective interest rate for the three and six months ended April 30, 2026 and 2025 was over <span id="xdx_90C_ecustom--InterestRateEffectivePercentageDescription_c20260201__20260430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourMaySeniorSecuredConvertibleNotesMember_zmm89fiG82x9" title="Interest rate effective percentage description"><span id="xdx_909_ecustom--InterestRateEffectivePercentageDescription_c20250201__20250430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourMaySeniorSecuredConvertibleNotesMember_zSCNyEPEAPF1" title="Interest rate effective percentage description"><span id="xdx_903_ecustom--InterestRateEffectivePercentageDescription_c20251101__20260430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourMaySeniorSecuredConvertibleNotesMember_zXTTabxNX98k" title="Interest rate effective percentage description"><span id="xdx_90B_ecustom--InterestRateEffectivePercentageDescription_c20241101__20250430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourMaySeniorSecuredConvertibleNotesMember_zDbs4sYAcboe" title="Interest rate effective percentage description">104,000</span></span></span></span>%. During the three and six months ended April 30, 2026 and 2025, the Company recorded accretion expense of $<span id="xdx_907_eus-gaap--AccretionExpense_c20260201__20260430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourMaySeniorSecuredConvertibleNotesMember_zNp64otS7Nn5">0</span> and $<span id="xdx_908_eus-gaap--AccretionExpense_c20250201__20250430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourMaySeniorSecuredConvertibleNotesMember_zEL5bBPaRWkh">0</span>, and $<span id="xdx_900_eus-gaap--AccretionExpense_c20251101__20260430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourMaySeniorSecuredConvertibleNotesMember_zODjAIJrjBRd">0</span> and $<span id="xdx_905_eus-gaap--AccretionExpense_c20241101__20250430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourMaySeniorSecuredConvertibleNotesMember_z71vfhaIT3Lb">0</span>, respectively, and a gain on the fair value of the warrant liability of $<span id="xdx_903_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_c20260201__20260430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourMaySeniorSecuredConvertibleNotesMember_zsDbx7DQYzM2">820</span> and $<span id="xdx_900_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_c20250201__20250430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourMaySeniorSecuredConvertibleNotesMember_zIPsTq2zU079">3,938</span>, and $<span id="xdx_903_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_c20251101__20260430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourMaySeniorSecuredConvertibleNotesMember_zcIgoyz5tUC6">4,055</span> and $<span id="xdx_907_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_c20241101__20250430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourMaySeniorSecuredConvertibleNotesMember_z4YfOZ9XXSd6">7,540</span>, respectively. On February 24, 2026, three of the four holders of the May Series 2024 Notes converted their notes with a face amount of $<span id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_iI_c20260224__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourMaySeniorSecuredConvertibleNotesMember_zUByGNCbTWy7" title="Face amount">250,000</span> to the Company’s Series A-1 Preferred stock. The remaining balance of the warrant liability related to these three notes of $<span id="xdx_906_eus-gaap--DerivativeLiabilities_iI_c20260224__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourMaySeniorSecuredConvertibleNotesMember_zP8E9ei8pGt5" title="Derivative warrant liability">25,210</span> was reclassified to Additional Paid-in Capital. Since the notes were converted at a discounted price, the Company recognized a $<span id="xdx_908_eus-gaap--GainsLossesOnExtinguishmentOfDebt_c20260224__20260224__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourMaySeniorSecuredConvertibleNotesMember_zHQidFKOr9yd" title="Gain loss on extinguishment of debt">166,700</span> loss on extinguishment of debt.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the three and six months ended April 30, 2026 and 2025, <span id="xdx_90F_eus-gaap--InterestExpenseDebt_do_c20251101__20260430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourSeniorSecuredConvertibleNotesMember_z7xScGJ3bMee" title="Interest expense, debt"><span id="xdx_90B_eus-gaap--InterestExpenseDebt_do_c20241101__20250430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourSeniorSecuredConvertibleNotesMember_z4yDxK5Xtbrf" title="Interest expense, debt">no</span></span> interest expense was recorded on the Series 2024 Notes. As of April 30, 2026 and October 31, 2025, <span id="xdx_901_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_do_c20260430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourSeniorSecuredConvertibleNotesMember_z3ni0L9wL3p4" title="Accrued interest"><span id="xdx_90C_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_do_c20251031__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourSeniorSecuredConvertibleNotesMember_zE9z8lF4Rxke" title="Accrued interest">no</span></span> accrued interest was recorded on the Series 2024 Notes.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The July Series 2024 Target note was extended to March 31, 2025, with an increase in the principal amount of $<span id="xdx_90B_eus-gaap--DebtInstrumentFaceAmount_iI_c20250331__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourSeniorNoteMember_zCgrwxyvfG0k" title="Principal amount">245,000</span> and pre-funded warrants were issued for a value of $<span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOfWarrants_c20250301__20250331__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourSeniorNoteMember_zA8ul6Gahg1i" title="Proceeds from issuance of warrants">990,000</span> as part of the extension transaction. In accordance with ASC 470, the Company has evaluated the consideration given for the extension of the Target note and has determined that the July Series 2024 Target note was extinguished, based on the conclusion that there was a greater than 10% change in the present value of the cash flows of the new loan, compared to the old loan. The Company has recorded a loss on extinguishment of debt of $<span id="xdx_904_eus-gaap--GainsLossesOnExtinguishmentOfDebt_c20251101__20260430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourSeniorNoteMember_zwQIK2xnC6Ck" title="Gain loss on extinguishment of debt">1,235,000</span> for the six months ended April 30, 2025. As of March 3, 2025, the Company had paid the July Series 2024 Target note’s entire balance of $<span id="xdx_900_eus-gaap--DebtInstrumentCarryingAmount_iI_c20250303__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourSeniorNoteMember_zfmt7wAH5yt7" title="Carrying amount">4,370,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>2025 Series Senior Secured Convertible Notes – Stock Settled</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 27, 2025, the Company entered into securities purchase agreements (the “February Purchase Agreements”) with an accredited investor, pursuant to which the Company issued and sold to the investor, in a private placement, (i) senior secured convertible notes (the “February Series 2025 Notes”) in the principal amount of $<span id="xdx_901_eus-gaap--DebtInstrumentFaceAmount_iI_c20250227__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFiveSeniorSecuredConvertibleNotesMember_ztoTnaeyfky1" title="Principal amount">6,250,000</span>, for a purchase price of $<span id="xdx_907_eus-gaap--ProceedsFromConvertibleDebt_c20250227__20250227__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFiveSeniorSecuredConvertibleNotesMember_z9LphSSuBDpl" title="Purchase price">5,000,000</span>, (reflecting a <span id="xdx_90F_ecustom--DebtInstrumentDiscountRate_dp_uPure_c20250227__20250227__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFiveSeniorSecuredConvertibleNotesMember_zCu9jDYwffoa" title="Discount rate">20</span>% original issue discount), and warrants to purchase shares of common stock of the Company (the “February Series 2025 Warrants”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 25, 2025, the Company received an additional $<span id="xdx_90C_eus-gaap--DebtInstrumentCarryingAmount_iI_c20250425__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFiveSeniorSecuredConvertibleNotesMember_zkZNJWLlV2zh" title="Additional principal amount received">350,000</span> from the same investor to be included in the February Series 2025 Note (the “April Purchase Agreement”) with an accredited investor, pursuant to which the Company issued and sold to the investor, in a private placement, (i) senior secured convertible notes (the “April Series 2025 Notes”) in the principal amount of $<span id="xdx_902_eus-gaap--DebtInstrumentFaceAmount_iI_c20250425__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFiveSeniorSecuredConvertibleNotesMember_zdLfSAfErpPi" title="Principal amount">437,500</span> for a purchase price of $<span id="xdx_905_eus-gaap--ProceedsFromConvertibleDebt_c20250425__20250425__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFiveSeniorSecuredConvertibleNotesMember_zFHBaB8fr8Z9" title="Purchase price">350,000</span> (reflecting a <span id="xdx_903_ecustom--DebtInstrumentDiscountRate_dp_uPure_c20250425__20250425__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFiveSeniorSecuredConvertibleNotesMember_zjPqQE1YdPUk" title="Discount rate">20</span>% original issue discount), and warrants to purchase shares of common stock of the Company (the “April Series 2025 Warrants”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 21, 2025, the Company received an additional $<span id="xdx_902_eus-gaap--Cash_iI_c20250521__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFiveSeniorSecuredConvertibleNotesMember_zCqpPu6Erld6" title="Advanced in cash">325,000</span> from the same investor to be included in the February Series 2025 Note (the “May Purchase Agreement”) with an accredited investor, pursuant to which the Company issued and sold to the investor, in a private placement, (i) senior secured convertible notes (the “May Series 2025 Notes”) in the principal amount of $<span id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_iI_c20250521__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFiveSeniorSecuredConvertibleNotesMember_z7Xq6dMErLWj" title="Principal amount">406,250</span> for a purchase price of $<span id="xdx_90E_eus-gaap--ProceedsFromConvertibleDebt_c20250521__20250521__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFiveSeniorSecuredConvertibleNotesMember_zLNHYNiiuw95" title="Purchase price">325,000</span> (reflecting a <span id="xdx_905_ecustom--DebtInstrumentDiscountRate_dp_uPure_c20250521__20250521__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFiveSeniorSecuredConvertibleNotesMember_zpGzX8xp3lVd" title="Discount rate">20</span>% original issue discount), and warrants to purchase shares of common stock of the Company (the “May Series 2025 Warrants”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On October 27, 2025, the Company received an additional $<span id="xdx_90B_eus-gaap--Cash_iI_c20251027__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFiveSeniorSecuredConvertibleNotesMember_z9DSNPitbGej" title="Advanced in cash">875,000</span> from the same investor to be included in the February Series 2025 Note (the “October Purchase Agreement”) with an accredited investor, pursuant to which the Company issued and sold to the investor, in a private placement, (i) senior secured convertible notes (the “October Series 2025 Notes”) in the principal amount of $<span id="xdx_908_eus-gaap--DebtInstrumentFaceAmount_iI_c20251027__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFiveSeniorSecuredConvertibleNotesMember_zOSmeoaAJLIl" title="Principal amount">1,093,750</span> for a purchase price of $<span id="xdx_906_eus-gaap--ProceedsFromConvertibleDebt_c20251027__20251027__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFiveSeniorSecuredConvertibleNotesMember_zwSNBU5Fb7Bf" title="Purchase price">875,000</span> (reflecting a <span id="xdx_906_ecustom--DebtInstrumentDiscountRate_dp_uPure_c20251027__20251027__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFiveSeniorSecuredConvertibleNotesMember_zIh8yBtkSQc" title="Discount rate">20</span>% original issue discount), and warrants to purchase shares of common stock of the Company (the “October Series 2025 Warrants”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The February Series 2025 Notes, April Series 2025 Notes, May Series 2025 Notes and October Series 2025 Notes are collectively the “Series 2025 Notes.” The February Series 2025 Warrants, April Series 2025 Warrants, May Series 2025 Warrants and October Series 2025 Warrants are collectively the “Series 2025 Warrants.”</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest on the Series 2025 Notes will accrue commencing on the earlier of the maturity date or upon an event of default, at the annual rate of 20%, due the first day of each calendar month following such date. The Series 2025 Notes will mature at the earlier of (i) February 27, 2026 (the “Original Maturity Date”) and (ii) the occurrence of a Liquidity Event (as defined in the Series 2025 Notes), provided that the Company may extend the maturity date for an additional year (the “Extension Period”). The Series 2025 Notes are secured by all of the Company’s assets pursuant to a security agreement between the Company and the investors. <span id="xdx_905_eus-gaap--DebtConversionDescription_c20251101__20260430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFiveSeniorSecuredConvertibleNotesMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesTwoThousandTwentyFiveWarrantsMember_zOz5Ef6BZIbk" title="Debt conversion, description">The Series 2025 Notes will be convertible, at the option of the investors, into common stock commencing on the maturity date, at a conversion price equal to the product of (x) the Liquidity Event Price (as defined in the Series 2025 Notes) and (y) 0.70 (or 0.60 if the Company has extended the maturity date), provided however, that if no Liquidity Event has occurred by the maturity date then the conversion price will be the amount obtained by dividing (i) $95,000,000 by (ii) the number of shares of common stock outstanding on such date calculated on a fully-diluted basis. In addition, the Company will have the right to effect conversion of the Series 2025 Notes if, at the time (a) a Liquidity Event has occurred and (b) the underlying shares are registered for resale. In October 2025, the parties amended the note to replace the $95,000,000 valuation, mentioned above, with a valuation resulting from a study by a mutually approved valuation expert.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_ecustom--WarrantExercisableRelatedToLiquidityEventDescription_c20251101__20260430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFiveSeniorSecuredConvertibleNotesMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesTwoThousandTwentyFiveWarrantsMember_zkAK3aj7J0Tf" title="Warrant exercisable and liquidity event description">The Series 2025 Warrants will be exercisable into the number the shares of common stock obtained by dividing 100% of the original principal amount of the Series 2025 Notes by (ii) the Liquidity Event Price (as defined in the Series 2024 Notes); provided, however, that if no Liquidity Event has occurred by the maturity date, then such percentage will be 150%. The Series 2025 Warrants will be exercisable for a period of five years and have an exercise price equal to the Liquidity Event Price provided however, that if no Liquidity Event has occurred by the maturity date then the exercise price will be the amount obtained by dividing (i) $95,000,000 by (ii) the number of shares of common stock outstanding on such date calculated on a fully-diluted basis.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company followed the guidance of Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) ASC 480 “Distinguishing Liabilities from Equity” to account for the stock settled debt, ASC 470 “Debt,” and ASC 815 “Derivatives and Hedging” to account for Series 2025 Notes and Series 2025 Warrants.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company contemplated ASC 815-15-25-1 related to the valuation of the embedded conversion feature contained in the Series 2025 Notes. The Company determined, per the guidance, the embedded conversion feature did not meet the criteria to be classified as a derivative.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company assessed the Series 2025 Warrants first under ASC 480. Based on the attributes of the Series 2025 Warrants, the Company determined that each are outside of the scope of ASC 480 and proceeded to assess each under ASC 815 to determine if any are considered indexed to the Company’s own common stock. Because the inputs which affect the number of shares to be issued upon exercise of the Series 2025 Warrants are not the inputs per 815-40-15-7E, none are deemed to be indexed to the Company’s own stock and have been recorded as liabilities under ASC 815 (Note 3) at the fair market value. Because the scenario under which the Series 2025 Notes are analyzed assumes a Liquidity Event, the scenarios under which to analyze the Series 2025 Warrants should also contain a Liquidity Event. As such, the assumed exercise price is $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFiveSeniorSecuredConvertibleNotesMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesTwoThousandTwentyFiveWarrantsMember_zl6k3cBVQrJ4" title="Warrant exercise price">5.50</span>, and the Company would issue <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20251101__20260430__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesTwoThousandTwentyFourWarrantsMember__us-gaap--DebtInstrumentAxis__custom--FebruaryTwoThousandTwentyFiveNotesMember_zzcLSfspFeDb">1,136,364</span> shares upon exercise of the February Series 2025 Warrants, <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20251101__20260430__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesTwoThousandTwentyFiveWarrantsMember__us-gaap--DebtInstrumentAxis__custom--AprilTwoThousandTwentyFiveWarrantsMember_zDQCAiBtGYj3" title="Issued for services">79,545</span> shares upon exercise of the April Series 2025 Warrants, <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20251101__20260430__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesTwoThousandTwentyFiveWarrantsMember__us-gaap--DebtInstrumentAxis__custom--MayTwoThousandTwentyFiveWarrantsMember_zq9ishdrN67i" title="Issued for services">73,864</span> shares upon exercise of the May Series 2025 Warrants and <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20251101__20260430__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesTwoThousandTwentyFiveWarrantsMember__us-gaap--DebtInstrumentAxis__custom--OctoberTwoThousandTwentyFiveWarrantsMember_zbiDrK8aH3Qc" title="Issued for services">198,864</span> shares upon exercise of the October Series 2025 Warrants. At issuance, the Company recorded a warrant liability of $<span id="xdx_90F_ecustom--DerivativeWarrantLiability_iI_c20260430__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwoThousandTwentyFourNotesAndAprilTwoThousandTwentyFourWarrantsMember_zyvwyro93Jpc" title="Derivative warrant liability">4,448,036</span> related to the February Series 2025 Warrants, $<span id="xdx_909_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_c20260430__us-gaap--FinancialInstrumentAxis__custom--FebruaryTwoThousandTwentyFourNotesAndAprilTwoThousandTwentyFourWarrantsMember_zDmFvzAc1hHg">312,079</span> related to the April Series 2025 Warrants, $<span id="xdx_907_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_c20260430__us-gaap--FinancialInstrumentAxis__custom--MayTwoThousandTwentyFiveWarrantsMember_zJz1bPFpNKY7">293,942</span> related to the May Series 2025 Warrants and $<span id="xdx_903_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_c20260430__us-gaap--FinancialInstrumentAxis__custom--OctoberTwoThousandTwentyFiveWarrantsMember_z2K8hBD48jud">529,019</span> related to the October Series 2025 Warrants, all of which are remeasured at fair market value at the end of each reporting period. The combination of the original issuance discount of $<span id="xdx_901_ecustom--OriginalIssuanceDiscount_c20251101__20260430__us-gaap--FinancialInstrumentAxis__custom--FebruaryTwoThousandTwentyFourNotesAndAprilTwoThousandTwentyFourWarrantsMember_zbEAgCTaTwai" title="Original issuance discount">1,250,000</span> and the warrant liability of $<span id="xdx_900_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_c20260430__us-gaap--FinancialInstrumentAxis__custom--FebruaryTwoThousandTwentyFiveNotesAndFebruaryTwoThousandTwentyFourWarrantsMember_zrjxCoKERHRb" title="Warrant liability">4,448,036</span> resulted in the recognition of a debt discount of $<span id="xdx_90E_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20260430__us-gaap--FinancialInstrumentAxis__custom--FebruaryTwoThousandTwentyFiveNotesAndFebruaryTwoThousandTwentyFourWarrantsMember_zfViHupzPBEi" title="Debt discount">5,698,036</span> at issuance of the February Series 2025 Notes and February Series 2025 Warrants. The combination of the original issuance discount of $<span id="xdx_90D_ecustom--OriginalIssuanceDiscount_c20251101__20260430__us-gaap--FinancialInstrumentAxis__custom--AprilTwoThousandTwentyFiveNotesAndAprilTwoThousandTwentyFourWarrantsMember_zRv2cz9KISo2" title="Original issuance discount">87,500</span> and the warrant liability of $<span id="xdx_901_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_c20260430__us-gaap--FinancialInstrumentAxis__custom--AprilTwoThousandTwentyFiveNotesAndAprilTwoThousandTwentyFourWarrantsMember_zFPtiPVAMj74">312,079</span> resulted in the recognition of a debt discount of $<span id="xdx_90A_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20260430__us-gaap--FinancialInstrumentAxis__custom--AprilTwoThousandTwentyFiveNotesAndAprilTwoThousandTwentyFourWarrantsMember_zeNvLEvW3Hy2" title="Debt discount">399,579</span> at issuance of the April Series 2025 Notes and April Series 2025 Warrants. The combination of the original issuance discount of $<span id="xdx_903_ecustom--OriginalIssuanceDiscount_c20251101__20260430__us-gaap--FinancialInstrumentAxis__custom--MayTwoThousandTwentyFiveNotesAndMayTwoThousandTwentyFiveWarrantsMember_z3rCGWGyEEW9" title="Original issuance discount">81,250</span> and the warrant liability of $<span id="xdx_90F_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_c20260430__us-gaap--FinancialInstrumentAxis__custom--MayTwoThousandTwentyFiveNotesAndMayTwoThousandTwentyFiveWarrantsMember_zsswgURjhMN4">293,942</span> resulted in the recognition of a debt discount of $<span id="xdx_90E_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20260430__us-gaap--FinancialInstrumentAxis__custom--MayTwoThousandTwentyFiveNotesAndMayTwoThousandTwentyFiveWarrantsMember_ziRiPwMcZCCf">375,192</span> at issuance of the May Series 2025 Notes and May Series 2025 Warrants. The combination of the original issuance discount of $<span id="xdx_903_ecustom--OriginalIssuanceDiscount_c20251101__20260430__us-gaap--FinancialInstrumentAxis__custom--OctoberTwoThousandTwentyFiveNotesAndOctoberTwoThousandTwentyFiveWarrantsMember_zwIVsK0zXSNd" title="Original issuance discount">218,750</span> and the warrant liability of $<span id="xdx_90C_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_c20260430__us-gaap--FinancialInstrumentAxis__custom--OctoberTwoThousandTwentyFiveNotesAndOctoberTwoThousandTwentyFiveWarrantsMember_zlGv0VhlBog2">529,019</span> resulted in the recognition of a debt discount of $<span id="xdx_90E_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20260430__us-gaap--FinancialInstrumentAxis__custom--OctoberTwoThousandTwentyFiveNotesAndOctoberTwoThousandTwentyFiveWarrantsMember_zeZAWJ44dJfl" title="Debt discount">747,769</span> at issuance of the October Series 2025 Notes and October Series 2025 Warrants.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The combination of the original issuance discount of $<span id="xdx_90B_ecustom--OriginalIssuanceDiscount_c20251101__20260430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFiveFebruarySeriesNotesMember_zEC4Pc6nrGQ" title="Original issuance discount">1,250,000</span> associated with the collected proceeds compared to the principal value of the February Series 2025 Notes and the $<span id="xdx_902_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20260430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFiveFebruarySeriesNotesMember_zLfxm1TYrE87" title="Debt discount">4,448,036</span> discount associated with the February Series 2025 Warrants results in a net discount of $<span id="xdx_902_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumNet_iI_c20260430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFiveFebruarySeriesNotesMember_zVYMTkUVgTbd" title="Net discount">5,698,036</span> that is accreted over twelve months utilizing the effective interest method. The effective interest rate for the three and six months ended April 30, 2026 and 2025, is <span id="xdx_900_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20260430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFiveFebruarySeriesNotesMember_zEZn6KK656c2" title="Effective interest rate">321</span>% and <span id="xdx_907_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20250430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFiveFebruarySeriesNotesMember_zrl0AEZGqVz3" title="Effective interest rate">321</span>%, and <span id="xdx_900_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20260430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFiveFebruarySeriesNotesMember_zl9WDHQpmyt9" title="Effective interest rate">321</span>% and <span id="xdx_907_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20250430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFiveFebruarySeriesNotesMember_zdMeVrdtX8p5" title="Effective interest rate">321</span>%, respectively, for the February issuance. During the three and six months ended April 30, 2026 and 2025, the Company recorded accretion expense of $<span id="xdx_905_eus-gaap--AccretionExpense_c20260201__20260430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFiveFebruarySeriesNotesMember_zm95JTGkA5u7" title="Accretion expense">0</span> and $<span id="xdx_902_eus-gaap--AccretionExpense_c20250201__20250430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFiveFebruarySeriesNotesMember_zUQRL7Ud9LF8" title="Accretion expense">0</span>, and $<span id="xdx_90D_eus-gaap--AccretionExpense_c20251101__20260430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFiveFebruarySeriesNotesMember_z8phaaeu7Qt4" title="Accretion expense">300,984</span> and $<span id="xdx_907_eus-gaap--AccretionExpense_c20241101__20250430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFiveFebruarySeriesNotesMember_zDfJWrJfmv37" title="Accretion expense">300,984</span>, respectively and a gain on the fair value of the warrant liability of $<span id="xdx_907_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_c20260201__20260430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFiveFebruarySeriesNotesMember_z6eEDr6ubmif" title="Fair value of the warrant liability">0</span> and $<span id="xdx_900_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_c20250201__20250430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFiveFebruarySeriesNotesMember_zvsoM9sRqZsg" title="Fair value of the warrant liability">0</span>, and $<span id="xdx_909_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_c20251101__20260430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFiveFebruarySeriesNotesMember_zVc3Nqojniua" title="Fair value of the warrant liability">6,628</span> and $<span id="xdx_907_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_c20241101__20250430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFiveFebruarySeriesNotesMember_zqoOr7WB92I" title="Fair value of the warrant liability">6,628</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The combination of the original issuance discount of $<span id="xdx_909_ecustom--OriginalIssuanceDiscount_c20251101__20260430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFiveAprilSeriesNotesMember_zd2A44SSMNd">87,500</span> associated with the collected proceeds compared to the principal value of the April Series 2025 Notes and the $<span id="xdx_901_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20260430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFiveAprilSeriesNotesMember_zNtbhtFn9Of9">312,079</span> discount associated with the April Series 2025 Warrants results in a net discount of $<span id="xdx_90B_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumNet_iI_c20260430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFiveAprilSeriesNotesMember_zy8hMBY7EDt6">399,579</span> that is accreted through the maturity date utilizing the effective interest method. The effective interest rate for the three and six months ended April 30, 2026 and 2025 is <span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20260430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFiveAprilSeriesNotesMember_zIlAzCrOfuke">409</span>% and <span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20250430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFiveAprilSeriesNotesMember_zLnsrYJX1Mgh">409</span>%, and <span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20260430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFiveAprilSeriesNotesMember_zjtvbrqizAyk">409</span>% and <span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20250430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFiveAprilSeriesNotesMember_z8smU1SlKE5h">409</span>%, respectively. During the three and six months ended April 30, 2026 and 2025, the Company recorded accretion expense of $<span id="xdx_90D_eus-gaap--AccretionExpense_c20260201__20260430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFiveAprilSeriesNotesMember_zV6MJwQCzihg" title="Accretion expense">0</span> and $<span id="xdx_901_eus-gaap--AccretionExpense_c20250201__20250430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFiveAprilSeriesNotesMember_z2SWhxCBvmA5" title="Accretion expense">0</span>, and $<span id="xdx_90A_eus-gaap--AccretionExpense_c20251101__20260430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFiveAprilSeriesNotesMember_zQoe1Jhf1IW7" title="Accretion expense">2,126</span> and $<span id="xdx_901_eus-gaap--AccretionExpense_c20241101__20250430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFiveAprilSeriesNotesMember_znDnYhdUBOi4" title="Accretion expense">2,126</span>, respectively, and a (gain) or loss on the fair value of the warrant liability of $<span id="xdx_90E_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_c20260201__20260430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFiveAprilSeriesNotesMember_z9ZiLxsMXdG6" title="Gain loss on fair value of warrant liability">0</span> and $<span id="xdx_90B_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_c20250201__20250430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFiveAprilSeriesNotesMember_zISkZAqQ0cti" title="Gain loss on fair value of warrant liability">0</span>, and <span id="xdx_90F_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_c20251101__20260430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFiveAprilSeriesNotesMember_zeZPT888yM6j" title="Gain loss on fair value of warrant liability">($252)</span> and <span id="xdx_908_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_c20241101__20250430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFiveAprilSeriesNotesMember_zVuJOcjGiG66" title="Gain loss on fair value of warrant liability">($252)</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The combination of the original issuance discount of $<span id="xdx_901_ecustom--OriginalIssuanceDiscount_c20251101__20260430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFiveMaySeriesNotesMember_zVHr2vCld2Cb" title="Original issuance discount">81,250</span> associated with the collected proceeds compared to the principal value of the May Series 2025 Notes and the $<span id="xdx_906_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20260430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFiveMaySeriesWarrantsMember_zEAjXtwC5KJb" title="Debt discount">289,787</span> discount associated with the May Series 2025 Warrants results in a net discount of $<span id="xdx_901_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumNet_iI_c20260430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFiveMaySeriesNotesMember_zhThXZpeyDi5">371,037</span> that is accreted through the maturity date utilizing the effective interest method. The effective interest rate for the three and six months ended April 30, 2026 and 2025 is <span id="xdx_901_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20260430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFiveMaySeriesNotesMember_z9XicMRcefHi">453</span>% and <span id="xdx_902_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20250430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFiveMaySeriesNotesMember_znNhRIQoSw4a">453</span>%, and <span id="xdx_901_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20260430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFiveMaySeriesNotesMember_zpz5RZ1Kqcp4">453</span>% and <span id="xdx_902_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20250430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFiveMaySeriesNotesMember_zgp5dhPz1szj">453</span>%, respectively. During the three and six months ended April 30, 2026 and 2025, the Company recorded accretion expense of $<span id="xdx_900_eus-gaap--AccretionExpense_c20260201__20260430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFiveMaySeriesNotesMember_zEnDRgvOZJ12">0</span> and $<span id="xdx_907_eus-gaap--AccretionExpense_c20250201__20250430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFiveMaySeriesNotesMember_zAUp17qBpIYf">0</span>, and $<span id="xdx_90A_eus-gaap--AccretionExpense_c20251101__20260430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFiveMaySeriesNotesMember_z83pm8Q8GOGg">0</span> and $<span id="xdx_909_eus-gaap--AccretionExpense_c20241101__20250430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFiveMaySeriesNotesMember_zA21oj73xJEd">0</span>, respectively, and a gain on the fair value of the warrant liability of $<span id="xdx_902_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_c20260201__20260430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFiveMaySeriesNotesMember_zCXLYIqdab75" title="Gain loss on fair value of warrant liability">0</span> and $<span id="xdx_90C_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_c20250201__20250430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFiveMaySeriesNotesMember_z2zhBgpHyFx3" title="Gain loss on fair value of warrant liability">0</span>, and $<span id="xdx_901_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_c20251101__20260430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFiveMaySeriesNotesMember_zfZvNnIkmuwd" title="Gain loss on fair value of warrant liability">0</span> and $<span id="xdx_90E_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_c20241101__20250430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFiveMaySeriesNotesMember_zmdCImsw2mif" title="Gain loss on fair value of warrant liability">0</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In association with the October Series 2025 Notes, the lender and the Company amended the original note to include the April, May and October Series and renegotiated the conversion methodology from using a $<span id="xdx_90C_eus-gaap--DebtInstrumentFaceAmount_iI_c20260430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFiveOctoberSeriesNotesMember_zcDKkPDOiYj2">95,000,000</span> valuation to an independent valuation completed by a mutual agreeable specialist at the time of conversion. In accordance with ASC 470, the Company has evaluated the changes to the original note and has determined that the original note was extinguished, based on the conclusion that there was a greater than 10% change in the present value of the cash flows of the new loan, compared to the old loan.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The combination of the original issuance discount of $<span id="xdx_908_ecustom--OriginalIssuanceDiscount_c20251101__20260430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFiveOctoberSeriesNotesMember_zExCbvErZ3m1" title="Original issuance discount">218,750</span> associated with the collected proceeds compared to the principal value of the October Series 2025 Notes and the $<span id="xdx_902_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20260430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFiveOctoberSeriesNotesMember_zcbZvi6CmkD9">2,169,669</span> revised discount associated with the Series 2025 Warrants results in a net discount of $<span id="xdx_90C_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumNet_iI_c20260430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFiveOctoberSeriesNotesMember_zRLA3nbqBon7" title="Net discount">2,388,419</span> that is accreted through the maturity date utilizing the effective interest method. The effective interest rate for the three and six months ended April 30, 2026 and 2025 is <span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20260430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFiveOctoberSeriesNotesMember_zDE4wNizO9L9" title="Effective interest rate">27</span>% and <span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20260430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFiveOctoberSeriesNotesMember_zLcYpteMWUWg" title="Effective interest rate">27</span>%, and <span id="xdx_902_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20250430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFiveOctoberSeriesNotesMember_zYO2KOuQu1H6" title="Effective interest rate">0</span>% and <span id="xdx_902_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20250430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFiveOctoberSeriesNotesMember_zVucCrXN9Fw6" title="Effective interest rate">0</span>%, respectively. During the three and six months ended April 30, 2026 and 2025, the Company recorded accretion expense of $<span id="xdx_903_eus-gaap--AccretionExpense_c20260201__20260430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFiveOctoberSeriesNotesMember_zS7oscIFOqL" title="Accretion expense">405,213</span> and $<span id="xdx_906_eus-gaap--AccretionExpense_c20251101__20260430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFiveOctoberSeriesNotesMember_zXQRTK3ZEqzd" title="Accretion expense">797,543</span>, and $<span id="xdx_907_eus-gaap--AccretionExpense_c20250201__20250430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFiveOctoberSeriesNotesMember_zBCkr0HQboN" title="Accretion expense">0</span> and $<span id="xdx_906_eus-gaap--AccretionExpense_c20241101__20250430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFiveOctoberSeriesNotesMember_za9G2cRhqCpi" title="Accretion expense">0</span>, respectively, and a gain on the fair value of the warrant liability of $<span id="xdx_908_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_c20260201__20260430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFiveOctoberSeriesNotesMember_zGyc9aA8R7c5" title="Gain loss on fair value of warrant liability">413,965</span> and $<span id="xdx_904_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_c20251101__20260430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFiveOctoberSeriesNotesMember_zADalGdtsWLd" title="Gain loss on fair value of warrant liability">696,114</span>, and $<span id="xdx_90A_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_c20250201__20250430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFiveOctoberSeriesNotesMember_z6rpfoh9fVH2" title="Gain loss on fair value of warrant liability">0</span> and $<span id="xdx_900_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_c20241101__20250430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFiveOctoberSeriesNotesMember_zEmGAU7NYd6i" title="Gain loss on fair value of warrant liability">0</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the three and six months ended April 30, 2026 and 2025, <span id="xdx_90E_eus-gaap--InterestExpenseDebt_do_c20260201__20260430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFiveSeniorSecuredConvertibleNotesMember_zEWjnjsrIxL8" title="Interest expense, debt"><span id="xdx_907_eus-gaap--InterestExpenseDebt_do_c20250201__20250430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFiveSeniorSecuredConvertibleNotesMember_zcayWQ0Rjfpl" title="Interest expense, debt"><span id="xdx_902_eus-gaap--InterestExpenseDebt_do_c20251101__20260430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFiveSeniorSecuredConvertibleNotesMember_zsi7P2nTzp18" title="Interest expense, debt"><span id="xdx_909_eus-gaap--InterestExpenseDebt_do_c20241101__20250430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFiveSeniorSecuredConvertibleNotesMember_zaWAKlz8vv7k" title="Interest expense, debt">no</span></span></span></span> interest expense was recorded on the Series 2025 Notes. As of April 30, 2026 and October 31, 2025, <span id="xdx_900_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_do_c20260430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFiveSeniorSecuredConvertibleNotesMember_zbwoJWIOXcEa" title="Accrued interest"><span id="xdx_90E_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_do_c20251031__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFiveSeniorSecuredConvertibleNotesMember_zASwrmzPX6j" title="Accrued interest">no</span></span> accrued interest was recorded on the Series 2025 Notes.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has exercised its right to a one year extension of these notes, with a new maturity date of <span id="xdx_900_eus-gaap--DebtInstrumentMaturityDate_pid_uPure_c20251101__20260430__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFiveSeniorSecuredConvertibleNotesMember_zj0EMhgJLXp7" title="Revised maturity date">February 27, 2027</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_892_eus-gaap--ScheduleOfDebtInstrumentsTextBlock_zTyMCXZsaotb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The table below presents outstanding debt instruments as of April 30, 2026 and October 31, 2025:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B9_zuwaxQQ7iVN9" style="display: none">SCHEDULE OF OUTSTANDING DEBT INSTRUMENTS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20260430_zXNP5Kxghvt5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">April 30, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20251031_zf9sfJdnu2K1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">October 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; font-style: italic; text-align: left">Short Term</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--ConvertibleSeriesSeniorSecureShortTermNotesPayableOne_iNI_di_msSTBz8gR_zYFDvMslhlZ1" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 60%; text-align: left">2024 Senior secured convertible notes payable</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">125,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">593,750</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_ecustom--ConvertibleSeriesSeniorSecureShortTermNotesPayableTwo_iNI_di_msSTBz8gR_z88U52o6pwi2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">2025 Senior secured convertible notes payable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><p style="margin: 0">8,187,500</p></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1304">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_406_ecustom--DiscountConvertibleSeriesSeniorSecureShortTermNotesPayable_iI_maSTBz8gR_zA467Gs81RZ2" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Discount 2025 Senior secured convertible notes payable</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><p style="margin: 0">(1,590,876</p></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><p style="margin: 0"><span style="-sec-ix-hidden: xdx2ixbrl1307">-</span></p></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--ShortTermBorrowings_iTI_maDLASCzQh4_mtSTBz8gR_zUT2wYS4gBHk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; font-style: italic; text-align: left">Total Short-Term Debt</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,721,624</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">593,750</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; font-style: italic; text-align: left">Long Term</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--UnsecuredDebtCurrent_iI_maLTDNzb5m_zF7FlqYzwAk7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Unsecured 6% note payable – related party</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">767,288</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">767,288</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_ecustom--UnsecuredNotePayableRelatedPartyNoncurrentOne_iI_maLTDNzb5m_zNfiZKKZCih9" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Unsecured 4% note payable – related party</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,221,958</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,221,958</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--ConvertibleLongTermNotesPayable_iI_maLTDNzb5m_zKVmsb3TPP2h" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">2022 Series convertible notes</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">200,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">200,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_ecustom--ConvertibleLongTermNotesPayableStockSettled_iI_maLTDNzb5m_zOT84e9el3J4" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">2023 Series convertible notes – stock settled</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">405,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">405,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_ecustom--ConvertibleLongTermNotesPayableSeriesDiscount_iNI_di_msLTDNzb5m_zCNHv5t3fTu1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Discount 2023 Series convertible notes</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(30,171</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(37,834</td><td style="text-align: left">)</td></tr> <tr id="xdx_401_ecustom--ConvertibleSeriesBLongTermNotesPayableStockSettled_iI_maLTDNzb5m_zyzs2sIbyCP7" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">2023 Series B convertible notes – stock settled</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,312,600</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,312,600</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_ecustom--ConvertibleSeriesBLongTermNotesPayableSeriesDiscount_iNI_di_msLTDNzb5m_zQuzTqTlyfMh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Discount 2023 Series B convertible notes</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(590,079</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(676,304</td><td style="text-align: left">)</td></tr> <tr id="xdx_40E_ecustom--SeniorSecuredConvertibleLongTermNotesPayable_iI_maLTDNzb5m_zVn6WiZO4sba" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">2025 Senior secured convertible notes payable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1333">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,187,500</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_ecustom--SeniorSecuredConvertibleLongTermNotesPayableDiscount_iNI_di_msLTDNzb5m_zf2hcheNOFEd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Discount 2025 Senior secured convertible notes payable</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1336">-</span></td><td style="padding-bottom: 1pt; text-align: left"></td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(2,388,419</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40E_eus-gaap--LongTermDebtNoncurrent_iTI_mtLTDNzb5m_maDLASCzQh4_zEm4plK0LmE6" style="vertical-align: bottom; background-color: White"> <td style="font-style: italic; text-align: left; padding-bottom: 1pt">Total Long-Term Debt</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">3,286,596</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">8,991,789</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--DebtLongtermAndShorttermCombinedAmount_iTI_mtDLASCzQh4_zLkyf8ckCeYl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-style: italic; text-align: left; padding-bottom: 2.5pt">Total Debt</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">10,008,220</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">9,585,539</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> -125000 -593750 -8187500 -1590876 6721624 593750 767288 767288 1221958 1221958 200000 200000 405000 405000 30171 37834 1312600 1312600 590079 676304 8187500 2388419 3286596 8991789 10008220 9585539 <p id="xdx_895_eus-gaap--ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_z0ZPr1xnoqkk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The table below presents the future maturities of outstanding debt obligations as of April 30, 2026:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BC_zfHsOpqkWJzl" style="display: none">SCHEDULE OF FUTURE MATURITIES OUTSTANDING DEBT OBLIGATIONS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: center"> </td><td style="text-align: center"> </td> <td style="text-align: center"> </td><td id="xdx_496_20260430_zyWzqousEqXi" style="text-align: center"> </td><td style="text-align: center"> </td></tr> <tr id="xdx_40F_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_iI_maLTDz6x0_zM2izD568994" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">Fiscal year 2026</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">125,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_maLTDz6x0_zbFUd7xDqFx" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Fiscal year 2027</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,387,500</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_maLTDz6x0_zxBLbHoclfa8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Fiscal year 2028</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,717,600</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_iI_maLTDz6x0_zCn8kktad9G9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Fiscal year 2029</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1353">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_iI_maLTDz6x0_zNHwSBvpDg7c" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Fiscal year 2030</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1355">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_iI_maLTDz6x0_zbRsY60So1x1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Fiscal year 2031</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,989,246</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--LongTermDebt_iTI_mtLTDz6x0_zgabJkW54a2c" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">12,219,346</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 125000 8387500 1717600 1989246 12219346 11225 22829 11226 22829 51923 201219 230313 2025-12-31 150000 11918 24238 11918 24238 268764 244526 2025-12-31 200000 200000 0.05 0.05 5000000 5000000 2438 4959 2438 4959 38192 33233 405000 0.08 787600 787600 0.08 0.08 525000 525000 0.08 0.08 5000000 0.75 200000000 0.25 0.75 16.25 1 to 26 reverse stock split P5Y 0.75 0.75 16.25 16.25 P5Y P5Y 2 73213 73213 73213 568574 568574 568574 354810 354180 354180 73213 0.130 0.130 0.130 0.130 3830 7663 3371 6745 -1798 -1843 25 33 568574 0.446 0.446 0.446 0.446 28169 54345 18457 35610 -13988 -14332 192 259 354810 0.395 0.395 0.395 0.395 16431 31881 11282 21891 -9324 -9554 128 173 7900 16067 7900 16067 15364 31245 15364 31245 10241 20827 10241 20827 107196 91129 194748 163503 120493 99666 2500000 1250000 2000000 1000000 0.20 0.20 218750 175000 0.20 375000 300000 0.20 3750000 300000 3300000 825000 4125000 The Series 2024 Notes will be convertible, at the option of the investors, into common stock commencing on the maturity date, at a conversion price equal to the product of (x) the Liquidity Event Price (as defined in the Series 2024 Notes) and (y) 0.70 (or 0.60 if the Company has extended the maturity date), provided however, that if no Liquidity Event has occurred by the maturity date then the conversion price will be the amount obtained by dividing (i) $95,000,000 by (ii) the number of shares of common stock outstanding on such date calculated on a fully-diluted basis. In addition, the Company will have the right to effect conversion of the Series 2024 Notes if, at the time (a) a Liquidity Event has occurred and (b) the underlying shares are registered for resale. The Series 2024 Warrants will be exercisable into the number the shares of common stock obtained by dividing 100% of the original principal amount of the Series 2024 Notes by (ii) the Liquidity Event Price (as defined in the Series 2024 Notes); provided, however, that if no Liquidity Event has occurred by the maturity date, then such percentage will be 150%. The Series 2024 Warrants will be exercisable for a period of five years and have an exercise price equal to the Liquidity Event Price provided however, that if no Liquidity Event has occurred by the maturity date then the exercise price will be the amount obtained by dividing (i) $95,000,000 by (ii) the number of shares of common stock outstanding on such date calculated on a fully-diluted basis. 15.00 250000 14583 25000 2732304 157733 269752 750000 2732304 3482304 43750 157733 201483 75000 269752 344752 750000 2732304 3482304 6.59 6.59 6.59 6.59 6.24 6.24 6.24 6.24 0 0 0 0 1713320 300000 75000 990719 740724 43750 157733 201483 5,000 5,000 5,000 5,000 0 0 0 0 450 2269 2365 4398 218750 22059 145850 75000 269752 344752 104,000 104,000 104,000 104,000 0 0 0 0 820 3938 4055 7540 250000 25210 166700 0 0 0 0 245000 990000 1235000 4370000 6250000 5000000 0.20 350000 437500 350000 0.20 325000 406250 325000 0.20 875000 1093750 875000 0.20 The Series 2025 Notes will be convertible, at the option of the investors, into common stock commencing on the maturity date, at a conversion price equal to the product of (x) the Liquidity Event Price (as defined in the Series 2025 Notes) and (y) 0.70 (or 0.60 if the Company has extended the maturity date), provided however, that if no Liquidity Event has occurred by the maturity date then the conversion price will be the amount obtained by dividing (i) $95,000,000 by (ii) the number of shares of common stock outstanding on such date calculated on a fully-diluted basis. In addition, the Company will have the right to effect conversion of the Series 2025 Notes if, at the time (a) a Liquidity Event has occurred and (b) the underlying shares are registered for resale. In October 2025, the parties amended the note to replace the $95,000,000 valuation, mentioned above, with a valuation resulting from a study by a mutually approved valuation expert. The Series 2025 Warrants will be exercisable into the number the shares of common stock obtained by dividing 100% of the original principal amount of the Series 2025 Notes by (ii) the Liquidity Event Price (as defined in the Series 2024 Notes); provided, however, that if no Liquidity Event has occurred by the maturity date, then such percentage will be 150%. The Series 2025 Warrants will be exercisable for a period of five years and have an exercise price equal to the Liquidity Event Price provided however, that if no Liquidity Event has occurred by the maturity date then the exercise price will be the amount obtained by dividing (i) $95,000,000 by (ii) the number of shares of common stock outstanding on such date calculated on a fully-diluted basis. 5.50 1136364 79545 73864 198864 4448036 312079 293942 529019 1250000 4448036 5698036 87500 312079 399579 81250 293942 375192 218750 529019 747769 1250000 4448036 5698036 3.21 3.21 3.21 3.21 0 0 300984 300984 0 0 6628 6628 87500 312079 399579 4.09 4.09 4.09 4.09 0 0 2126 2126 0 0 -252 -252 81250 289787 371037 4.53 4.53 4.53 4.53 0 0 0 0 0 0 0 0 95000000 218750 2169669 2388419 0.27 0.27 0 0 405213 797543 0 0 413965 696114 0 0 0 0 0 0 0 0 2027-02-27 <p id="xdx_800_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zcnNj0LND4U7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 8– <span id="xdx_826_zcffWXjbKkNg">STOCKHOLDERS’ EQUITY</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Preferred Stock</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has authorized <span id="xdx_901_eus-gaap--PreferredStockSharesAuthorized_iI_c20260430_zkNfMuHAM0Zj" title="Preferred stock, shares authorized">5,000,000</span> shares of $<span id="xdx_905_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20260430_zBuRTkkvUVn8" title="Preferred stock, par value">0.001</span> par value Preferred Stock, of which <span id="xdx_907_eus-gaap--PreferredStockSharesAuthorized_iI_c20260430__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zD99X0TFFuOg" title="Preferred stock, shares authorized">250,000</span> were designated as Series A Convertible Preferred Shares. In May 2025, the Company designated <span id="xdx_900_eus-gaap--PreferredStockSharesAuthorized_iI_c20250531__us-gaap--StatementClassOfStockAxis__custom--SeriesAOneConvertiblePreferredStockMember_zz1S2pQTiR37" title="Preferred stock, shares authorized">750,000</span> shares as Series A-1 Convertible Preferred Shares for a private placement of the A-1 stock for a maximum of $<span id="xdx_907_eus-gaap--PreferredStockValue_iI_pn6n6_c20250531__us-gaap--StatementClassOfStockAxis__custom--SeriesAOneConvertiblePreferredStockMember_zzqLKDTsiY87" title="Preferred stock, value">15</span> million. As of April 30, 2026 and October 31, 2025, <span id="xdx_909_eus-gaap--PreferredStockSharesIssued_iI_c20260430__us-gaap--StatementClassOfStockAxis__custom--SeriesAOneConvertiblePreferredStockMember_z2mcLWeLwmk3" title="Preferred stock, shares issued"><span id="xdx_908_eus-gaap--PreferredStockSharesOutstanding_iI_c20260430__us-gaap--StatementClassOfStockAxis__custom--SeriesAOneConvertiblePreferredStockMember_zqkhYWqq3zb6" title="Preferred stock, shares outstanding">129,065</span></span> and <span id="xdx_90F_eus-gaap--PreferredStockSharesIssued_iI_c20251031__us-gaap--StatementClassOfStockAxis__custom--SeriesAOneConvertiblePreferredStockMember_z1Rd2m4Y64hi" title="Preferred stock, shares issued"><span id="xdx_906_eus-gaap--PreferredStockSharesOutstanding_iI_c20251031__us-gaap--StatementClassOfStockAxis__custom--SeriesAOneConvertiblePreferredStockMember_zstsFlwdXZVe" title="Preferred stock, shares outstanding">35,000</span></span> shares of Series A-1 Convertible Preferred Stock were issued and outstanding. During the three and six months ended April 30, 2026, dividends of $<span id="xdx_90E_eus-gaap--DividendsPreferredStock_c20260201__20260430_zUOmfh3na4Ja" title="Dividend preferred stock">39,912</span> and $<span id="xdx_90B_eus-gaap--DividendsPreferredStock_c20251101__20260430_zNxJ1IZ0F7xh" title="Dividend preferred stock">66,959</span> were recorded, respectively. As of April 30, 2026 and October 31, 2025, the accrued dividend on the outstanding preferred was $<span id="xdx_909_eus-gaap--Dividends_c20251101__20260430_z9SZtSMGP2Ja" title="Dividend">83,375</span> and $<span id="xdx_905_eus-gaap--Dividends_c20241101__20251031_zclvJ7rlRwti" title="Dividend">16,416</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following is a summary of the rights and preferences of the Preferred A-1 Stock:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The holders of the Preferred A-1 Stock are entitled to a liquidation preference with respect to the Preferred A-1 Stock in the amount of $<span id="xdx_90A_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20260430__us-gaap--StatementClassOfStockAxis__custom--AOnePreferredStockMember_zYtkZeqOfrT4" title="Preferred stock, stated value">20</span> per share (“Stated Value”), subordinate to the stated value of any outstanding shares of preferred stock ranking senior to the Preferred A Stock, <i>pari passu</i> with the stated value of the series A-1 Preferred Stock, and senior to the rights of the holders of common stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The holders of the Preferred A-1 Stock are entitled to cumulative dividends at the annual rate of <span id="xdx_90C_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20251101__20260430__us-gaap--StatementClassOfStockAxis__custom--AOnePreferredStockMember_zxifgjl5LNR1" title="Cumulative dividend percentage">8</span>% based on the Stated Value per share, payable on the maturity date, which is five years from the date of issuance. Dividends are payable in the form of shares of common stock valued at $<span id="xdx_904_eus-gaap--PreferredStockConvertibleConversionPrice_iI_c20260430__us-gaap--StatementClassOfStockAxis__custom--AOnePreferredStockMember_zWviB5EPKhRe" title="Conversion price per share">4.00</span> per share.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Preferred A-1 Stock may be redeemed by the Company, in whole or in part, at any time or from time to time by notice to the holders. In the event of redemption, the Company shall be obligated to pay to each holder the Stated Value per share plus any accrued but unpaid dividends.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Preferred A-1 Shares are convertible into common stock at $<span id="xdx_900_eus-gaap--PreferredStockConvertibleConversionPrice_iI_c20260430__us-gaap--StatementClassOfStockAxis__custom--AOnePreferredStockMember_zVkksotjYOd5" title="Conversion price per share">4.00</span> per share and may be converted at the discretion of the holder. The Preferred A-1 Stock shall automatically convert into the Company’s common stock if (a) (i) the common stock into which the Preferred A-1 Shares are convertible is registered with the SEC, (ii) there exists a public trading market for the common stock, and (iii) the trading price of the Company’s common stock has equaled or exceeded 200% of the conversion price as then in effect for ten or more consecutive trading days or (b) the Company effects a merger, consolidation or sale of assets and is not the surviving entity.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The holders of the Preferred A-1 Shares have the right to vote with the holders of the common stock on any matters presented to the stockholders at any regular or special meeting of the stockholders of the Company on an “as-converted” basis. The holders of the Series A-1 Stock are also entitled to vote as a class in the event the Company intends to create and/or issue shares of preferred stock that are senior to the Series A-1 Stock or if the Company attempts to amend its Articles of Incorporation to alter or amend the powers, privileges, rights, restrictions or conditions of the Series A-1 Stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company assessed the Series A-1 under ASC 480. The Company determined that the Series A-1 is outside the scope of ASC 480 as the redemption of Series A-1 shares are solely the right of the Company and the number of common shares to be issued at conversion were at a fixed monetary value. The Company then assessed the Series A-1 under ASC 815 to determine if the Series A-1 is more debt-like or more equity like. While the dividend rights and protective provisions make the Series A-1 more debt-like, the fact that the Company is in control of any redemption of the shares, that the Series A-1 contains certain mandatory conversion provisions and the holders have optional conversion rights, and the Series A-1 shares have voting rights on an as-converted basis make the Series more equity-like. We determined based on the above that the Series A-1 is more equity-like. Since the Series A-1 does not contain a put option and the Series A-1 shares are not redeemable upon an event outside of the Company’s control, we have recorded the Series A-1 shares as permanent equity.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Activity for the six months ended April 30, 2026 and the year ended October 31, 2025</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the three months ended April 30, 2026, the Company issued <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20260201__20260430__us-gaap--StatementClassOfStockAxis__custom--SeriesAOneConvertiblePreferredStockMember_zTqERf4Z8v5h" title="Issued for shares">5,000</span> shares of its Series A-1 Convertible Preferred Stock for proceeds of $<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20260201__20260430__us-gaap--StatementClassOfStockAxis__custom--SeriesAOneConvertiblePreferredStockMember_zQHXwlcLaCch" title="Issued for shares, value">100,000</span> as part of an ongoing private placement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the three months ended April 30, 2026, the Company issued <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_pid_c20260201__20260430__us-gaap--StatementClassOfStockAxis__custom--SeriesAOneConvertiblePreferredStockMember_zLBauNqIilsi" title="Issued for conversion">39,065</span> shares of its Series A-1 Convertible Preferred Stock for conversion of $<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueConversionOfUnits_c20260201__20260430__us-gaap--StatementClassOfStockAxis__custom--SeriesAOneConvertiblePreferredStockMember_zd9mHhO2UOG4" title="Issued for conversion, value">468,750</span> of 2024 Series Senior Secured Convertible Notes as part of an ongoing private placement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the three months ended January 31, 2026, the Company issued <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_c20260201__20260430__us-gaap--StatementClassOfStockAxis__custom--SeriesAOneConvertiblePreferredStockMember_zRZKSzJXZI6" title="Issued for services">50,000</span> shares of its Series A-1 Convertible Preferred Stock for proceeds of $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_pn6n6_c20260201__20260430__us-gaap--StatementClassOfStockAxis__custom--SeriesAOneConvertiblePreferredStockMember_zMWFD1sTyzKl" title="Issued for services, value">1</span> million as part of an ongoing private placement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended October 31, 2025, the Company issued <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_c20241101__20251031__us-gaap--StatementClassOfStockAxis__custom--SeriesAOneConvertiblePreferredStockMember_zBLvPYQQHsXl" title="Issued for services">35,000</span> shares of its Series A-1 Convertible Preferred Stock for proceeds of $<span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_pid_c20241101__20251031__us-gaap--StatementClassOfStockAxis__custom--SeriesAOneConvertiblePreferredStockMember_zKNxqFihwkzk" title="Issued for services value">700,000</span> as part of an ongoing private placement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common Stock</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of April 30, 2026, the Company had authorized <span id="xdx_906_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20260430_zUeXU1xCeWEg" title="Common stock, shares authorized">19,230,770</span> shares of $<span id="xdx_908_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20260430_z5E2sAEgyYvc" title="Common stock, par value">0.001</span> par value common stock. As of April 30, 2026 and October 31, 2025, <span id="xdx_901_eus-gaap--CommonStockSharesIssued_iI_pid_c20260430_zRTuWgFFI7c8" title="Common stock, shares issued"><span id="xdx_907_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20260430_z3gOs1dHj6gc" title="Common stock, shares outstanding">4,517,651</span></span>, and <span id="xdx_90E_eus-gaap--CommonStockSharesIssued_iI_pid_c20251031_zZVhYZxlKUN3" title="Common stock, shares issued"><span id="xdx_90E_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20251031_zFnx3ElEYndh" title="Common stock, shares outstanding">4,460,535</span></span> shares were issued and outstanding, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective January 5, 2026, an option holder exercised their right to complete a cashless exercise exchanging <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20260105__20260105_zVGo55XcqVB4" title="Stock option exercised">84,615</span> options for <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesOther_pid_c20260105__20260105__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z6k6B0kwdrKd" title="Issuance common stock">57,116</span> shares of common stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There were no grants of common shares or exercise of options during the year ended October 31, 2025.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock-Based Compensation</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There were <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_do_c20251101__20260430_zm9GHXaZhrCa" title="Number of shares granted"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_do_c20241101__20250430_zJQtDHLHaoi7" title="Number of shares granted">no</span></span> grants of stock purchase options during the six months ended April 30, 2026 or 2025.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89E_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z2ygImRALF08" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The table below presents option activity for the six months ended April 30, 2026 and the year ended October 31, 2025:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B9_zD1R52zTG7Kk" style="display: none">SCHEDULE OF OPTION ACTIVITY</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shares</b></span></p></td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price per Share</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Life (in years)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Aggregate</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>intrinsic value</b></span></p></td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%">Balance at October 31, 2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20241101__20251031_zkODbuUD0p2c" style="width: 12%; text-align: right" title="Number of Shares, Balance">1,112,923</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20241101__20251031_z9ckPd3mONz9" style="width: 12%; text-align: right" title="Weighted Average Exercise Price per Share, Balance">10.84</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20231101__20241031_z1vXlSOJaIc1" title="Weighted Average Remaining Contractual Life (in years)">5.64</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20241101__20251031_zttDwczJIwJj" style="width: 12%; text-align: right" title="Aggregate intrinsic value, Balance">1,560,431</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Options exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20241101__20251031_zMxJC2AQu25k" style="text-align: right" title="Number of Shares, Options exercised"><span style="-sec-ix-hidden: xdx2ixbrl2029">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20241101__20251031_z6QOShBDUAq1" style="text-align: right" title="Weighted Average Exercise Price per Share, Options exercised"><span style="-sec-ix-hidden: xdx2ixbrl2031">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Options granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20241101__20251031_zFhQbtdqFVT3" style="text-align: right" title="Number of Shares, Options granted"><span style="-sec-ix-hidden: xdx2ixbrl2033">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20241101__20251031_zdubBsrQTuq5" style="text-align: right" title="Weighted Average Exercise Price per Share, Options granted"><span style="-sec-ix-hidden: xdx2ixbrl2035">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Options expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_pid_c20241101__20251031_zd60oxhlDae5" style="text-align: right" title="Number of Shares, Options expired"><span style="-sec-ix-hidden: xdx2ixbrl2037">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20241101__20251031_zjEGFvPTn5T1" style="text-align: right" title="Weighted Average Exercise Price per Share, Options expired"><span style="-sec-ix-hidden: xdx2ixbrl2039">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Options forfeited</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20241101__20251031_zqxexS29SZB2" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Shares, Options forfeited"><span style="-sec-ix-hidden: xdx2ixbrl2041">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_iN_di_c20241101__20251031_zK6MtM96nJ4b" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price per Share, Options forfeited"><span style="-sec-ix-hidden: xdx2ixbrl2043">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Balance at October 31, 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20251101__20260430_zFAEFw384f2g" style="text-align: right" title="Number of Shares, Balance">1,112,923</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20251101__20260430_zuYLaPglBJpf" style="text-align: right" title="Weighted Average Exercise Price per Share, Balance">10.84</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20241101__20251031_z4oJmFyr1sT7" title="Weighted Average Remaining Contractual Life (in years)">4.64</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20251101__20260430_z5NNjqZ8Wrsa" style="text-align: right" title="Aggregate intrinsic value, Balance">501,923</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Options exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20251101__20260430_zMZF8or5fkj4" style="text-align: right" title="Number of Shares, Options exercised">(84,615</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20251101__20260430_zN4qAYjtdPpk" style="text-align: right" title="Weighted Average Exercise Price per Share, Options exercised">1.30</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Options granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20251101__20260430_zXGNU9J5aW9g" style="text-align: right" title="Number of Shares, Options granted"><span style="-sec-ix-hidden: xdx2ixbrl2057">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20251101__20260430_z7wpzIbN1cAf" style="text-align: right" title="Weighted Average Exercise Price per Share, Options granted"><span style="-sec-ix-hidden: xdx2ixbrl2059">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Options expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_pid_c20251101__20260430_zRPPun7E41R6" style="text-align: right" title="Number of Shares, Options expired"><span style="-sec-ix-hidden: xdx2ixbrl2061">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20251101__20260430_z0DBEhEIvo2e" style="text-align: right" title="Weighted Average Exercise Price per Share, Options expired"><span style="-sec-ix-hidden: xdx2ixbrl2063">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Options forfeited</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20251101__20260430_zvJgW2oG12wl" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Shares, Options forfeited"><span style="-sec-ix-hidden: xdx2ixbrl2065">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_iN_di_c20251101__20260430_zyiyFTLBl0r4" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price per Share, Options forfeited"><span style="-sec-ix-hidden: xdx2ixbrl2067">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance at April 30, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20251101__20260430_zXIAQjv0XgHe" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Balance">1,028,308</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20251101__20260430_zVqH9yBTucoc" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price per Share, Balance">10.84</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20251101__20260430_zronZ8rarbO6" title="Weighted Average Remaining Contractual Life (in years)">4.32</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20251101__20260430_zz73MZqFrqq7" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value, Balance">375,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AF_z9hpEEBhiwae" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock based compensation expense related to options for the three and six months ended April 30, 2026 and 2025 amounted to $<span id="xdx_90E_eus-gaap--ShareBasedCompensation_c20260201__20260430_zHoKLfWfjxl1" title="Stock based compensation expense">240,621</span> and $<span id="xdx_90E_eus-gaap--ShareBasedCompensation_c20251101__20260430_zSwZ2ZbElX1h" title="Stock based compensation expense">532,251</span>, and $<span id="xdx_90B_eus-gaap--ShareBasedCompensation_c20250201__20250430_zKZ9QBTSJJNk" title="Stock based compensation expense">322,734</span> and $<span id="xdx_900_eus-gaap--ShareBasedCompensation_c20241101__20250430_z3WNbbIe6622" title="Stock based compensation expense">730,968</span>, respectively. As of April 30, 2026 and October 31, 2025, <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20260430_z5hg6qWgnUE6" title="Share based compensation options, exercisable">977,923</span> and <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20251031_zf2SIjgaBMU6" title="Share based compensation options, exercisable">1,058,692</span> options were exercisable, respectively. Unrecognized compensation expense related to outstanding options amounted to $<span id="xdx_901_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_c20260430_zt5W6EABfgR2" title="Unrecognized compensation expense">260,652</span> and $<span id="xdx_904_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_c20251031_zMicDLRZapui" title="Unrecognized compensation expense">792,903</span> as of April 30, 2026 and October 31, 2025, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Warrants</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Activity for the six months ended April 30, 2026</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the six months ended April 30, 2026 the Company issued <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20260430__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z2G983426dT1" title="Warrants to purchase common stock">28,846</span> warrants with an exercise price of $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260430__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zAHCADWXSd26" title="Warrants exercise price per share">16.25</span> in connection with the conversion of 2024 Senior Secured Notes.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Activity for the year ended October 31, 2025</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective November 16, 2024, the Company granted <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241116__us-gaap--ClassOfWarrantOrRightAxis__custom--PrefundedWarrantsMember_z5YZxKwjSRu9" title="Warrants to purchase common stock">180,000</span> pre-funded warrants with an exercise price of $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241116__us-gaap--ClassOfWarrantOrRightAxis__custom--PrefundedWarrantsMember_z1wdLLx4f3wg" title="Warrants exercise price per share">0.001</span> to the majority holder of the 2024 Senior Secured Convertible Notes for a fair value of $<span id="xdx_90B_eus-gaap--ConvertibleDebtFairValueDisclosures_iI_c20241116_zJ52PaofWRF7" title="Convertible notes for fair value">990,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 27, 2025, the Company granted <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250127__us-gaap--ClassOfWarrantOrRightAxis__custom--PrefundedWarrantsMember_zi1K1OMpIPh6">96,000</span> pre-funded warrants with an exercise price of $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250127__us-gaap--ClassOfWarrantOrRightAxis__custom--PrefundedWarrantsMember_zI2P2BC6shgg">0.001</span> to a consultant to the Company for consulting services provided for a fair value of $<span id="xdx_90B_eus-gaap--ConvertibleDebtFairValueDisclosures_iI_c20250127__us-gaap--ClassOfWarrantOrRightAxis__custom--PrefundedWarrantsMember_zQEPgUYq1Hwe" title="Convertible notes for fair value">528,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>A &amp; B Warrants</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_890_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_gL3SOSENWORTB-FE_zZKWxu5oNko9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A summary of the Company’s common stock underlying its outstanding A and B warrants as of April 30, 2026 and October 31, 2025 is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B9_z6Z1Y99KYLKi" style="display: none">SCHEDULE OF COMMON STOCK UNDERLYING OUTSTANDING WARRANTS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Underlying</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of<br/> Shares </b></span></p></td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Average <br/> Exercise<br/> Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted <br/> Average <br/> Life</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%">Outstanding – October 31, 2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20241101__20251031_zJfpxEvNY7lc" style="width: 14%; text-align: right" title="Underlying number of shares beginning">261,650</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_c20241101__20251031_zuvn2Md28PDj" style="width: 14%; text-align: right" title="Average exercise price beginning">26.00</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"><span id="xdx_90E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageRemainingContractualTerm2_dtY_c20231101__20241031_zHSqtiHOqYv6" title="Weighted average life">1.31</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrants A – Granted during the period</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20241101__20251031__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsAMember_z85BzeoeBYBh" style="text-align: right" title="Underlying number of shares granted"><span style="-sec-ix-hidden: xdx2ixbrl2119">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedWeightedAverageExercisePrice_c20241101__20251031__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsAMember_zCpsfkjXSYBh" style="text-align: right" title="Average exercise price, granted"><span style="-sec-ix-hidden: xdx2ixbrl2121">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrants B – Granted during the period</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20241101__20251031__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsBMember_zQKXF1O4E4W5" style="text-align: right" title="Underlying number of shares granted"><span style="-sec-ix-hidden: xdx2ixbrl2123">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedWeightedAverageExercisePrice_c20241101__20251031__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsBMember_zI5tkMyKqxcj" style="text-align: right" title="Average exercise price, granted"><span style="-sec-ix-hidden: xdx2ixbrl2125">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrants A – Expired during the period</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20241101__20251031__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsAMember_zf709gCsYjp6" style="text-align: right" title="Underlying number of shares expired">(78,846</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExpiredWeightedAverageExercisePrice_c20241101__20251031__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsAMember_zGfTg9TXYgse" style="text-align: right" title="Average exercise price, expired">26.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Warrants B – Expired during the period</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20241101__20251031__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsBMember_zv56jPIVbm57" style="border-bottom: Black 1pt solid; text-align: right" title="Underlying number of shares expired"><span style="-sec-ix-hidden: xdx2ixbrl2131">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExpiredWeightedAverageExercisePrice_c20241101__20251031__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsBMember_zVqVZI0xNX6a" style="border-bottom: Black 1pt solid; text-align: right" title="Average exercise price, expired"><span style="-sec-ix-hidden: xdx2ixbrl2133">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Outstanding – October 31, 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20251101__20260430_zKRgyV4oxhL2" style="text-align: right" title="Underlying number of shares beginning">182,804</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_c20251101__20260430_zUCdgCyfvQr9" style="text-align: right" title="Average exercise price beginning">26.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageRemainingContractualTerm2_dtY_c20241101__20251031_z4KXRZB4Hwt5" title="Weighted average life">0.70</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrants A – Granted during the period</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20251101__20260430__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsAMember_zIb3Ttn6uji" style="text-align: right" title="Underlying number of shares granted"><span style="-sec-ix-hidden: xdx2ixbrl2141">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedWeightedAverageExercisePrice_c20251101__20260430__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsAMember_zpWDtyOBmpZ1" style="text-align: right" title="Average exercise price, granted"><span style="-sec-ix-hidden: xdx2ixbrl2143">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrants B – Granted during the period</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20251101__20260430__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsBMember_z3mo0Vp4dtWa" style="text-align: right" title="Underlying number of shares granted"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2145">-</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedWeightedAverageExercisePrice_c20251101__20260430__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsBMember_zsf6D2Ncuhkl" style="text-align: right" title="Average exercise price, granted"><span style="-sec-ix-hidden: xdx2ixbrl2147">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrants A – Expired during the period</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20251101__20260430__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsAMember_zfrURs9sHlg2" style="text-align: right" title="Underlying number of shares expired"><span style="-sec-ix-hidden: xdx2ixbrl2149">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExpiredWeightedAverageExercisePrice_c20251101__20260430__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsAMember_zWpjPBssNLL3" style="text-align: right" title="Average exercise price, expired"><span style="-sec-ix-hidden: xdx2ixbrl2151">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Warrants B – Expired during the period</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20251101__20260430__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsBMember_zfqjYQZxKrI1" style="border-bottom: Black 1pt solid; text-align: right" title="Underlying number of shares expired">(33,077</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExpiredWeightedAverageExercisePrice_c20251101__20260430__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsBMember_zhh2zvndOZQ3" style="border-bottom: Black 1pt solid; text-align: right" title="Average exercise price, expired"><span style="-sec-ix-hidden: xdx2ixbrl2155">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Pre-Funded Warrants – Exercised during the period</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20251101__20260430__us-gaap--ClassOfWarrantOrRightAxis__custom--PrefundedWarrantsMember_z9dkDpCoEMjh" style="text-align: right" title="Underlying number of shares exercised"><span style="-sec-ix-hidden: xdx2ixbrl2157">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisedWeightedAverageExercisePrice_c20251101__20260430__us-gaap--ClassOfWarrantOrRightAxis__custom--PrefundedWarrantsMember_zv0I6bxN8oa3" style="text-align: right" title="Average exercise price, exercised"><span style="-sec-ix-hidden: xdx2ixbrl2159">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding – April 30, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20251101__20260430_zKb2qI659Fx7" style="border-bottom: Black 2.5pt double; text-align: right" title="Underlying number of shares ending">149,727</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iE_c20251101__20260430_z2oyh8p52tC1" style="border-bottom: Black 2.5pt double; text-align: right" title="Average exercise price ending">26.00</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageRemainingContractualTerm2_dtY_c20251101__20260430_zuE2JP9MmBkd" title="Weighted average life">0.3</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A9_zenscS3fPBD1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Pre-Funded Warrants</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A summary of the Company’s common stock underlying its outstanding pre-funded warrants as of April 30, 2026 and October 31, 2025 is as follows:</span></p> <div id="xdx_C04_gL3SOSENWORTB-FE_z8ieUIIu7Bxi"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" id="xdx_30F_134_z4l2VgH7m773" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SCHEDULE OF COMMON STOCK UNDERLYING OUTSTANDING WARRANTS (Details)"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Underlying</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of<br/> Shares </b></span></p></td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Average <br/> Exercise<br/> Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted <br/> Average <br/> Life</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%">Outstanding – October 31, 2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20241101__20251031__us-gaap--ClassOfWarrantOrRightAxis__custom--PrefundedWarrantsMember_zp7C6StTci66" style="width: 14%; text-align: right" title="Underlying number of shares beginning">1,107,500</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_c20241101__20251031__us-gaap--ClassOfWarrantOrRightAxis__custom--PrefundedWarrantsMember_zZGGZp1B5BM1" style="width: 14%; text-align: right" title="Average exercise price beginning">0.001</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Pre-Funded Warrants – Granted during the period</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20241101__20251031__us-gaap--ClassOfWarrantOrRightAxis__custom--PrefundedWarrantsMember_zGw5HxkkMX7f" style="text-align: right" title="Underlying number of shares granted">276,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedWeightedAverageExercisePrice_c20241101__20251031__us-gaap--ClassOfWarrantOrRightAxis__custom--PrefundedWarrantsMember_zEbPSsinkcSb" style="text-align: right" title="Average exercise price, granted">0.001</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Pre-Funded Warrants – Exercised during the period</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20241101__20251031__us-gaap--ClassOfWarrantOrRightAxis__custom--PrefundedWarrantsMember_zGzw9q6mTztf" style="text-align: right" title="Underlying number of shares exercised"><span style="-sec-ix-hidden: xdx2ixbrl2175">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisedWeightedAverageExercisePrice_c20241101__20251031__us-gaap--ClassOfWarrantOrRightAxis__custom--PrefundedWarrantsMember_zEzrNOCVFd91" style="text-align: right" title="Average exercise price, exercised"><span style="-sec-ix-hidden: xdx2ixbrl2177">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Pre-Funded Warrants – Expired during the period</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20241101__20251031__us-gaap--ClassOfWarrantOrRightAxis__custom--PrefundedWarrantsMember_z4fpI6NdWwX9" style="border-bottom: Black 1pt solid; text-align: right" title="Underlying number of shares expirations"><span style="-sec-ix-hidden: xdx2ixbrl2179">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExpiredWeightedAverageExercisePrice_c20241101__20251031__us-gaap--ClassOfWarrantOrRightAxis__custom--PrefundedWarrantsMember_zZOTqrHbhK7f" style="border-bottom: Black 1pt solid; text-align: right" title="Average exercise price, expired"><span style="-sec-ix-hidden: xdx2ixbrl2181">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Outstanding – October 31, 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20251101__20260430__us-gaap--ClassOfWarrantOrRightAxis__custom--PrefundedWarrantsMember_zEXYh24Gw4wd" style="text-align: right" title="Underlying number of shares beginning">1,383,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_c20251101__20260430__us-gaap--ClassOfWarrantOrRightAxis__custom--PrefundedWarrantsMember_ztukFNVIYsac" style="text-align: right" title="Average exercise price beginning">0.001</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Pre-Funded Warrants – Granted during the period</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20251101__20260430__us-gaap--ClassOfWarrantOrRightAxis__custom--PrefundedWarrantsMember_zypbOReB5eBk" style="text-align: right" title="Underlying number of shares granted"><span style="-sec-ix-hidden: xdx2ixbrl2187">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedWeightedAverageExercisePrice_c20251101__20260430__us-gaap--ClassOfWarrantOrRightAxis__custom--PrefundedWarrantsMember_zgFUp2AFVrr6" style="text-align: right" title="Average exercise price, granted"><span style="-sec-ix-hidden: xdx2ixbrl2189">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Pre-Funded Warrants – Exercised during the period</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20251101__20260430__us-gaap--ClassOfWarrantOrRightAxis__custom--PrefundedWarrantsMember_zvbd4C3yaRT2" style="text-align: right" title="Underlying number of shares exercised"><span style="-sec-ix-hidden: xdx2ixbrl2191">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisedWeightedAverageExercisePrice_c20251101__20260430__us-gaap--ClassOfWarrantOrRightAxis__custom--PrefundedWarrantsMember_zdUEpxt4Lbp6" style="text-align: right" title="Average exercise price, exercised"><span style="-sec-ix-hidden: xdx2ixbrl2193">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Pre-Funded Warrants – Expired during the period</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20251101__20260430__us-gaap--ClassOfWarrantOrRightAxis__custom--PrefundedWarrantsMember_zxGPQZj50lwc" style="border-bottom: Black 1pt solid; text-align: right" title="Underlying number of shares expirations"><span style="-sec-ix-hidden: xdx2ixbrl2195">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExpiredWeightedAverageExercisePrice_c20251101__20260430__us-gaap--ClassOfWarrantOrRightAxis__custom--PrefundedWarrantsMember_zb5x2swrcWa9" style="border-bottom: Black 1pt solid; text-align: right" title="Average exercise price, expired"><span style="-sec-ix-hidden: xdx2ixbrl2197">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding – April 30, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20251101__20260430__us-gaap--ClassOfWarrantOrRightAxis__custom--PrefundedWarrantsMember_ziNqJ3OJA6Qh" style="border-bottom: Black 2.5pt double; text-align: right" title="Underlying number of shares ending">1,383,500</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iE_c20251101__20260430__us-gaap--ClassOfWarrantOrRightAxis__custom--PrefundedWarrantsMember_z6to09n1qsH6" style="border-bottom: Black 2.5pt double; text-align: right" title="Average exercise price ending">0.001</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_C03_gL3SOSENWORTB-FE_z9IfpKoTEFRi"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Other Warrants</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A summary of the Company’s common stock underlying other warrants as of April 30, 2026 and October 31, 2025 is as follows:</span></p> <div id="xdx_C07_gL3SOSENWORTB-FE_zjiVIacbqOT1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" id="xdx_302_134_z5Y5TWrLjUe7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SCHEDULE OF COMMON STOCK UNDERLYING OUTSTANDING WARRANTS (Details)"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Underlying</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of<br/> Shares </b></span></p></td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Average <br/> Exercise<br/> Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted <br/> Average <br/> Life</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Outstanding – October 31, 2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20241101__20251031__us-gaap--ClassOfWarrantOrRightAxis__custom--OtherWarrantsMember_z7wdWoDwZyQf" style="text-align: right" title="Underlying number of shares beginning"><span style="-sec-ix-hidden: xdx2ixbrl2203">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_c20241101__20251031__us-gaap--ClassOfWarrantOrRightAxis__custom--OtherWarrantsMember_zjvmGtBZ8uJ" style="text-align: right" title="Average exercise price beginning"><span style="-sec-ix-hidden: xdx2ixbrl2205">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrants – Issued during the period</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20241101__20251031__us-gaap--ClassOfWarrantOrRightAxis__custom--OtherWarrantsMember_zdNOGQLX6u7" style="text-align: right" title="Underlying number of shares issued"><span style="-sec-ix-hidden: xdx2ixbrl2207">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedWeightedAverageExercisePrice_c20241101__20251031__us-gaap--ClassOfWarrantOrRightAxis__custom--OtherWarrantsMember_zmr4rTJAC0Wl" style="text-align: right" title="Average exercise price, issued"><span style="-sec-ix-hidden: xdx2ixbrl2209">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrants – Exercised during the period</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20241101__20251031__us-gaap--ClassOfWarrantOrRightAxis__custom--OtherWarrantsMember_zgM9cibgzXIl" style="text-align: right" title="Underlying number of shares exercised"><span style="-sec-ix-hidden: xdx2ixbrl2211">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisedWeightedAverageExercisePrice_c20241101__20251031__us-gaap--ClassOfWarrantOrRightAxis__custom--OtherWarrantsMember_z1xx9zwNf9u9" style="text-align: right" title="Average exercise price, exercised"><span style="-sec-ix-hidden: xdx2ixbrl2213">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Warrants – Expired during the period</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20241101__20251031__us-gaap--ClassOfWarrantOrRightAxis__custom--OtherWarrantsMember_zLVBX5O4SzQi" style="border-bottom: Black 1pt solid; text-align: right" title="Underlying number of shares expired"><span style="-sec-ix-hidden: xdx2ixbrl2215">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExpiredWeightedAverageExercisePrice_c20241101__20251031__us-gaap--ClassOfWarrantOrRightAxis__custom--OtherWarrantsMember_zPPzkw2fwMld" style="border-bottom: Black 1pt solid; text-align: right" title="Average exercise price, expired"><span style="-sec-ix-hidden: xdx2ixbrl2217">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Outstanding – October 31, 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20251101__20260430__us-gaap--ClassOfWarrantOrRightAxis__custom--OtherWarrantsMember_zospQPLuVdbb" style="text-align: right" title="Underlying number of shares beginning"><span style="-sec-ix-hidden: xdx2ixbrl2219">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_c20251101__20260430__us-gaap--ClassOfWarrantOrRightAxis__custom--OtherWarrantsMember_ztSxmAPJTgU6" style="text-align: right" title="Average exercise price beginning"><span style="-sec-ix-hidden: xdx2ixbrl2221">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 46%; text-align: left">Warrants – Issued during the period</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20251101__20260430__us-gaap--ClassOfWarrantOrRightAxis__custom--OtherWarrantsMember_zrKnmjkFHGHl" style="width: 14%; text-align: right" title="Underlying number of shares issued">28,846</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedWeightedAverageExercisePrice_c20251101__20260430__us-gaap--ClassOfWarrantOrRightAxis__custom--OtherWarrantsMember_zdeIdnEEJbw5" style="width: 14%; text-align: right" title="Average exercise price, issued"><span style="-sec-ix-hidden: xdx2ixbrl2225">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"><span id="xdx_903_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageRemainingContractualTermIssued_dtY_c20251101__20260430__us-gaap--ClassOfWarrantOrRightAxis__custom--OtherWarrantsMember_zx6yU5hxpI81" title="Weighted average life, issued">16.25</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrants – Exercised during the period</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20251101__20260430__us-gaap--ClassOfWarrantOrRightAxis__custom--OtherWarrantsMember_z5WMsWvPfW03" style="text-align: right" title="Underlying number of shares exercised"><span style="-sec-ix-hidden: xdx2ixbrl2229">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisedWeightedAverageExercisePrice_c20251101__20260430__us-gaap--ClassOfWarrantOrRightAxis__custom--OtherWarrantsMember_zECRWdcojVM" style="text-align: right" title="Average exercise price, exercised"><span style="-sec-ix-hidden: xdx2ixbrl2231">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Warrants – Expired during the period</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20251101__20260430__us-gaap--ClassOfWarrantOrRightAxis__custom--OtherWarrantsMember_zGE21w4suoKd" style="border-bottom: Black 1pt solid; text-align: right" title="Underlying number of shares expired"><span style="-sec-ix-hidden: xdx2ixbrl2233">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExpiredWeightedAverageExercisePrice_c20251101__20260430__us-gaap--ClassOfWarrantOrRightAxis__custom--OtherWarrantsMember_zegDB9mJ9Qxl" style="border-bottom: Black 1pt solid; text-align: right" title="Average exercise price, expired"><span style="-sec-ix-hidden: xdx2ixbrl2235">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding – April 30, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20251101__20260430__us-gaap--ClassOfWarrantOrRightAxis__custom--OtherWarrantsMember_zeYyoLyTfS89" style="border-bottom: Black 2.5pt double; text-align: right" title="Underlying number of shares ending">28,846</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iE_c20251101__20260430__us-gaap--ClassOfWarrantOrRightAxis__custom--OtherWarrantsMember_zOJbntOkSBf5" style="border-bottom: Black 2.5pt double; text-align: right" title="Average exercise price ending"><span style="-sec-ix-hidden: xdx2ixbrl2239">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageRemainingContractualTerm2_dtY_c20251101__20260430__us-gaap--ClassOfWarrantOrRightAxis__custom--OtherWarrantsMember_zJpeL6vYi5f4" title="Weighted average life">16.25</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_C04_gL3SOSENWORTB-FE_zlMHwnfxzPfb"> </span></span></p> 5000000 0.001 250000 750000 15000000 129065 129065 35000 35000 39912 66959 83375 16416 20 0.08 4.00 4.00 5000 100000 39065 468750 50000 1000000 35000 700000 19230770 0.001 4517651 4517651 4460535 4460535 84615 57116 0 0 <p id="xdx_89E_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z2ygImRALF08" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The table below presents option activity for the six months ended April 30, 2026 and the year ended October 31, 2025:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B9_zD1R52zTG7Kk" style="display: none">SCHEDULE OF OPTION ACTIVITY</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shares</b></span></p></td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price per Share</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Life (in years)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Aggregate</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>intrinsic value</b></span></p></td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%">Balance at October 31, 2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20241101__20251031_zkODbuUD0p2c" style="width: 12%; text-align: right" title="Number of Shares, Balance">1,112,923</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20241101__20251031_z9ckPd3mONz9" style="width: 12%; text-align: right" title="Weighted Average Exercise Price per Share, Balance">10.84</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20231101__20241031_z1vXlSOJaIc1" title="Weighted Average Remaining Contractual Life (in years)">5.64</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20241101__20251031_zttDwczJIwJj" style="width: 12%; text-align: right" title="Aggregate intrinsic value, Balance">1,560,431</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Options exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20241101__20251031_zMxJC2AQu25k" style="text-align: right" title="Number of Shares, Options exercised"><span style="-sec-ix-hidden: xdx2ixbrl2029">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20241101__20251031_z6QOShBDUAq1" style="text-align: right" title="Weighted Average Exercise Price per Share, Options exercised"><span style="-sec-ix-hidden: xdx2ixbrl2031">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Options granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20241101__20251031_zFhQbtdqFVT3" style="text-align: right" title="Number of Shares, Options granted"><span style="-sec-ix-hidden: xdx2ixbrl2033">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20241101__20251031_zdubBsrQTuq5" style="text-align: right" title="Weighted Average Exercise Price per Share, Options granted"><span style="-sec-ix-hidden: xdx2ixbrl2035">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Options expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_pid_c20241101__20251031_zd60oxhlDae5" style="text-align: right" title="Number of Shares, Options expired"><span style="-sec-ix-hidden: xdx2ixbrl2037">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20241101__20251031_zjEGFvPTn5T1" style="text-align: right" title="Weighted Average Exercise Price per Share, Options expired"><span style="-sec-ix-hidden: xdx2ixbrl2039">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Options forfeited</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20241101__20251031_zqxexS29SZB2" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Shares, Options forfeited"><span style="-sec-ix-hidden: xdx2ixbrl2041">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_iN_di_c20241101__20251031_zK6MtM96nJ4b" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price per Share, Options forfeited"><span style="-sec-ix-hidden: xdx2ixbrl2043">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Balance at October 31, 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20251101__20260430_zFAEFw384f2g" style="text-align: right" title="Number of Shares, Balance">1,112,923</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20251101__20260430_zuYLaPglBJpf" style="text-align: right" title="Weighted Average Exercise Price per Share, Balance">10.84</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20241101__20251031_z4oJmFyr1sT7" title="Weighted Average Remaining Contractual Life (in years)">4.64</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20251101__20260430_z5NNjqZ8Wrsa" style="text-align: right" title="Aggregate intrinsic value, Balance">501,923</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Options exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20251101__20260430_zMZF8or5fkj4" style="text-align: right" title="Number of Shares, Options exercised">(84,615</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20251101__20260430_zN4qAYjtdPpk" style="text-align: right" title="Weighted Average Exercise Price per Share, Options exercised">1.30</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Options granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20251101__20260430_zXGNU9J5aW9g" style="text-align: right" title="Number of Shares, Options granted"><span style="-sec-ix-hidden: xdx2ixbrl2057">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20251101__20260430_z7wpzIbN1cAf" style="text-align: right" title="Weighted Average Exercise Price per Share, Options granted"><span style="-sec-ix-hidden: xdx2ixbrl2059">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Options expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_pid_c20251101__20260430_zRPPun7E41R6" style="text-align: right" title="Number of Shares, Options expired"><span style="-sec-ix-hidden: xdx2ixbrl2061">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20251101__20260430_z0DBEhEIvo2e" style="text-align: right" title="Weighted Average Exercise Price per Share, Options expired"><span style="-sec-ix-hidden: xdx2ixbrl2063">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Options forfeited</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20251101__20260430_zvJgW2oG12wl" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Shares, Options forfeited"><span style="-sec-ix-hidden: xdx2ixbrl2065">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_iN_di_c20251101__20260430_zyiyFTLBl0r4" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price per Share, Options forfeited"><span style="-sec-ix-hidden: xdx2ixbrl2067">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance at April 30, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20251101__20260430_zXIAQjv0XgHe" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Balance">1,028,308</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20251101__20260430_zVqH9yBTucoc" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price per Share, Balance">10.84</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20251101__20260430_zronZ8rarbO6" title="Weighted Average Remaining Contractual Life (in years)">4.32</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20251101__20260430_zz73MZqFrqq7" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value, Balance">375,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 1112923 10.84 P5Y7M20D 1560431 1112923 10.84 P4Y7M20D 501923 84615 1.30 1028308 10.84 P4Y3M25D 375000 240621 532251 322734 730968 977923 1058692 260652 792903 28846 16.25 180000 0.001 990000 96000 0.001 528000 <p id="xdx_890_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_gL3SOSENWORTB-FE_zZKWxu5oNko9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A summary of the Company’s common stock underlying its outstanding A and B warrants as of April 30, 2026 and October 31, 2025 is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B9_z6Z1Y99KYLKi" style="display: none">SCHEDULE OF COMMON STOCK UNDERLYING OUTSTANDING WARRANTS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Underlying</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of<br/> Shares </b></span></p></td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Average <br/> Exercise<br/> Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted <br/> Average <br/> Life</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%">Outstanding – October 31, 2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20241101__20251031_zJfpxEvNY7lc" style="width: 14%; text-align: right" title="Underlying number of shares beginning">261,650</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_c20241101__20251031_zuvn2Md28PDj" style="width: 14%; text-align: right" title="Average exercise price beginning">26.00</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"><span id="xdx_90E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageRemainingContractualTerm2_dtY_c20231101__20241031_zHSqtiHOqYv6" title="Weighted average life">1.31</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrants A – Granted during the period</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20241101__20251031__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsAMember_z85BzeoeBYBh" style="text-align: right" title="Underlying number of shares granted"><span style="-sec-ix-hidden: xdx2ixbrl2119">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedWeightedAverageExercisePrice_c20241101__20251031__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsAMember_zCpsfkjXSYBh" style="text-align: right" title="Average exercise price, granted"><span style="-sec-ix-hidden: xdx2ixbrl2121">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrants B – Granted during the period</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20241101__20251031__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsBMember_zQKXF1O4E4W5" style="text-align: right" title="Underlying number of shares granted"><span style="-sec-ix-hidden: xdx2ixbrl2123">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedWeightedAverageExercisePrice_c20241101__20251031__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsBMember_zI5tkMyKqxcj" style="text-align: right" title="Average exercise price, granted"><span style="-sec-ix-hidden: xdx2ixbrl2125">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrants A – Expired during the period</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20241101__20251031__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsAMember_zf709gCsYjp6" style="text-align: right" title="Underlying number of shares expired">(78,846</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExpiredWeightedAverageExercisePrice_c20241101__20251031__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsAMember_zGfTg9TXYgse" style="text-align: right" title="Average exercise price, expired">26.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Warrants B – Expired during the period</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20241101__20251031__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsBMember_zv56jPIVbm57" style="border-bottom: Black 1pt solid; text-align: right" title="Underlying number of shares expired"><span style="-sec-ix-hidden: xdx2ixbrl2131">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExpiredWeightedAverageExercisePrice_c20241101__20251031__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsBMember_zVqVZI0xNX6a" style="border-bottom: Black 1pt solid; text-align: right" title="Average exercise price, expired"><span style="-sec-ix-hidden: xdx2ixbrl2133">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Outstanding – October 31, 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20251101__20260430_zKRgyV4oxhL2" style="text-align: right" title="Underlying number of shares beginning">182,804</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_c20251101__20260430_zUCdgCyfvQr9" style="text-align: right" title="Average exercise price beginning">26.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageRemainingContractualTerm2_dtY_c20241101__20251031_z4KXRZB4Hwt5" title="Weighted average life">0.70</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrants A – Granted during the period</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20251101__20260430__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsAMember_zIb3Ttn6uji" style="text-align: right" title="Underlying number of shares granted"><span style="-sec-ix-hidden: xdx2ixbrl2141">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedWeightedAverageExercisePrice_c20251101__20260430__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsAMember_zpWDtyOBmpZ1" style="text-align: right" title="Average exercise price, granted"><span style="-sec-ix-hidden: xdx2ixbrl2143">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrants B – Granted during the period</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20251101__20260430__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsBMember_z3mo0Vp4dtWa" style="text-align: right" title="Underlying number of shares granted"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2145">-</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedWeightedAverageExercisePrice_c20251101__20260430__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsBMember_zsf6D2Ncuhkl" style="text-align: right" title="Average exercise price, granted"><span style="-sec-ix-hidden: xdx2ixbrl2147">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrants A – Expired during the period</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20251101__20260430__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsAMember_zfrURs9sHlg2" style="text-align: right" title="Underlying number of shares expired"><span style="-sec-ix-hidden: xdx2ixbrl2149">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExpiredWeightedAverageExercisePrice_c20251101__20260430__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsAMember_zWpjPBssNLL3" style="text-align: right" title="Average exercise price, expired"><span style="-sec-ix-hidden: xdx2ixbrl2151">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Warrants B – Expired during the period</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20251101__20260430__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsBMember_zfqjYQZxKrI1" style="border-bottom: Black 1pt solid; text-align: right" title="Underlying number of shares expired">(33,077</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExpiredWeightedAverageExercisePrice_c20251101__20260430__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsBMember_zhh2zvndOZQ3" style="border-bottom: Black 1pt solid; text-align: right" title="Average exercise price, expired"><span style="-sec-ix-hidden: xdx2ixbrl2155">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Pre-Funded Warrants – Exercised during the period</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20251101__20260430__us-gaap--ClassOfWarrantOrRightAxis__custom--PrefundedWarrantsMember_z9dkDpCoEMjh" style="text-align: right" title="Underlying number of shares exercised"><span style="-sec-ix-hidden: xdx2ixbrl2157">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisedWeightedAverageExercisePrice_c20251101__20260430__us-gaap--ClassOfWarrantOrRightAxis__custom--PrefundedWarrantsMember_zv0I6bxN8oa3" style="text-align: right" title="Average exercise price, exercised"><span style="-sec-ix-hidden: xdx2ixbrl2159">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding – April 30, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20251101__20260430_zKb2qI659Fx7" style="border-bottom: Black 2.5pt double; text-align: right" title="Underlying number of shares ending">149,727</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iE_c20251101__20260430_z2oyh8p52tC1" style="border-bottom: Black 2.5pt double; text-align: right" title="Average exercise price ending">26.00</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageRemainingContractualTerm2_dtY_c20251101__20260430_zuE2JP9MmBkd" title="Weighted average life">0.3</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" id="xdx_30F_134_z4l2VgH7m773" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SCHEDULE OF COMMON STOCK UNDERLYING OUTSTANDING WARRANTS (Details)"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Underlying</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of<br/> Shares </b></span></p></td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Average <br/> Exercise<br/> Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted <br/> Average <br/> Life</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%">Outstanding – October 31, 2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20241101__20251031__us-gaap--ClassOfWarrantOrRightAxis__custom--PrefundedWarrantsMember_zp7C6StTci66" style="width: 14%; text-align: right" title="Underlying number of shares beginning">1,107,500</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_c20241101__20251031__us-gaap--ClassOfWarrantOrRightAxis__custom--PrefundedWarrantsMember_zZGGZp1B5BM1" style="width: 14%; text-align: right" title="Average exercise price beginning">0.001</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Pre-Funded Warrants – Granted during the period</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20241101__20251031__us-gaap--ClassOfWarrantOrRightAxis__custom--PrefundedWarrantsMember_zGw5HxkkMX7f" style="text-align: right" title="Underlying number of shares granted">276,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedWeightedAverageExercisePrice_c20241101__20251031__us-gaap--ClassOfWarrantOrRightAxis__custom--PrefundedWarrantsMember_zEbPSsinkcSb" style="text-align: right" title="Average exercise price, granted">0.001</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Pre-Funded Warrants – Exercised during the period</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20241101__20251031__us-gaap--ClassOfWarrantOrRightAxis__custom--PrefundedWarrantsMember_zGzw9q6mTztf" style="text-align: right" title="Underlying number of shares exercised"><span style="-sec-ix-hidden: xdx2ixbrl2175">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisedWeightedAverageExercisePrice_c20241101__20251031__us-gaap--ClassOfWarrantOrRightAxis__custom--PrefundedWarrantsMember_zEzrNOCVFd91" style="text-align: right" title="Average exercise price, exercised"><span style="-sec-ix-hidden: xdx2ixbrl2177">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Pre-Funded Warrants – Expired during the period</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20241101__20251031__us-gaap--ClassOfWarrantOrRightAxis__custom--PrefundedWarrantsMember_z4fpI6NdWwX9" style="border-bottom: Black 1pt solid; text-align: right" title="Underlying number of shares expirations"><span style="-sec-ix-hidden: xdx2ixbrl2179">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExpiredWeightedAverageExercisePrice_c20241101__20251031__us-gaap--ClassOfWarrantOrRightAxis__custom--PrefundedWarrantsMember_zZOTqrHbhK7f" style="border-bottom: Black 1pt solid; text-align: right" title="Average exercise price, expired"><span style="-sec-ix-hidden: xdx2ixbrl2181">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Outstanding – October 31, 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20251101__20260430__us-gaap--ClassOfWarrantOrRightAxis__custom--PrefundedWarrantsMember_zEXYh24Gw4wd" style="text-align: right" title="Underlying number of shares beginning">1,383,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_c20251101__20260430__us-gaap--ClassOfWarrantOrRightAxis__custom--PrefundedWarrantsMember_ztukFNVIYsac" style="text-align: right" title="Average exercise price beginning">0.001</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Pre-Funded Warrants – Granted during the period</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20251101__20260430__us-gaap--ClassOfWarrantOrRightAxis__custom--PrefundedWarrantsMember_zypbOReB5eBk" style="text-align: right" title="Underlying number of shares granted"><span style="-sec-ix-hidden: xdx2ixbrl2187">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedWeightedAverageExercisePrice_c20251101__20260430__us-gaap--ClassOfWarrantOrRightAxis__custom--PrefundedWarrantsMember_zgFUp2AFVrr6" style="text-align: right" title="Average exercise price, granted"><span style="-sec-ix-hidden: xdx2ixbrl2189">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Pre-Funded Warrants – Exercised during the period</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20251101__20260430__us-gaap--ClassOfWarrantOrRightAxis__custom--PrefundedWarrantsMember_zvbd4C3yaRT2" style="text-align: right" title="Underlying number of shares exercised"><span style="-sec-ix-hidden: xdx2ixbrl2191">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisedWeightedAverageExercisePrice_c20251101__20260430__us-gaap--ClassOfWarrantOrRightAxis__custom--PrefundedWarrantsMember_zdUEpxt4Lbp6" style="text-align: right" title="Average exercise price, exercised"><span style="-sec-ix-hidden: xdx2ixbrl2193">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Pre-Funded Warrants – Expired during the period</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20251101__20260430__us-gaap--ClassOfWarrantOrRightAxis__custom--PrefundedWarrantsMember_zxGPQZj50lwc" style="border-bottom: Black 1pt solid; text-align: right" title="Underlying number of shares expirations"><span style="-sec-ix-hidden: xdx2ixbrl2195">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExpiredWeightedAverageExercisePrice_c20251101__20260430__us-gaap--ClassOfWarrantOrRightAxis__custom--PrefundedWarrantsMember_zb5x2swrcWa9" style="border-bottom: Black 1pt solid; text-align: right" title="Average exercise price, expired"><span style="-sec-ix-hidden: xdx2ixbrl2197">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding – April 30, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20251101__20260430__us-gaap--ClassOfWarrantOrRightAxis__custom--PrefundedWarrantsMember_ziNqJ3OJA6Qh" style="border-bottom: Black 2.5pt double; text-align: right" title="Underlying number of shares ending">1,383,500</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iE_c20251101__20260430__us-gaap--ClassOfWarrantOrRightAxis__custom--PrefundedWarrantsMember_z6to09n1qsH6" style="border-bottom: Black 2.5pt double; text-align: right" title="Average exercise price ending">0.001</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" id="xdx_302_134_z5Y5TWrLjUe7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SCHEDULE OF COMMON STOCK UNDERLYING OUTSTANDING WARRANTS (Details)"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Underlying</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of<br/> Shares </b></span></p></td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Average <br/> Exercise<br/> Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted <br/> Average <br/> Life</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Outstanding – October 31, 2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20241101__20251031__us-gaap--ClassOfWarrantOrRightAxis__custom--OtherWarrantsMember_z7wdWoDwZyQf" style="text-align: right" title="Underlying number of shares beginning"><span style="-sec-ix-hidden: xdx2ixbrl2203">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_c20241101__20251031__us-gaap--ClassOfWarrantOrRightAxis__custom--OtherWarrantsMember_zjvmGtBZ8uJ" style="text-align: right" title="Average exercise price beginning"><span style="-sec-ix-hidden: xdx2ixbrl2205">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrants – Issued during the period</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20241101__20251031__us-gaap--ClassOfWarrantOrRightAxis__custom--OtherWarrantsMember_zdNOGQLX6u7" style="text-align: right" title="Underlying number of shares issued"><span style="-sec-ix-hidden: xdx2ixbrl2207">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedWeightedAverageExercisePrice_c20241101__20251031__us-gaap--ClassOfWarrantOrRightAxis__custom--OtherWarrantsMember_zmr4rTJAC0Wl" style="text-align: right" title="Average exercise price, issued"><span style="-sec-ix-hidden: xdx2ixbrl2209">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrants – Exercised during the period</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20241101__20251031__us-gaap--ClassOfWarrantOrRightAxis__custom--OtherWarrantsMember_zgM9cibgzXIl" style="text-align: right" title="Underlying number of shares exercised"><span style="-sec-ix-hidden: xdx2ixbrl2211">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisedWeightedAverageExercisePrice_c20241101__20251031__us-gaap--ClassOfWarrantOrRightAxis__custom--OtherWarrantsMember_z1xx9zwNf9u9" style="text-align: right" title="Average exercise price, exercised"><span style="-sec-ix-hidden: xdx2ixbrl2213">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Warrants – Expired during the period</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20241101__20251031__us-gaap--ClassOfWarrantOrRightAxis__custom--OtherWarrantsMember_zLVBX5O4SzQi" style="border-bottom: Black 1pt solid; text-align: right" title="Underlying number of shares expired"><span style="-sec-ix-hidden: xdx2ixbrl2215">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExpiredWeightedAverageExercisePrice_c20241101__20251031__us-gaap--ClassOfWarrantOrRightAxis__custom--OtherWarrantsMember_zPPzkw2fwMld" style="border-bottom: Black 1pt solid; text-align: right" title="Average exercise price, expired"><span style="-sec-ix-hidden: xdx2ixbrl2217">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Outstanding – October 31, 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20251101__20260430__us-gaap--ClassOfWarrantOrRightAxis__custom--OtherWarrantsMember_zospQPLuVdbb" style="text-align: right" title="Underlying number of shares beginning"><span style="-sec-ix-hidden: xdx2ixbrl2219">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_c20251101__20260430__us-gaap--ClassOfWarrantOrRightAxis__custom--OtherWarrantsMember_ztSxmAPJTgU6" style="text-align: right" title="Average exercise price beginning"><span style="-sec-ix-hidden: xdx2ixbrl2221">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 46%; text-align: left">Warrants – Issued during the period</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20251101__20260430__us-gaap--ClassOfWarrantOrRightAxis__custom--OtherWarrantsMember_zrKnmjkFHGHl" style="width: 14%; text-align: right" title="Underlying number of shares issued">28,846</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedWeightedAverageExercisePrice_c20251101__20260430__us-gaap--ClassOfWarrantOrRightAxis__custom--OtherWarrantsMember_zdeIdnEEJbw5" style="width: 14%; text-align: right" title="Average exercise price, issued"><span style="-sec-ix-hidden: xdx2ixbrl2225">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"><span id="xdx_903_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageRemainingContractualTermIssued_dtY_c20251101__20260430__us-gaap--ClassOfWarrantOrRightAxis__custom--OtherWarrantsMember_zx6yU5hxpI81" title="Weighted average life, issued">16.25</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrants – Exercised during the period</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20251101__20260430__us-gaap--ClassOfWarrantOrRightAxis__custom--OtherWarrantsMember_z5WMsWvPfW03" style="text-align: right" title="Underlying number of shares exercised"><span style="-sec-ix-hidden: xdx2ixbrl2229">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisedWeightedAverageExercisePrice_c20251101__20260430__us-gaap--ClassOfWarrantOrRightAxis__custom--OtherWarrantsMember_zECRWdcojVM" style="text-align: right" title="Average exercise price, exercised"><span style="-sec-ix-hidden: xdx2ixbrl2231">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Warrants – Expired during the period</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20251101__20260430__us-gaap--ClassOfWarrantOrRightAxis__custom--OtherWarrantsMember_zGE21w4suoKd" style="border-bottom: Black 1pt solid; text-align: right" title="Underlying number of shares expired"><span style="-sec-ix-hidden: xdx2ixbrl2233">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExpiredWeightedAverageExercisePrice_c20251101__20260430__us-gaap--ClassOfWarrantOrRightAxis__custom--OtherWarrantsMember_zegDB9mJ9Qxl" style="border-bottom: Black 1pt solid; text-align: right" title="Average exercise price, expired"><span style="-sec-ix-hidden: xdx2ixbrl2235">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding – April 30, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20251101__20260430__us-gaap--ClassOfWarrantOrRightAxis__custom--OtherWarrantsMember_zeYyoLyTfS89" style="border-bottom: Black 2.5pt double; text-align: right" title="Underlying number of shares ending">28,846</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iE_c20251101__20260430__us-gaap--ClassOfWarrantOrRightAxis__custom--OtherWarrantsMember_zOJbntOkSBf5" style="border-bottom: Black 2.5pt double; text-align: right" title="Average exercise price ending"><span style="-sec-ix-hidden: xdx2ixbrl2239">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageRemainingContractualTerm2_dtY_c20251101__20260430__us-gaap--ClassOfWarrantOrRightAxis__custom--OtherWarrantsMember_zJpeL6vYi5f4" title="Weighted average life">16.25</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   261650 26.00 P1Y3M21D 78846 26.00 182804 26.00 P0Y8M12D 33077 149727 26.00 P0Y3M18D 1107500 0.001 276000 0.001 1383500 0.001 1383500 0.001 28846 P16Y3M 28846 P16Y3M <p id="xdx_808_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_z7DBSXWQapnf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 9 – <span id="xdx_821_zAIVIWFoGMqi">COMMITMENTS AND CONTINGENCIES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Employment agreements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 6, 2022, the Company hired Christopher Furman as its new Chief Executive Officer. Mr. Furman will receive an annual base salary of $<span id="xdx_909_eus-gaap--SalariesWagesAndOfficersCompensation_c20220705__20220706__srt--TitleOfIndividualAxis__custom--ChristopherFurmanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementsMember_zxqu9yx8dWh3" title="Annual base salary">400,000</span> and an annual bonus of up to <span id="xdx_90C_ecustom--AnnualBonusPercentage_pid_dp_uPure_c20220705__20220706__srt--TitleOfIndividualAxis__custom--ChristopherFurmanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementsMember_zcBolWarGhT8" title="Annual bonus percentage">100</span>% of his base salary. In addition, Mr. Furman received <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_c20220705__20220706__srt--TitleOfIndividualAxis__custom--ChristopherFurmanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementsMember_zE1MNM4nHcve" title=" Common stock purchase options">192,307</span> options to purchase common stock at an exercise price of $<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220705__20220706__srt--TitleOfIndividualAxis__custom--ChristopherFurmanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementsMember_zbq9scuvtd14" title="Common stock purchase options exercise price">26.00</span> per common share. On July 6, 2022, <span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20220705__20220706__srt--TitleOfIndividualAxis__custom--ChristopherFurmanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementsMember_ztTDSjxRq9qa" title="Share based compensation, options vested">38,461</span> of these options vested, with an additional <span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20220705__20220706__srt--TitleOfIndividualAxis__custom--ChristopherFurmanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementsMember_zSFaIOf4jQyi" title="Share based compensation, options vested">38,461</span> options vesting on July 6 in each of the next four years so long as Mr. Furman remains affiliated with the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 1, 2021, the Company and John Evans, a former CFO of the Company, entered into a Consulting Agreement (“Evans Consulting Agreement”). Under the terms of the Evans Consulting Agreement, Mr. Evans is to provide advisory services to the CEO and CFO of the Company. The Evans Consulting Agreement expires on December 1, 2025. Per mutual verbal agreement, the Company has deferred and accrued $<span id="xdx_900_eus-gaap--OfficersCompensation_c20251101__20260430__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__srt--TitleOfIndividualAxis__custom--JohnEvansMember_z66a00cwKzJ9" title="Officers compensation">146,333</span> of such compensation as of April 30, 2026. The Company will continue to make payments to Mr. Evans after the expiration of the agreement to retire this accrued liability.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 1, 2020, the Company entered into a new employment agreement with James Musick, Chief Science Officer (the “Musick Agreement”). Pursuant to the terms of the Musick Agreement, the Company agreed to pay Dr. Musick a base salary of $<span id="xdx_905_eus-gaap--SalariesWagesAndOfficersCompensation_c20201201__20201201__srt--TitleOfIndividualAxis__custom--JamesMusickMember__us-gaap--TypeOfArrangementAxis__custom--MusickAgreementMember_zXReAEPDL6q5" title="Base salary">150,000</span> per annum for a term of <span id="xdx_90C_ecustom--AgreementTerm_dc_c20201201__20201201__srt--TitleOfIndividualAxis__custom--JamesMusickMember__us-gaap--TypeOfArrangementAxis__custom--MusickAgreementMember_zEY8ngkhTSUb" title="Agreement term">five years</span>. In addition, Dr. Musick is eligible to receive an annual bonus in the form of cash in the amount of up to <span id="xdx_904_ecustom--AnnualBonusPercentage_pid_dp_uPure_c20201201__20201201__srt--TitleOfIndividualAxis__custom--JamesMusickMember__us-gaap--TypeOfArrangementAxis__custom--MusickAgreementMember_zxchJEfHDvlc" title="Annual bonus percentage">100</span>% of his base salary at the discretion of the CEO and the Board of Directors. Following expiration of the initial five-year term, the Musick Agreement renews in one-year periods unless either Dr. Musick or the Company gives notice that the agreement will not be renewed with a 90-day notice. In the event of a change in control, termination of his employment by the Company without cause or termination by Dr. Musick with good reason, the Company would be obligated to pay him certain severance payments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span> </p> 400000 1 192307 26.00 38461 38461 146333 150000 P5Y 1 <p id="xdx_806_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zOWGBcoPK1Dc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 10 – <span id="xdx_82E_zuG4kCbPe2W4">RELATED PARTY TRANSACTIONS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Accounts Receivable and Revenues</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. Zamora, former CEO and 29% stockholder, is also a customer of the Company in his capacity as a practicing physician. As of April 30, 2026 and October 31, 2025, Dr. Zamora owed the Company $<span id="xdx_902_eus-gaap--OtherReceivablesNetCurrent_iI_c20260430__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JackZamoraMember_zKcXE8V7vIL5" title="Due from related parties, current">0</span> and $<span id="xdx_90C_eus-gaap--OtherReceivablesNetCurrent_iI_c20251031__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JackZamoraMember_z21gaT3pcMGg" title="Due from related parties, current">2,250</span>, respectively. During the three and six months ended April 30, 2026 and 2025, Dr. Zamora accounted for $<span id="xdx_90F_eus-gaap--Revenues_c20260201__20260430__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JackZamoraMember_zy8wYN6C2OHd" title="Product sales">0</span> and $<span id="xdx_90A_eus-gaap--Revenues_c20250201__20250430__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JackZamoraMember_zB1rkpVV6hMa" title="Product sales">0</span>, and $<span id="xdx_905_eus-gaap--Revenues_c20251101__20260430__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JackZamoraMember_zBSndPdJmPWh" title="Product sales">2,250</span> and $<span id="xdx_907_eus-gaap--Revenues_c20241101__20250430__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JackZamoraMember_zmTG4l8csyog" title="Product sales">18,000</span> in product sales, respectively. These sales amounts were <span id="xdx_909_ecustom--ProductSalesPercentage_pid_dp_uPure_c20260201__20260430__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JackZamoraMember_zF1rZhRjh5wf" title="Product sales percentage">0</span>% and <span id="xdx_90C_ecustom--ProductSalesPercentage_pid_dp_uPure_c20250201__20250430__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JackZamoraMember_zJb7dWH3YkHa" title="Product sales percentage">0</span>%, and <span id="xdx_900_ecustom--ProductSalesPercentage_pid_dp_uPure_c20251101__20260430__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JackZamoraMember_zuskX6rW6dEf" title="Product sales percentage">0</span>% and <span id="xdx_907_ecustom--ProductSalesPercentage_pid_dp_uPure_c20241101__20250430__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JackZamoraMember_zZKu1dpibq4f" title="Product sales percentage">2</span>%, respectively, for the three and six months ended April 30, 2026 and 2025, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Accounts Payable and Other Accrued Liabilities</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The spouse of the Company’s Chief Science Officer, through an entity she controls, leases office and lab space to the Company. As of April 30, 2026 and October 31, 2025, the Company owes this entity $<span id="xdx_900_eus-gaap--AccruedRentCurrent_iI_c20260430_zysqdV36u4ql" title="Rent">0</span> and $<span id="xdx_906_eus-gaap--AccruedRentCurrent_iI_c20251031_zlMeBYRiOFvc" title="Rent">0</span>, respectively, in past due rent. The rental rates charged to the Company are $<span id="xdx_90E_eus-gaap--PaymentsForRent_c20251101__20260430_zNi4Ej4j3eU4" title="Rent per month">5,645</span> per month, with no escalators, and the lease runs through June of 2030.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the six months ended April 30, 2026, the Company paid it’s founder a total of $<span id="xdx_902_ecustom--AccruedInterest_iI_c20260430_z05KXa6GOjQ6" title="Accrued interest">51,923</span> of the accrued interest on the 6% Notes. As of April 30, 2026 and October 31, 2025, the Company owed the Company’s CEO $<span id="xdx_905_eus-gaap--TravelAndEntertainmentExpense_c20251101__20260430__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zJ1z3I1eGaeg" title="Travel expense reimbursement">22,610</span> in travel expense reimbursements and $<span id="xdx_90B_ecustom--ConvertibleShortTermNotePayableRelatedPartyCurrent_iI_c20251031__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zVS30YrrAcZ4" title="Accrued unpaid bonuses">970,000</span> in accrued, but unpaid, bonuses.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 0 2250 0 0 2250 18000 0 0 0 0.02 0 0 5645 51923 22610 970000 <p id="xdx_80A_eus-gaap--SegmentReportingDisclosureTextBlock_znjuu47yUJdi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 11</b> – <b><span id="xdx_823_z5rRo5lLDAV4">SEGMENT INFORMATION</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We manage our business activities on a consolidated basis and operate as a <span id="xdx_90A_eus-gaap--NumberOfReportableSegments_dc_uSegment_c20251101__20260430_zN5kAtnx5Sf5" style="display: none" title="Number of operating segments"> one </span>single operating segment dedicated to developing and marketing products for various medical conditions. We derive our revenue from product sales of the AlloRx™ and AlloEx product lines. The accounting policies of the segment are the same as those described in Note 1 – Nature of Organization and Summary of Significant Accounting Policies.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our Chief Operating Decision Maker (“CODM”) is our Chief Executive Officer, Chris Furman. The CODM uses net loss, as reported in our consolidated statements of operations, in evaluating the performance of the segment and determining how to allocate our resources as a whole. The CODM does not review assets in evaluating the results of the segment, and therefore, such information is not presented.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89D_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zZkLC913DcA4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents the operating results of the segment:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BC_zrDa9wJ43kPc" style="display: none">SCHEDULE OF OPERATING RESULTS OF THE SEGMENT</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20260201__20260430__us-gaap--StatementBusinessSegmentsAxis__custom--OperationSegmentsMember_zCKPPwOHfdo9" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Three Months</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>April 30, 2026</b></span></p></td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20250201__20250430__us-gaap--StatementBusinessSegmentsAxis__custom--OperationSegmentsMember_zbQ8m4AKKXzd" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Three Months</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>April 30, 2025</b></span></p></td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_40F_eus-gaap--Revenues_zID27Sh5kpY8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Revenues</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">446,295</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">511,584</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Less Significant Segment Expenses:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--CostOfGoodsAndServicesSold_iN_di_zHSpgerf9wD5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Cost of Sales</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(103,798</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(134,827</td><td style="text-align: left">)</td></tr> <tr id="xdx_40F_ecustom--TotalCompensationAndBenefitsCost_zDPzIjovpAj6" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Total Compensation and Benefits Cost</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(411,252</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(348,945</td><td style="text-align: left">)</td></tr> <tr id="xdx_404_eus-gaap--OtherResearchAndDevelopmentExpense_iN_di_zSvmvhObYpS2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Research and Development</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(109,806</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(222,431</td><td style="text-align: left">)</td></tr> <tr id="xdx_40B_eus-gaap--OperatingExpenses_zxY35rIqXMhl" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">All Other Operating Expenses (Excluding Depreciation, Amortization and Stock Based Compensation) <span id="xdx_F48_zuM34X6WsLug">(a)</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(738,216</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(531,806</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Other Segment Items:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--DepreciationDepletionAndAmortization_iN_di_zPtYzCMLlZti" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: left">Depreciation, Amortization and Stock-Based Compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(255,279</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(354,887</td><td style="text-align: left">)</td></tr> <tr id="xdx_403_eus-gaap--InterestExpenseOther_iN_di_zGPneEjzyGk4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; text-align: left">Interest Expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(508,965</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(395,960</td><td style="text-align: left">)</td></tr> <tr id="xdx_40E_eus-gaap--OtherOperatingIncomeExpenseNet_z3dnawqJTr96" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Other Income (Expense), Net</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">127,796</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(514</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--NetIncomeLoss_iT_z0FBsOTtGZ78" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Consolidated Net Loss</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1,553,225</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1,478,786</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F00_zvKMp50WThGh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F12_zc9Y7bdYu4Vk" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All other operating expenses included in consolidated net loss include professional fees, lease expenses, insurance costs, travel and entertainment expenses, and all other selling, general and administrative expenses.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents the operating results of the segment:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20251101__20260430__us-gaap--StatementBusinessSegmentsAxis__custom--OperationSegmentsMember_zVnKIVioJf57" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Six Months</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>April 30, 2026</b></span></p></td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20241101__20250430__us-gaap--StatementBusinessSegmentsAxis__custom--OperationSegmentsMember_zmCUs0Fge08i" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Six Months</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>April 30, 2025</b></span></p></td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_40F_eus-gaap--Revenues_zueWF0jiuLx7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Revenues</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">975,712</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">961,458</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Less Significant Segment Expenses:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--CostOfGoodsAndServicesSold_iN_di_zVdPe3AKQV3a" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Cost of Sales</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(221,261</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(227,919</td><td style="text-align: left">)</td></tr> <tr id="xdx_40F_ecustom--TotalCompensationAndBenefitsCost_z9pQPWCOz9jj" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Total Compensation and Benefits Cost</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(854,779</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(774,162</td><td style="text-align: left">)</td></tr> <tr id="xdx_40C_eus-gaap--OtherResearchAndDevelopmentExpense_iN_di_zqWQXDwc8Rmg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Research and Development</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(279,027</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(296,314</td><td style="text-align: left">)</td></tr> <tr id="xdx_407_eus-gaap--AssetImpairmentCharges_iN_di_zNYI2RPpHBC9" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Impairment Expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(99,700</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2346">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--OperatingExpenses_z3ViqTaYCSi8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">All Other Operating Expenses (Excluding Depreciation, Amortization and Stock Based Compensation) <span id="xdx_F43_zPZW1S4PAOti">(a)</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,321,411</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,782,720</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Other Segment Items:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--DepreciationDepletionAndAmortization_iN_di_zC6HbquwE50c" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; text-align: left">Depreciation, Amortization and Stock-Based Compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(563,532</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(808,173</td><td style="text-align: left">)</td></tr> <tr id="xdx_403_eus-gaap--InterestExpenseOther_iN_di_z3jEmPSRpeG2" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: left">Interest Expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,011,695</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(499,653</td><td style="text-align: left">)</td></tr> <tr id="xdx_40E_eus-gaap--OtherOperatingIncomeExpenseNet_zt09uJxf37p8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Other Income (Expense), Net</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">715,500</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(885,965</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--NetIncomeLoss_iT_zdV66d5cf9He" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Consolidated Net Loss</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(2,660,193</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(4,313,448</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_F09_zceYyjJm46Cb" style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F18_zS8auwzKRKZc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All other operating expenses included in consolidated net loss include professional fees, lease expenses, insurance costs, travel and entertainment expenses, and all other selling, general and administrative expenses.</span></td></tr> </table> <p id="xdx_8AD_zIjfhBoIGoOi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 1 <p id="xdx_89D_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zZkLC913DcA4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents the operating results of the segment:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BC_zrDa9wJ43kPc" style="display: none">SCHEDULE OF OPERATING RESULTS OF THE SEGMENT</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20260201__20260430__us-gaap--StatementBusinessSegmentsAxis__custom--OperationSegmentsMember_zCKPPwOHfdo9" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Three Months</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>April 30, 2026</b></span></p></td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20250201__20250430__us-gaap--StatementBusinessSegmentsAxis__custom--OperationSegmentsMember_zbQ8m4AKKXzd" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Three Months</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>April 30, 2025</b></span></p></td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_40F_eus-gaap--Revenues_zID27Sh5kpY8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Revenues</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">446,295</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">511,584</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Less Significant Segment Expenses:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--CostOfGoodsAndServicesSold_iN_di_zHSpgerf9wD5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Cost of Sales</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(103,798</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(134,827</td><td style="text-align: left">)</td></tr> <tr id="xdx_40F_ecustom--TotalCompensationAndBenefitsCost_zDPzIjovpAj6" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Total Compensation and Benefits Cost</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(411,252</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(348,945</td><td style="text-align: left">)</td></tr> <tr id="xdx_404_eus-gaap--OtherResearchAndDevelopmentExpense_iN_di_zSvmvhObYpS2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Research and Development</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(109,806</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(222,431</td><td style="text-align: left">)</td></tr> <tr id="xdx_40B_eus-gaap--OperatingExpenses_zxY35rIqXMhl" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">All Other Operating Expenses (Excluding Depreciation, Amortization and Stock Based Compensation) <span id="xdx_F48_zuM34X6WsLug">(a)</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(738,216</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(531,806</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Other Segment Items:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--DepreciationDepletionAndAmortization_iN_di_zPtYzCMLlZti" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: left">Depreciation, Amortization and Stock-Based Compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(255,279</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(354,887</td><td style="text-align: left">)</td></tr> <tr id="xdx_403_eus-gaap--InterestExpenseOther_iN_di_zGPneEjzyGk4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; text-align: left">Interest Expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(508,965</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(395,960</td><td style="text-align: left">)</td></tr> <tr id="xdx_40E_eus-gaap--OtherOperatingIncomeExpenseNet_z3dnawqJTr96" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Other Income (Expense), Net</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">127,796</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(514</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--NetIncomeLoss_iT_z0FBsOTtGZ78" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Consolidated Net Loss</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1,553,225</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1,478,786</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F00_zvKMp50WThGh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F12_zc9Y7bdYu4Vk" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All other operating expenses included in consolidated net loss include professional fees, lease expenses, insurance costs, travel and entertainment expenses, and all other selling, general and administrative expenses.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents the operating results of the segment:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20251101__20260430__us-gaap--StatementBusinessSegmentsAxis__custom--OperationSegmentsMember_zVnKIVioJf57" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Six Months</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>April 30, 2026</b></span></p></td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20241101__20250430__us-gaap--StatementBusinessSegmentsAxis__custom--OperationSegmentsMember_zmCUs0Fge08i" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Six Months</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>April 30, 2025</b></span></p></td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_40F_eus-gaap--Revenues_zueWF0jiuLx7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Revenues</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">975,712</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">961,458</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Less Significant Segment Expenses:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--CostOfGoodsAndServicesSold_iN_di_zVdPe3AKQV3a" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Cost of Sales</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(221,261</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(227,919</td><td style="text-align: left">)</td></tr> <tr id="xdx_40F_ecustom--TotalCompensationAndBenefitsCost_z9pQPWCOz9jj" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Total Compensation and Benefits Cost</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(854,779</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(774,162</td><td style="text-align: left">)</td></tr> <tr id="xdx_40C_eus-gaap--OtherResearchAndDevelopmentExpense_iN_di_zqWQXDwc8Rmg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Research and Development</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(279,027</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(296,314</td><td style="text-align: left">)</td></tr> <tr id="xdx_407_eus-gaap--AssetImpairmentCharges_iN_di_zNYI2RPpHBC9" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Impairment Expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(99,700</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2346">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--OperatingExpenses_z3ViqTaYCSi8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">All Other Operating Expenses (Excluding Depreciation, Amortization and Stock Based Compensation) <span id="xdx_F43_zPZW1S4PAOti">(a)</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,321,411</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,782,720</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Other Segment Items:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--DepreciationDepletionAndAmortization_iN_di_zC6HbquwE50c" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; text-align: left">Depreciation, Amortization and Stock-Based Compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(563,532</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(808,173</td><td style="text-align: left">)</td></tr> <tr id="xdx_403_eus-gaap--InterestExpenseOther_iN_di_z3jEmPSRpeG2" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: left">Interest Expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,011,695</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(499,653</td><td style="text-align: left">)</td></tr> <tr id="xdx_40E_eus-gaap--OtherOperatingIncomeExpenseNet_zt09uJxf37p8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Other Income (Expense), Net</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">715,500</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(885,965</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--NetIncomeLoss_iT_zdV66d5cf9He" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Consolidated Net Loss</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(2,660,193</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(4,313,448</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_F09_zceYyjJm46Cb" style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F18_zS8auwzKRKZc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All other operating expenses included in consolidated net loss include professional fees, lease expenses, insurance costs, travel and entertainment expenses, and all other selling, general and administrative expenses.</span></td></tr> </table> 446295 511584 103798 134827 -411252 -348945 109806 222431 -738216 -531806 255279 354887 508965 395960 127796 -514 -1553225 -1478786 975712 961458 221261 227919 -854779 -774162 279027 296314 99700 -1321411 -1782720 563532 808173 1011695 499653 715500 -885965 -2660193 -4313448 <p id="xdx_805_eus-gaap--SubsequentEventsTextBlock_zQo6QsTCGMx2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 12</b> – <b><span id="xdx_820_zHDiL67LYETj">SUBSEQUENT EVENTS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective May 1, the Company reached agreement with the holder of the Series 2025 Senior Secured Convertible Note whereby the note holder would convert their note to the Company’s Series A-1 Preferred Stock when the Company raised a total of $<span id="xdx_907_eus-gaap--ProceedsFromIssuanceOfConvertiblePreferredStock_pn5n6_c20260501__20260501__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember_zJpStaWGPqb3" title="Proceeds from issuance of convertible preferred stock">8.5</span> million in proceeds from sale of the Series A-1 Preferred Stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 15, 2026, a group of investors invested a total of $<span id="xdx_904_eus-gaap--Investments_iI_pn5n6_c20260515__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember_zqBhVHYK9Jxi">7.3</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million in the Company’s Series A-1 Preferred Stock in its ongoing private placement, bringing the total raised to $<span id="xdx_902_eus-gaap--Investments_iI_pn5n6_c20260515__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zHonGPYio6Ph">9.2</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million. This triggered the conversion of the 2025 Senior Secured Convertible Note noted above, resulting in the issuance of <span id="xdx_901_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_c20260515__us-gaap--LongtermDebtTypeAxis__custom--TwoThousandTwentyFiveSeriesNotesMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zIFU2LNazmph" title="Conversion of Series A-1 preferred stock">682,292</span> shares of the Company’s Series A-1 Preferred Stock. In addition, this investment triggered the conversion of the 2022 Series Notes and related accrued interest into <span id="xdx_906_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_c20260515__us-gaap--LongtermDebtTypeAxis__custom--TwoThousandTwentyTwoSeriesNotesMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zbuTSw8OEZZg" title="Conversion of Series A-1 preferred stock">11,931</span> shares of the Company’s Series A-1 Preferred Stock and conversion of the 2023 Series Notes into <span id="xdx_90B_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_c20260515__us-gaap--LongtermDebtTypeAxis__custom--TwoThousandTwentyThreeSeriesNotesMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zVnTtDyz2kKg" title="Conversion of Series A-1 preferred stock">143,050</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of the Company’s Series A-1 Preferred Stock. The total number of shares of Series A-1 Preferred Stock issued, based on these conversions, was <span id="xdx_90B_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_c20260515__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember_zAMomEydqcb9" title="Conversion of Series A-1 preferred stock">837,273 shares</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As part of the conversion of notes and the investment of the $<span id="xdx_908_eus-gaap--Investments_iI_pn5n6_c20260515__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember_zfDXWEohNVEg" title="Investments">7.3</span> million, the Company added certain redemption features for the benefit of all holders of the Series A-1 Preferred Stock.</span></p> 8500000 7300000 9200000 682292 11931 143050 837273 7300000 The discount rate used for the operating lease is based on the Company’s incremental borrowing rate at lease commencement and may be adjusted if modification to lease terms or lease reassessments occur. The discount rate used for finance leases is based on the rates implicit in the leases. All other operating expenses included in consolidated net loss include professional fees, lease expenses, insurance costs, travel and entertainment expenses, and all other selling, general and administrative expenses. All other operating expenses included in consolidated net loss include professional fees, lease expenses, insurance costs, travel and entertainment expenses, and all other selling, general and administrative expenses.